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ABSTRACT
Kate Gleason College of Engineering
Rochester Institute of Technology
Degree: Doctor of Philosophy Program: Microsystems Engineering
Author: Nicholas J. Conn
Advisor: David A. Borkholder
Dissertation Title: Robust Algorithms for Unattended Monitoring of Cardiovascular Health
Cardiovascular disease is the leading cause of death in the United States. Tracking daily
changes in one’s cardiovascular health can be critical in diagnosing and managing cardio-
vascular disease, such as heart failure and hypertension. A toilet seat is the ideal device for
monitoring parameters relating to a subject’s cardiac health in his or her home, because it
is used consistently and requires no change in daily habit. The present work demonstrates
the ability to accurately capture clinically relevant ECG metrics, pulse transit time based
blood pressures, and other parameters across subjects and physiological states using a toilet
seat-based cardiovascular monitoring system, enabled through advanced signal processing
algorithms and techniques. The algorithms described herein have been designed for use
with noisy physiologic signals measured at non-standard locations. A key component of
these algorithms is the classification of signal quality, which allows automatic rejection of
noisy segments before feature delineation and interval extractions. The present delineation
algorithms have been designed to work on poor quality signals while maintaining the high-
est possible temporal resolution. When validated on standard databases, the custom QRS
delineation algorithm has best-in-class sensitivity and precision, while the photoplethysmo-
gram delineation algorithm has best-in-class temporal resolution. Human subject testing on
normative and heart failure subjects is used to evaluate the efficacy of the proposed mon-
itoring system and algorithms. Results show that the accuracy of the measured heart rate
and blood pressure are well within the limits of AAMI standards. For the first time, a sin-
gle device is capable of monitoring long-term trends in these parameters while facilitating
daily measurements that are taken at rest, prior to the consumption of food and stimulants,
and at consistent times each day. This system has the potential to revolutionize in-home
cardiovascular monitoring.
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I can do all things through Christ who strengthens me.
Philippians 4:13
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Chapter 1
Introduction
1.1 Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death both in the United States (US)
and internationally. CVD consists of many diseases that impact the structure or function of
the heart, including heart failure, coronary artery disease, heart attack, heart arrhythmias,
vascular disease, and many more. It accounted for over 30% of all reported deaths in the
US in 2011. Cardiovascular disease is expected to remain the single leading cause of death
internationally, and it is expected to reach 23.3 million deaths a year by 2030 [1]. The
direct costs associated with cardiovascular disease is expected to rise to over $1.2 trillion a
year in the US by 2030, detailed in Figure 1.1 [2].
There are currently many challenges with detecting, diagnosing, and managing cardio-
vascular disease. It is very common for cardiovascular disease to be detected well after
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Figure 1.1: Direct medical costs associated with CVD in the US are expected to continually
increase from $656 billion a year in 2015 [2].
the initial onset of the disease. Diagnosis often requires many doctor and hospital visits,
a stress test, and an echocardiogram, which results in delayed diagnosis and large direct
costs. By the time a subject is diagnosed with cardiovascular disease they may require
an implantable cardiac device, such as a pacemaker, an implantable cardiac defibrillator, a
stent, or a ventricular assist device.
Once a subject has been diagnosed with cardiovascular disease, there can be significant cost
associated with continued care. The Centers for Medicare and Medicaid Services (CMS)
makes a single, prospectively determined bundled payment to the hospital that encom-
passes all services furnished by the hospital, physicians, and other practitioners during the
episode of care, which lasts the entire inpatient stay [3] for a single heart failure subject.
This payment includes all hospital and professional services for 90 days after the index
admission. The hospital has a loss if it spends more than the bundled payment. The pro-
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gram is currently voluntary, but will eventually be required and associated with penalties
for non-compliance nation wide.
Figure 1.2: The costs per setting for heart failure subjects is often greater than the bundled
payment provided by the Centers for Medicare and Medicaid Services. This data indicates
that readmission is often the largest percentage of costs per patient. Courtesy of Karl Q.
Schwarz, MD.
In a real life example, the predetermined bundled payment for the University of Rochester
Medical Center is $17,200 per patient. The average episode cost for five fiscal quarters is
compared to the CMS bundled rate in Figure 1.2. Readmission is the most important cost,
sometimes exceeding the index admission. Readmission rates for heart failure patients
are 7.5% within the first 7 days after discharge and 28% after the first 30 days. 90%
of readmission is due to either patient non-compliance, medical management issues, or
disease exacerbation as illustrated in Figure 1.3. Consistent monitoring of these subjects is
required to ensure a subject’s health is not declining.
As an example, when a subject is diagnosed with heart failure they must track their weight
and blood pressure daily in order to keep monitor of their cardiac health. Despite a subject’s
best intentions patient compliance can be very low, which can significantly reduce the
3
Figure 1.3: Readmission statistics for the University or Rochester Medical Center indi-
cate that 90% of readmissions are due to non-compliance, management issues, or disease
exacerbation. Courtesy of Karl Q. Schwarz, MD.
chances of recovery and add to costs associated with continued disease management [4].
Patient compliance is the extent to which a patient or subject consistently and accurately
follows medically relevant instructions. Any lapse in diligence results in unreliable data
with reduced clinical value. Something as simple as eating before measuring blood pressure
in the morning can result in drastically inconsistent blood pressures.
1.2 Opportunities for In-Home Trend Monitoring
There are many devices that a subject can use to monitor their cardiac health in the home.
The two most prevalent devices are a blood pressure monitor and a bathroom scale, both
of which heart failure patients should use on a daily basis. The blood pressure monitor
determines an individual’s systolic and diastolic blood pressure, providing insights into
cardiac function and overall cardiovascular health. Similarly, tracking a subject’s weight
over time is extremely important for heart failure patients, as a sharp increase in weight can
indicate water retention and deteriorating condition.
4
Blood pressure and weight can change drastically throughout the day as a subject eats,
drinks caffeine, smokes, exercises, or becomes stressed, confounding trend analysis. If
blood pressure and weight are only monitored at the hospital or during doctor visits, impor-
tant trends could easily be obscured by the natural variation of these parameters throughout
the day.
Another medical device often used for in-home cardiovascular monitoring is a Holter mon-
itor, which is an ambulatory electrocardiogram that is typically worn for short period of
time as prescribed by a physician. Holter monitors are worn for 24, 48, 72 hours etc., up
to a total of 7 days, and are not practical for long-term use [5, 6]. Typically, it is used for
at least 24 hours in order to determine if a subject has any arrhythmias throughout the day
or night. It can also allow a cardiologist to determine if a certain medication is working ef-
fectively [7]. While a Holter monitor can provide invaluable information about a subject’s
cardiac health for a short period, it can be uncomfortable and very disruptive to a subject’s
lifestyle.
Alternately, the single lead ECG can play an important role in the diagnosis and man-
agement of cardiovascular disease. The ECG is clinically important because it is used to
diagnose myocardial ischemia and infarction, atrial fibrillation, left ventricular hypertro-
phy/dilatation, left bundle branch block and intraventricular conduction delays, and left
atrial abnormality [8]. These disease states can be diagnosed by monitoring rhythm and
morphology changes in a single lead ECG. Daily, long-term monitoring of a single lead
ECG has the potential to augment the type of information provided by a Holter monitor
and if done correctly, can increase the quality of life for subjects.
The following example highlights the need for accurate in-home monitoring:
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Subjects that are diagnosed with heart failure are often required to measure their weight
every day as rapid weight gain due to water retention can signify a further decline in ones
cardiovascular health. The data shown in Figure 1.4 provides an example of a subject’s
daily weight immediately before he was diagnosed with heart failure [9]. From July to
October the subject did their best to be active and lose weight, as can be seen by their
steady weight loss throughout these months.
Figure 1.4: Daily weight measurements from a subject before and after being diagnosed
with heart failure. Unexpected and rapid weight gain can indicate water retention, and thus
heart failure [9].
Having changed nothing about their daily routine, the subject had two months of rapid
weight gain starting in October. This prompted the subject to see a cardiologist, where he
was then diagnosed with heart failure. This diagnosis may not have been made for many
months if the subject was not tracking his weight. Imagine if the subject did not track their
weight and only went to the doctor in July and November. The doctor would have only
seen a weight gain of 10 pounds, which could be considered normal and could have been
easily overlooked.
Many subjects wait until they have chest pain or issues during exercise before being exam-
ined by a cardiologist. By the time it would be diagnosed, the subject’s heart failure could
have progressed to the point that it could no longer be managed with medication, poten-
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Figure 1.5: After being put on medication for heart failure and water retention, the subject
looses the excess water weight very quickly [9].
tially requiring a transplant, an implantable cardiac device, or a more invasive type of heart
surgery. Once this subject was given medication for heart failure, he lost approximately 40
pounds of water in the course of a month, as shown in Figure 1.5.
“The good news is that with just some medications, all this extra retained
water drained off quickly, my symptoms disappeared, and I am back to feeling
“normal” and have a normal level of physical activity including daily exer-
cise.” - Erv Walter [9]
This is a remarkable example of how trends in a physiological signal can indicate a serious
medical condition that could be missed if not monitored daily. Not all subjects are as
diligent as the one depicted in this example, highlighting the need for inconspicuous daily
medical monitoring.
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1.3 An Ideal System for In-Home Monitoring
Each of the aforementioned devices have one thing in common: they either require a doc-
tors visit or require the subject to change their daily habits when monitoring their health.
Even if expensive connected versions of these devices are purchased, the subject must still
take the time every day to perform the measurement at the correct time of day. This makes
it difficult for physicians to monitor a subject remotely, where trends and patterns in a
subject’s measurements could indicate an improvement or a decline in health.
By integrating multiple medical instruments into a toilet seat, many of the challenges as-
sociated with in-home monitoring are addressed. The resulting cardiovascular monitoring
system can be integrated into the natural routine of a subject, enabling measurements to
be taken at the same time of the day before any stimulants (e.g., sugar, caffeine, nicotine)
or food. This results in a stable daily measurement over time that is critical for accurate
trend analysis. Issues with preparation and subject error are greatly reduced, since skin
contact is automatic and has sufficient pressure to create a consistent electrode interface at
a consistent location for each individual.
The fully integrated toilet (FIT) seat incorporates a single-lead electrocardiogram (ECG)
for measuring the electrical activity of the heart, a photoplethysmogram (PPG) for measur-
ing blood oxygenation and for estimating blood pressure, a ballistocardiogram (BCG) for
measuring cardiac function and for estimating blood pressure, and a body weight sensor
that can replace the bathroom scale (Figure 1.6). It is completely self contained, battery
powered, wireless, and cleanable with all of the sensors and instrumentation integrated
inside of the seat to facilitate user acceptance.
In-home physiological monitoring of all kinds (e.g., heart rate, blood pressure, weight)
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Figure 1.6: The final in-home version of the FIT seat is completely self-contained and will
work on any standard toilet seat.
presents unique challenges that are not present in a hospital environment or doctor’s office.
A trained expert is not on hand to make any real-time changes that would ensure cor-
rect electrode placement, signal integrity, and measurement accuracy. Additionally, patient
compliance is often very low resulting in measurements that are not taken consistently nor
at a consistent physiologic state, which is a requirement for accurate trend analysis. Com-
pliance is hampered if the in-home device is not easy to use or if a significant change of
habit is required.
The key to successful cardiac monitoring and the early detection of changes associated with
emerging or deteriorating health conditions is ensuring patient compliance, daily measure-
ments, and a consistent physiological state at the time of measurement. Additionally, many
medical devices such as the ECG require skin contact to achieve robust measurements and
to ensure that the fine features of the waveform are accurately captured.
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An integrated toilet seat is proposed as an ideal device for inconspicuous daily cardiovascu-
lar monitoring. This seat contains multiple sensors and microprocessors with wireless com-
munication capabilities, providing a fully self-contained bioinstrumentation system that
automatically captures medically relevant data on a daily basis.
Such a system is beneficial since many individuals will go to the bathroom in the morning
before eating breakfast, having coffee, smoking a cigarette, and before any physical activ-
ity. This is the ideal time to take physiological measurements due to the known physiologi-
cal state and consistent nature of the use of this device. Furthermore, patient compliance is
automatic since subjects do not need to change their daily habits when using this device. A
commercially available version of the FIT seat is expected to operate unattended and have
multiple years of battery life, increasing the chance of user adoption. There are no special
installation instructions since the FIT seat can be installed in the same manner as a regular
toilet seat.
The extraction of accurate medical parameters from the FIT seat would not be possible
without the custom algorithms presented herein. The present algorithms are the major
contribution of this work, since there is a lack of robust algorithms in the current body of
knowledge for working with non-ideal, noisy physiologic signals captured in the home.
These algorithms allow the system to function with no interaction from the subject and
allow it to seamlessly integrate into their daily life. This will facilitate the daily cardiac
monitoring of subjects at a consistent physiological state, as required for accurate long-
term trend analysis.
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1.4 Research Overview
The outcome of this research is intended to be advanced custom algorithms that enable true,
daily in-home monitoring of cardiovascular health, utilizing a completely self-contained
unconventional cardiovascular monitoring system. The main contribution of this work is
the development of automated algorithms for use with unconventional, noisy physiologic
signals. Novel approaches will be used to rejection noisy sections of waveforms before
analysis, specifically designed to recognize in-band noise. Delineation algorithms will be
designed from the ground up with a focus on temporal resolution and ability to perform
well on real-world signals, specifically with a dry electrode based ECG.
The monitoring system and custom algorithms have been designed and verified using data
captured from two rounds of institute review board approved human subject testing both
at the Rochester Institute of Technology and the University of Rochester Medical Center.
Initial verification of blood pressure trend data from a seat deployed in the home is also
presented.
Background theory on the cardiovascular system and medical instrumentation is discussed
in Chapter 2 in order to provide the necessary information to understand the fully integrated
toilet seat system, which is presented in Chapter 3. The algorithms and signal processing
techniques that have been developed for use with noisy in-home data is discussed in Chapter
4. The structure of both human subject studies are discussed in Chapter 5, while the results
for each medical instrument are presented in Chapter 6, and Chapter 7. True sub-Nyquist
compressed sensing is discussed in Chapter 8, before outlining suggested future work that
would leverage the systems and processes developed herein.
This work paves the way for future studies that would investigate the clinical utility of
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the FIT seat for heart failure subjects and the ability of a deployed, self-contained, toilet
seat based system and algorithms to monitor long-term trends in the home. Such a device
has the potential to capture long-term trend data that has been previously unattainable, as
it facilitates daily measurements taken at rest prior to food and stimulants (e.g., caffeine,
nicotine) at consistent times each day, with no required change in habit. This, in combi-
nation with intra-day circadian trends will enable new approaches and capabilities in the
diagnosis and treatment of cardiovascular disease for those with heart failure, hypertension,
and those undergoing chemotherapy treatments.
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Chapter 2
Cardiac Theory and Physiological
Signals
2.1 Introduction
This chapter provides all necessary background on the cardiovascular system and the med-
ical instrumentation used during the diagnosis and management of cardiovascular disease,
within the scope of the present work. Specifically, background and device theory for
the electrocardiogram (ECG), the photoplethysmogram (PPG), and the ballistocardiogram
(BCG) are provided, as each of these instruments have been embedded within the fully
integrated toilet seat.
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2.2 The Cardiovascular System
The cardiovascular system, also known as the circulatory system, is responsible for pump-
ing blood throughout the body. The heart is at the center of the cardiovascular system
and pumps blood through the vascular system, which consisting of arteries that bring oxy-
genated blood to tissue and veins that bring blood back to the heart. The heart can be
thought of as two electrically controlled mechanical pumps, which consists of four cham-
bers: two atria and two ventricles. The smaller right ventricle (RV) pumps blood to the
lungs and the larger left ventricle (LV) pumps blood to the rest of the body. This can be
seen in Figure 2.1.
Figure 2.1: The four chambers of the heart are shown. The right atria pumps deoxygenated
blood into the lungs and the left ventricle pumps oxygenated blood into the body through
the aorta [10].
At the start of systole, the left ventricle begins to contract causing the aortic valve (AV)
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to open, causing blood to be ejected from the left ventricle into the aorta through the left
ventricular outflow tract (LVOT). The resulting pulse wave propagates upward to the aortic
arch, changing directions to continue down the torso through the descending aorta, which
is shown in Figure 2.2. Following systole, diastole begins, which is when the ventricles
relax and the heart refills with blood.
Figure 2.2: The aorta starts at the left ventricle and moves upwards before arcing down-
ward towards the lower body. The aorta then branches directly below the abdomen into the
two common iliac arteries.
A single cardiac cycle is initiated starts with an action potential generated by the sinoatrial
(SA) node, as shown in Figure 2.3. The SA node consists of self-excitatory myocardium,
allowing the creation of action potentials that result in a series of heart beats [11]. The elec-
trical action potential stimulates the atria causing atrial contraction, which forces the blood
in the atria into the ventricles. The action potential then continues through the atrioven-
tricular (AV) node, and then after a small delay, continues down the left and right branch
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before stimulating the ventricles through the Purkinji fibers [11]. As the ventricles contract,
the pressure in the ventricles increases until the aortic valve opens. Once the aortic valve
opens, blood is injected into the aorta.
Figure 2.3: The electrical conduction system of the heart is shown, from the sinoatrial
node to the Purkinje fibers [12].
The electrical activity of the heart can be measured using the electrocardiogram (ECG) and
the mechanical forces of the heart can be measured using the ballistocardiogram (BCG).
The photoplethysmogram (PPG) is an optical measure of local blood volume, which when
used in combination with the ECG and BCG can illicit additional details relating to periph-
eral blood flow.
2.3 Electrocardiogram
The electrocardiogram (ECG) is a non-invasive medical device which differentially mea-
sures the changes in surface body potential caused by the depolarization and repolarization
of cardiac tissue [11].
An example showing two typical ECG beats is shown in Figure 2.4. The ECG consists
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Figure 2.4: Two normal ECG beats are shown. A single ECG beat consists of the P-wave,
the QRS complex, and the T-wave [13].
the P-wave, the QRS complex, and the T-wave [11]. The P-wave is generated from the
contraction and activation of the atria, whose amplitude is significantly less than that of
the QRS complex, which is the most prominent waveform in the ECG as it is created
from the activation of the ventricles [11]. The beat-to-beat interval between neighboring
R-peaks are typically used to determine the heart rate. It is also used as a reference point
for delineation algorithms due to the fact that it is the most prominent and easiest feature
to locate. Finally, the last wave in a normal beat is the T-wave, which is caused by the
recovery, or repolarization, of the ventricles. T-wave morphology can vary greatly from
individual to individual due to drug effects and metabolic factors [14].
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(a)
(b)
Figure 2.5: Each lead location for the 12-lead system is shown in (a) [15]. The Wilson
central terminal is the reference for the unipolar leads. This is shown with Einthoven’s
triangle in (b) [15].
The ECG is measured differentially to reduce common mode noise, so lead placement be-
comes very important. There are many different methods for placing ECG leads, but the
most popular and standard lead placement system is the 12-lead ECG system, shown in
Figure 2.5a [11, 14]. The 12-lead system contains three differential limb leads correspond-
ing to Einthoven’s triangle (shown in Figure 2.5a and Figure 2.5b). Next there are three
augmented limb leads, which are differential measurements between each limb lead with
respect to the average of the other two limb leads. Finally, there are six unipolar leads. The
unipolar leads are still measured differentially, but are all measured relative to the Wilson
central terminal (CT) which will contain the common mode noise on the body. This point
is considered the zero-point of the ECG and is extracted from the three limb leads via 5 k
resistors as shown in Figure 2.5b).
The leads in the 12-lead ECG system can be used to reconstruct the orthogonal Frank leads,
which represent the heart vector and consist of three orthogonal leads, one for each spatial
dimension. This allows the entire cardiac cycle to be modeled as if the heart were a time-
varying, rotating dipole with a variable magnitude [11]. This dipole is formed as cardiac
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tissue repolarizes after depolarization creating a moving charge gradient; this is illustrated
in Figure 2.6. Contour and rotation of the heart dipole is not easily represented in the 12-
Lead system; this is the main reason for using the Frank leads when working directly with
this signal [16].
Figure 2.6: The heart can be represented as a rotating dipole created by the depolarization
and repolarization of cardiac tissue [15].
As the lungs expand and contract during respiration, the heart will move and the impedance
of the thorax changes. The impedance of the thorax and movement of the heart within the
body affect the apparent orientation of the heart dipole, and thus the signal on each ECG
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lead. A 1 cm variation in location of the heart can result in a 24% change in surface potential
as measured by the ECG [17]. Furthermore, it has been shown that respiration manifests
itself as a rotation of the heart dipole along the orthogonal axes [18, 19]. The degree of
rotation caused by respiration is approximately 10 degrees [19]. This is the mechanism
that explains why each of the 12-leads in the standard ECG have different waveform mor-
phology. The morphology of an ECG captured at an arbitrary point is likewise determined
from the dot product of the electrode lead vector and the heart dipole [20, 21, 22].
The single lead ECG plays an important role in the diagnosis and management of cardio-
vascular disease. The ECG is clinically important because it is used to diagnose myocardial
ischemia and infarction, atrial fibrillation, left ventricular hypertrophy/dilatation, left bun-
dle branch block and intraventricular conduction delays, and left atrial abnormality [8].
These disease states can be diagnosed by monitoring rhythm and morphology changes in a
single lead ECG. For example, changes in orientation could indicate myocardial infarction,
such as when the T-wave is not in the same direction as R-wave or if the ST segment is
elevated [23, 24]. Change in morphology and timing, such as a PR interval, could indicate
conduction system dysfunction [25]. Similarly right ventricular hypertrophy (RVH) can be
detected 87% of the time using ECG; an important prognostic as RHV tied to a 4.3-fold
increase risk of death [26]. The heart rate (HR), heart rate variability (HRV), QRS duration,
and corrected QT (QTc) interval are of specific interest for the work presented herein.
The HR is calculated is calculated from the ECG by taking the average interval between
consecutive R-peaks (RR-interval) across a set period of time. Heart rate variability is a
measure of the variation between RR-intervals across time, often calculated as the stan-
dard deviation of RR-intervals across 5 minutes or 24 hours [27]. Changes in both HR
and HRV can be used to predict cardiovascular events. For patients with (and without)
coronary artery disease, resting HR is a predictor for mortality, independent of other risk
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factors [28, 29]. An elevated resting heart rate is associated with increased risk for incident
heart failure in asymptomatic patients, and is related to development of regional and global
left ventricular dysfunction independent of subclinical atherosclerosis and coronary heart
disease [30]. Low HRV is associated with a 32-45% increased risk of a first cardiovascular
event for patients with no previous history of cardiovascular disease, and is also associated
with chronic heart failure, diabetes, and alcoholic cardiomyopathy [31]. In patients with
advanced chronic heart failure, decreased HRV indices are an independent risk factor for
mortality post myocardial infarction [32]. Additionally, a subject’s heart rate variability
(HRV) offers prognostic information and is significantly associated with risk for angina
pectoris, myocardial infarction, coronary heart disease death, or congestive heart failure
[33].
The QRS duration is defined as the time between the Q-wave onset and the S-wave end.
An increase in QRS duration can be used to diagnose disease state and can be used as a
predictor for sudden death [34]. As an example, a QRS width greater than 120 ms suggests
that cardiac dyssynchrony may be present [35]. Additionally, QRS duration may have sec-
ondary value in predicting the prognosis in patients with heart failure [34]. Implantable
cardiac defibrillator patients with heart failure (HF) that had a wide underlying QRS com-
plex showed more than double the cardiac mortality compared to those with a narrow QRS
complex [36]. The degree of QRS prolongation is correlated to an increase in severity of
left ventricular systolic dysfunction, left ventricular dilation, and mitral regurgitation [37].
Left ventricular function worsens as the QRS duration increases [36, 37, 38, 39], making it
an important parameter to monitor over time.
The QT interval is defined as the interval between the Q-wave onset and the T-wave end.
Correcting the QT interval for different heart rates is necessary when looking for trends
or comparison across recordings. The corrected QT interval (QTc) is calculated using the
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Bazett formula [40] in (2.1).
QTc =
QT√
RR
(2.1)
A prolonged QTc interval is a strong, independent predictor of adverse outcomes in pa-
tients with heart failure, as the interval is related to ventricular polarization and repolar-
ization [41]. Many drugs prescribed to cardiovascular patients change the PR interval and
the QRS duration, however, they can also prolong the QT interval, which can be very dan-
gerous. A drug induced prolongation of the QT interval is associated with Torsades de
Pointes (a polymorphic ventricular tachycardia), which is the leading cause of sudden car-
diac death (unexpected cardiovascular collapse without warning) [42, 43]. It is important
for physicians to monitor QT prolongation when prescribing drugs to those with cardio-
vascular disease or when evaluating new drugs (drug screening). By looking at long term
trends, each of these parameters can be used to monitor the progression of disease state
over time.
2.4 Pulse Wave Velocity and Blood Pressure
Ventricular ejection starts only after the pressure in the left ventricle exceeds that of aortic
pressure, at which time the aortic valve opens. At the end of ventricular systole, pressure
falls in the left ventricle and the aortic valve closes. The time between the start of the QRS
and aortic valve opening is called the pre-ejection period (PEP), the time that the aortic
valve is open is the systolic ejection period, and the time between when the aortic valve
closes and ventricular pressure reduces to its diastolic nadir, permitting the mitral valve to
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open, is the isovolumetric relaxation time.
The aortic PWV can be calculated by determining the length of the arterial segment divided
by the pulse transit time (PTT) over that length. The velocity is the distance divided by the
time. The PTT is determined by the start of ventricular ejection (when the aortic valve
opens), as well as the point in time when the pulse wave reaches a specific end-point in the
periphery.
The pulse arrival time (PAT) is a summation of the PEP and the PTT. The PEP starts at the
beginning of ventricular contraction and ends with the start of ventricular ejection (when
the aortic valve opens). The pulse transit time begins when the aortic valve opens and
ends when the pressure wave reaches the distal measurement point. For blood pressure and
aortic compliance, the ideal distal location is the end of the aorta, close to the start of the
femoral artery.
The length of the arterial segment can be determined by various methods, including direct
subject measurement on a user by user basis (discussed in Chapter 7). However, it is
possible that the length can be estimated without direct measurement by using population
statistics [44]. The aortic pulse wave velocity (PWV) is this estimated aortic length divided
by the PTT.
Historically, there are four measurement techniques that are used for estimation of a pulse
wave velocity. First, the clinical gold standard uses tonometry where a transducer is held
against the carotid artery (neck) and a thigh pressure cuff is used to measure when the pulse
wave reaches the femoral artery [45]. The distance between the two measurement points,
coupled with the pulse transit time (PTT) is used to determine an aortic pulse wave velocity
(PWV) and estimate aortic compliance.
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In the second technique, two points on the same artery are used to measure an arterial PTT,
with the distance between measurement points determining PWV [46, 47]. This is often
done using two photoplethysmography (PPG) sensors with known separation between the
two positions on the radial artery of the arm, or in the finger (using the foot to foot mea-
surement of the two PPG waveforms). This technique estimates the PWV in the measured
peripheral artery, not in the aorta, and is therefore not useful for determining aortic com-
pliance, but is often used to estimate blood pressure [47].
The third technique uses the R-wave peak of the ECG is used as the starting point, with a
peripheral PPG measurement (often finger, toe, or ear) used as the distal point [48, 49]. This
measurement is called the pulse arrival time (PAT) and is often used as a surrogate for PTT
(and PWV) in estimating blood pressure [50]. However, as this measurement technique
includes the PEP it has no basis in physiology and fundamental pulse wave velocity/blood
pressure theory [51, 52].
In the fourth technique, the BCG is used as the starting point (estimating aortic ejection)
and PPG at the periphery (toe or ear) is used as the distal point for estimation of a PWV
[53, 54, 55]. This approach measures an averaged PWV of the aorta and femoral artery. It
has been used for aortic compliance estimation. However, it is not an accurate measurement
of the true aorta PWV due to the contribution of the femoral artery distance from the end
of the aorta to the toe and the carotid arterial distance from the aorta to the ear.
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2.5 Photoplethysmogram
The photoplethysmogram (PPG) is a medical device that optically measures changes in
local blood volume, based on the amount of light reflected or transmitted through tissue.
The PPG requires a light source to illuminate the tissue in order to measure the change in
light intensity. The raw signal measured by either a photodiode or phototransistor contains
a large DC component caused by ambient light and the scattering of light within the tissue.
The pulsatile AC signal caused by the pulse wave is much smaller. The AC component of
the PPG is typically 0.1-1.5% of the DC component [56].
A standard PPG waveform is shown in Figure 2.7. It is a low frequency waveform with a
bandwidth of 0.5 Hz to 17 Hz [56]. The PPG contains three major features: the PPG foot,
the peak, and the dicrotic notch. The PPG foot represents the onset of the pulse wave; this
point of the waveform is used to determine the end point of the pulse transit time (PTT) and
pulse wave velocity (PWV). The PPG peak is the maximum of pulse wave and the dicrotic
notch is caused by a second, reflected peak in the PPG [57].
  Foot
Peak
Dicrotic Notch
Figure 2.7: A single PPG beat consists of the foot (also known as the beat onset), the peak,
and the dicrotic notch. The foot is created when the pulse wave reaches the localized tissue.
The PPG is most commonly found in a pulse oximeter, which is a medical device that uses
two PPG signals measured at different wavelengths to estimate blood oxygenation levels
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(SpO2). This is possible since oxygenated blood and deoxygenated blood have different
absorption spectra. The absorption spectra of oxygenated and deoxygenated hemoglobin is
shown in Figure 2.8.
Figure 2.8: The absorption spectrum for oxygenated and deoxygenated hemoglobin is
different, allowing a pulse oximeter to estimate the blood oxygen saturation of the localized
tissue [58]. Typically, red (660 nm) and infrared (940 nm) wavelengths are used.
The FIT bPPG is used when estimating both pulse transit time and blood oxygenation
(SpO2). The FIT seat is capable of measuring a subject’s peripheral oxygen saturation
(SpO2) using a dual wavelength reflectance mode photoplethysmogram (pulse oximeter),
positioned to make contact with the upper thigh. A pulse oximeter measures blood oxy-
genation by illuminating tissue with two different wavelengths of light and measuring the
returned light intensity with a photodiode. The illumination is provided by a red LED with
a wavelength of 645nm, and an infrared LED with a wavelength of 940nm. The critical
value extracted from the raw data which is used to calculate SpO2 is the “R-value”. This is
the compound ratio of the AC to DC amplitudes for each wavelength, as shown in (2.2).
R =
AC645nmDC645nm
AC940nmDC940nm
(2.2)
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Normally, the light source is either reflected off of a bone, as is the case in the finger and
forehead, or transmitted completely through the tissue, as is the case in the earlobe or the
finger. This research investigates the use of the PPG on the buttocks and hamstring. At this
location, the PPG will not be operating in reflective mode nor will it be able to transmit
light through the tissue. This presents a unique problem for both the PPG instrumentation
and the sensor construction. It expected for a buttocks PPG (bPPG) to work due to the
scattering of light in the local tissue. This will require the distance between the light source
and photosensor to be optimized and as well as the sensitivity of the analog-front-end to be
maximized.
The correlation between R-value and SpO2 is highly linear for changes in SpO2 of about
10%, and remains approximately linear over the entire range of possible values. The corre-
lation is highly dependent on the two wavelengths of light chosen, and to a small degree the
position on the body where the measurement is taken. Furthermore, the device hardware
and optics impact the relationship between the R-value and SpO2. As such, all commercial
pulse oximeters need to undergo calibration. The FIT seat is no exception.
Commercial pulse oximeters must undergo testing according to ISO 80601-2-61:2011,
which includes R-curve determination using a set of subjects undergoing a controlled de-
saturation study while monitored by the pulse oximeters under test and an in vivo SaO2
monitor. This is out of the scope of this study, so a hospital finger pulse oximeter was sub-
stituted as our reference while a subject underwent controlled desaturation. Two subjects
underwent the desaturation test, taking their SpO2 from a resting value of approximately
100% down under 80% over the course of several minutes, and then returning back to
100%. The R-curve is plotted against SpO2 for both subjects in order to calibrate the de-
vice.
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2.6 Ballistocardiogram
The ballistocardiogram (BCG) measures the ballistic forces of the heart. Unlike the ECG
which measures the electrical activity of the heart, the BCG can provide insights into the
myocardium function and cardiac output [59]. The BCG was pioneered in the 50’s and 60’s
by Starr for use in diagnosing issues with cardiac output, cardiac infarction, and chronic
angina pectoris [60, 61, 59, 62, 63, 64]. In addition to these disease states and metrics, the
BCG can be used to determine coronary disease, ventricular asynchronism, hypokinesia,
hypertension, and age related weakening of the heart [65].
After about 30 years of continuous and consistent BCG research, the instrument’s use saw
a significant decline [66]. Despite a recent resurgence of interest in the BCG, there are no
commercially available clinical BCG systems. With improved modern sensing techniques,
the BCG can now be reliably measured in bathroom scales and in wearable technology
such as an ear based accelerometer [67, 68, 69, 70].
Figure 2.9: A typical BCG waveform as measured by Starr. Adapted from [60].
The original technique for measuring the BCG involved a suspended bed on which the
subject laid [60]. The displacement of the suspended bed was measured and related to
heart function. Other systems involved measuring a subject lying on a bed suspended in
mercury [71]. Systems utilizing load-cells and piezoelectric sensors directly measure the
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change in force due to the ballistic forces of the heart [72, 67].
An example of the BCG waveform measured by Starr is shown in Figure 2.9 [60]. This
BCG waveform contains the following features: H, I, J, K, L, M, and N. It is theorized, but
not proven, that the H peak is related to the motion of the heart early in systole, and that the
IJK complex is related to the ventricular ejection and resulting aortic flow [66]. The cause
of the other waves is not known [66].
2.7 Conclusion
Each of these devices are utilized in the fully integrated toilet seat. The ECG is used
to extract key timing intervals and to provide a reference point for all other analysis. A
seated BCG is captured in order to estimate cardiac function and the timing of aortic valve
opening, which is the start of the pulse wave at the aortic root. The PPG is used to measure
the end of the pulse wave velocity at the end of the aorta, and to provide SpO2.
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Chapter 3
A Toilet Seat for In-Home
Cardiovascular Monitoring
3.1 Introduction
The design and verification of the fully integrated toilet (FIT) seat is described in this
chapter. Specialized hardware required for measurements in non-standard locations are
presented. Each version of the FIT seat, and subsequent improvements are detailed with
a focus on the systems used for human subject testing. Finally, expected use cases are
presented with the results from an in-home ethnographic study.
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3.2 System Introduction and Overview
Advances in ultra-low power electronics, signal processing techniques, sensor technolo-
gies, and wireless interconnectivity offer new opportunities for truly inconspicuous daily
medical analyses. Of particular interest is measurement of the electrocardiogram (ECG),
ballistocardiogram (BCG), and photoplethysmogram (PCG), enabling a broad range of
clinically relevant and predictive analyses when these signals are simultaneously captured.The
entire FIT seat system is shown in Figure 3.1.
Figure 3.1: A rendered view of the complete integrated FIT system, showing all internal
instrumentation.
There are examples in literature demonstrating that it is possible to capture an ECG from a
toilet seat [73, 74, 75, 76, 77, 78, 79]. Only the work presented in [76] has quantitatively
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compared the seated ECG on a toilet seat to a gold-standard ECG measure, where both non-
contact and wet electrodes placed on the thigh were compared to a standard limb lead ECG.
Their results showed that manual R-peak delineation resulted in less than a 2 ms error in
location and that the estimated HR was within 0.003 bpm for a single test subject. Similarly,
it has been demonstrated that the PPG can be acquired from a toilet seat in [74, 80, 79].
Only the work presented in [80] provided a quantitative measure of the PPG compared to
an ECG in order to determine the optimal location for the optical sensor. Results showed
that the front of a toilet seat is the optimal location to measure the PPG.
Bioimpedance has been used in [81, 75] to estimate body composition. In [81] the body fat
ratio estimated from the impedance measures were verified in a controlled study with 86
subjects, resulting in a high linear correlation (R=0.87). Blood pressure has been estimated
from a toilet seat using the volume-oscillometric method in [82] and pulse arrival (PAT)
based method in [79, 83]. The work presented in [83] showed a quantitative comparison
of toilet seat based blood pressure across three subjects. Their results show that the blood
pressure estimation error had a average error of 12.3 mmHg.
The proposed system expands on what has been accomplished in literature in a number of
ways. Every sensor in the proposed system is completely integrate into the seat and does
not require any external equipment or devices for proper operation. In [84, 85] weight
was measured by placing the entire toilet on a platform and the ECG was measured from
electrodes on the seat. In the work presented in [81], weight was acquired using load-cell
between the seat and the toilet, however the system did not have a hinge and required the
subject to lift up their feet. This work also proposed a shaft based cantilever system for
monitoring weight, and verified the system using only dead weight.
The following list describes all of the measurements that will be extracted from the pro-
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posed FIT seat:
Heart rate
The average heart rate (HR) of an individual will be calculated from the bECG and
bPPG.
HRV
The heart rate variability will be calculated from the ECG. Low HRV can indication
an impending cardiac event and can be used to estimate stress levels.
QT interval
The QT interval represents the recovery time of the ventricles after contraction. This
metric is often used to determine the effect of medication on the heart.
QRS duration
The duration of the QRS complex can indicate heart failure and other cardiovascular
issues.
SpO2
The blood oxygen saturation (SpO2) percentage can be measured using a two wave-
length bPPG. Low SpO2 values can be used to indicate heart failure.
Aortic pulse transit time
The pulse transit time (PTT) is the time that it takes the pulse wave to propagate
through the length of the aorta. This is defined as the interval between aortic valve
opening and the start of the pulse wave at a peripheral location. This can be calculated
from the BCG and the bPPG, where the bPPG foot is the end of the pulse transit time.
Aortic pulse wave velocity
The pulse wave velocity (PWV) is calculated using the aortic PTT and the length of
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the aorta. The length of the aorta can be determined on a subject-by-subject basis or
using demographic statistics.
Cardiac output
Cardiac output can be estimated from the BCG, as the IJ-amplitude has a linear cor-
relation to cardiac output. This is the leading indicator of heart failure.
Blood pressure
The blood pressure (BP) can theoretically be estimated using the PWV. This is a
useful tool for tracking the progress of patients with cardiovascular disease.
The captured data can be wirelessly transmitted to either a base station in the home or a
subject’s smart phone or tablet or transfered over a USB connection for real-time visualiza-
tions. The resulting data can then either be kept solely on the user’s device or uploaded to
the cloud. This would allow physicians and family member to monitor an individuals car-
diac heath if desired. This device has the potential aid in the prevention of cardiovascular
disease through preventative monitoring and to revolutionize how cardiovascular disease is
currently managed.
The functional differences between the normative system and the integrated system are
shown below in Figure 3.2. These differences are discussed throughout this chapter.
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Figure 3.2: The system block diagram for the FIT seat details every sensor in the norma-
tive seat (left) as well as the differences between the normative system and the integrated
system.
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3.3 Hardware
3.3.1 ECG Instrumentation
The ECG is a very small signal: the amplitude of the limb leads are typically less than 2
mV and it has a frequency range of 0.05 to 100 Hz [14]. Ambient electromagnetic noise in
the environment is significantly larger than the ECG signal. For this reason, the ECG signal
is measured differentially so that the common noise across the body can be rejected during
amplification. This works under the assumption that the environmental noise should be
approximately the same across the whole body. As such, each ECG waveform is a measure
of the difference between two electrodes.
A standard single channel ECG consists of three electrodes, two differential electrodes,
and one reference electrode. The two differential electrodes are amplified by a differential
amplifier before further amplification and analog filtering. An instrumentation amplifier
(INA) is commonly used in an ECG analog-front-end (AFE) due to its high common mode
rejection. An example of basic ECG instrumentation is shown in Figure 3.3. Details on the
electrode/skin interface and sources are discussed in the following section.
The reference electrode can either be tied to a reference voltage such as ground, or driven
by the amplified and inverted common mode signal. The common mode signal can be
found at the center point of an INA’s gain resistor, as shown in Figure 3.3. The signal is
then greatly amplified using an inverting amplifier, and fed back into the electrode through
a current limiting resistor. Additional sources of noise include motion artifacts, baseline
wander, and the electromyogram (EMG).
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Figure 3.3: A basic ECG amplifier is shown, which amplifies a single differential channel
using an instrumentation amplifier. In this configuration, a driven right leg circuit is used
for the third electrode.
After the initial amplification stage, the ECG can be high-pass filtered using a passive
filter with a cutoff frequency of 1 Hz in order to limit baseline wander from the electrode
interface. Then the signal can be further amplified, low-pass filtered, and sometimes notch
filtered (to remove line noise) before the analog signal is converted to a digital signal.
Despite using an instrumentation amplified for high common mode rejection, power line
noise can still dominate the acquired signal. In the United States the line noise is at 60
Hz, in many other countries the line noise is at 50 Hz. The digital ECG signal then un-
dergoes digital signal processing to remove any remaining noise, before being analyzed, as
discussed in Chapter 4.
The ECG system utilized in the FIT seat will be a single channel ECG with a grounded
right leg. The hardware will be capable of having a driven right leg, however this will
not be used for subject testing. An active ECG AFE has been used that incorporates a
high-pass filter (1.6) Hz and buffer, which is differentially amplified by an instrumentation
amplifier (G=1100) before being bandpass filtered. A two stage bandpass filter has been
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used, consisting of a high-pass filter and then a low-pass filter (0.5-40 Hz). This signal
is then acquired either by an external data acquisition system (DAQ) or an internal DAQ
depending on the testing being performed.
3.3.2 ECG Electrode and Body Modeling
One of the largest factors that impact noise and motion artifacts is the electrode interface.
When designing an ECG, understanding how the impedance of the body and the electrode
impact performance allow for a more robust device. The electrode interface and human
body can be electrically simulated and modeled using the electrical properties of the mate-
rials and tissue involved.
The electrode impedance can be modeled for electrical simulation using capacitors and
resistors. Similarly, the signal source and the body/skin can be modeled using capacitors
and resistors. A simplified electrical model of the body and electrode interface for an ECG
is shown in Figure 3.3. The heart dipole is simulated using two voltage sources of opposite
polarity, and the common mode noise is simulated as Vcom.
Understanding the electrode interface and skin impedance is a key part of designing a
successful ECG AFE. When a wet electrode is used (one with conductive gel between
the skin and the metal contact), the overall impedance is low and is dominated by the
skin impedance. When the skin impedance dominates, the dominant element becomes the
resistance and a standard high-impedance instrumentation amplifier can be used.
Often, a dry electrode must be used for certain applications, such as wearable devices. Wet
electrodes can dry up, limiting the potential measurement duration. Additionally, wet elec-
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trodes must be physically placed on a subject’s prepared skin before use. Dry electrodes
do not rely on conductive gel between the skin and metal contact, but have a significantly
larger impedance. The interface is now dominated by the electrode skin/interface. Despite
the high impedance, the interface is still dominated by the resistive component of the in-
terface. The SNR can be further impacted by long lead length, since the high impedance
electrode/skin interface is much more prone to electromagnetic noise pickup and impacts
the common mode rejection of the instrumentation amplifier.
Another option for measuring the ECG is a capacitive electrode. This electrode is insulated
and does not make a resistive connection with the skin. In this case, the electrode is capac-
itively coupled to the body. This results in an interface that is dominated by the capacitive
element. The resulting instrumentation must be capable of amplifying a capacitive sensor
in addition to ensuring the capacitance does not filter out frequencies that are present in the
ECG. Capacitive electrodes are not used in the work presented herein.
When using a dry electrode, active electrode circuitry is needed to buffer the impedance
between the electrode and instrumentation amplifier. It is important to minimize the lead
length between the skin interface and the active electrode amplifier. This increases signal
to noise ratio (SNR) and reduces the amount of electromagnetic noise pickup. An example
active electrode is shown in Figure 3.4. A non-inverting amplifier at unity gain is used to
buffer the impedance. Since there is no amplification, the common mode rejection of the
INA does not suffer due to component mismatch.
The circuity used in the FIT seat contains ESD protection diodes, and a high-pass filter
with a cutoff frequency of 1.6 Hz. The op-amp used is an OPA376 from Texas Instruments,
which has a voltage noise of 75 nV/rtHz at 1 kHz. The V+ is a 3V regulated rail and AGND
is a 1.5V regulated rail. Bypass capacitors are placed in close proximity to the op-amp on
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Figure 3.4: Two active electrode analog front end circuits are used with an instrumentation
amplifier to increase the SNR of dry electrodes (a). The active front-end used in the FIT
seat with associated component values is also shown in (b).
the circuit board. Two matching pairs of active electrode feed into an integrated ECG AFE
from Analog Devices (AD8232).
When using an active electrode, it is important for the metal contact to be as close to the
op-amp as possible. In this FIT seat, this distance is kept to less than 1 cm by directly
soldering the electrode wire to the active ECG instrumentation circuitry. The electrode
wire is connected to the stainless steel electrode using conductive epoxy in the integrated
seat and is welded in the normative seat.
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3.3.3 PPG Instrumentation
In the most basic form, a PPG analog-front-end (AFE) can consist of a phototransistor, a
buffer, a high-pass filter, and low-pass gain stage, as illustrated in Figure 3.5.
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Figure 3.5: A simple PPG AFE built using a phototransistor, a low-pass filter, and an
amplifier.
There are generally two types of sensors that can be used to measure light intensity in the
PPG: photodiodes and phototransistors. For low-power systems, the LED must be pulsed
with a very low duty cycle in order to minimize power consumption. This requires a fast
photosensor that will stabilize quickly so the LED can be turned off sooner. Commercially
available phototransistors do not have a sufficient response time, so for this reason, the
photodiode is used in the FIT seat. The schematic for the normative PPG AFE is shown in
Figure 3.6. For the normative seat, VCC is a 3.3V regulated rail.
The overall power consumption of the PPG is limited by the LED light source, resulting
in the PPG consuming more power compared to other cardiac instrumentation. In order to
reduce the power consumption in portable instrumentation, the light source is pulsed at a
low duty-cycle (¡20%). The signal is then sampled while the LED is on after the analog-
front-end stabilizes. This is a mandatory design choice for any portable pulse oximeter
or PPG. It is for this reason that the simple PPG circuit shown in Figure 3.5 (used in the
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Figure 3.6: The PPG analog-front-end for the normative FIT seat utilizes a photodiode
with a transimpedance amplifier, rather than a phototransistor.
normative system) is not used in portable or battery powered applications.
When pulsing the LED, the resulting waveform can no longer be thought of as a continuous
waveform. As such, it cannot be low-pass or high-pass filtered in the analog domain to
remove ambient light noise at the power line frequency (e.g. 60 Hz) and its harmonics
(e.g. 120 Hz). Since this noise cannot be removed with analog filtering, the signal must
be oversampled to avoid aliasing so that it can removed digitally after sampling. Despite
the increased sample rate, the overall power consumption is still significantly lower when
compared to a non-pulsed design solution, as dictated by the LED duty cycle. Typical
sample rates for the PPG are 240 Hz and 480 Hz [90, 91].
The DC level is removed using active DC cancellation, since an analog high-pass filter
cannot be used. A differential amplifier is used to amplify the difference between the sensor
output and a DC level, which is generated using a digital to analog converter (DAC) and
a microcontroller (MCU). The DC level is calculated using a microcontroller that samples
the output from the photodiode transimpednace amplifier (TIA) before the analog signal is
amplified. A schematic detailing this process is shown in Figure 3.7.
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Figure 3.7: The PPG analog front end utilizes a red and IR LED (only one shown) with a
photodiode amplified with a transismpedance amplifier (TIA) to measure the signal. Since
the LED is pulsed in order to reduce power consumption, the DC offset from the TIA
cannot be removed with a high-pass filter. The DC offset is actively removed by digitally
generating a DC reference for a differential amplifier, calculated using a moving average
of the measured DC values from the output of transimpedance amplifier.
The schematic for the two wavelength custom PPG AFE that is utilized in the FIT seat is
shown in Figure 3.8. Both the red (660 nm) and IR (940 nm) LEDs have variable current
control so that power consumption and SNR can be optimized by the MCU. Both LEDs
utilize the same analog circuitry since only one of them will be on at a time. The output
from a single wide-band photodiode is fed into a transimpedance amplifier (TIA) based
on the OPA2313 with a slew rate of 0.5V/µs; this allows the LEDs to be pulsed for 294 µs
resulting in a duty cycle of 5% for a sample rate of 170 Hz. After the active DC cancellation
using an instrumentation amplifier, the signal undergoes amplification with a total gain of
301 V/V. The output signal is then acquired by an external data acquisition system (DAQ)
for the normative FIT seat or an internal DAQ for the integrated FIT seat.
The main challenge with measuring the PPG on the buttock is that the sensor does not op-
erate in reflective mode nor in transmission mode. The resulting signal quality is greatly
reduced since it is believed the signal measured relies on the scattering of light in the lo-
cal tissue. This has the potential to be inconsistent between subject due to different body
composition and varying sensor locations. When measuring the PPG on the buttock, the
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Figure 3.8: The PPG AFE in the FIT seat has variable power controlled LEDs and ac-
tive DC cancellation. The integrated MCU samples the DC level directly after the tran-
simpedance amplifier, and then calculates the average DC value. This is then used as the
negative input on the instrumentation amplifier to remove the DC level. The high level
concept of this is shown in (a), while the implemented version is shown in (b).
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LED power needs to be much higher since the signal must scatter through the local tissue.
This is especially challenging when the system has a power consumption constraint, since
the LED power cannot be ramped up to the maximum possible intensity. A potential solu-
tion to reducing the PPG power while maintaining high signal quality is to use compressed
sensing and high-speed circuitry.
3.3.4 BCG Instrumentation
The system utilized in the fully integrated toilet seat measures the BCG using force sensors
integrated into four standoffs. The sensors investigated in this work include the A401-
25 FlexiForce piezoresistive sensor, LDT0-028K piezoelectric sensors from Measurement
Specialties, and unmarked strain gauge based load-cells (available from SparkFun Elec-
tronics).
The schematic used for the FlexiForce sensor is shown in Figure 3.9. The FlexiForce sensor
changes resistance based on the force applied. The first stage is an inverting amplifier
where the output is related to the bias voltage across the sensor (-V) and the resistance of
the sensor. The FlexiForce sensor can measure both dynamic and static forces since it is a
piezoresistive sensor. The DC output can be buffered and captured to estimate the DC static
weight of a subject sitting on the seat. The following stage is a high-pass filter that will
remove any low frequency signal including DC weight. The final stage is a non-inverting
amplifier with a built-in low-pass filter for removing high frequency motion and noise.
The piezoelectric sensor cannot measure static forces, but it is significantly more sensitive
to small dynamic changes than the piezoresistive sensor. A piezoelectric sensor can be
thought of as an ideal voltage source with a capacitor in series or as a voltage source with
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Figure 3.9: The AFE for the FlexiForce piezoresistive sensors includes a high-pass filter
and a gain stage. If desired, the DC response can be measured by branching off the sensor
output before the high-pass filter. The high level overview of the schematic is shown in (a)
and the schematic used for the normative system is shown in (b).
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a capacitor in parallel. There are two different circuit configurations that can be used in the
piezoelectric AFE, one that amplifies the voltage across a load resistor, and the other that
directly amplifies the charge across the sensor. The circuit configuration that amplified the
voltage across the load resistor is used in the FIT seat, as shown in Figure 3.10.
Figure 3.10: The PZT instrumentation in the FIT seat consists of a non-inverting gain
stage, followed by a band-pass filter with a bandwidth of 0.34 Hz to 34 Hz. The load
resistor for the PZT must be large to maximum the signal amplitude for low frequencies,
as the PZT sensor has a capacitance of 480 pF. With a load resistor of 100 megaohm, the
cutoff frequency is 3.3 Hz.
Due to the shortcomings of the PRT and PZT sensors, as discussed in Chapter 7, a third
design is proposed utilizing a load-cell. A load-cell is commonly found in bathroom scales
and provides very accurate and repeatable static weight measurements with a very high
repeatability. The load-cell output is amplified using an instrumentation amplifier in a half
bridge configuration, where each load-cell contains two complementary sensing elements.
The BCG signal is very small compared to the static weight on the sensor, so the INA827
was chosen as the instrumentation amplifier. It has a very low noise of 17 nV/
√
Hz, a
common mode rejection ratio (CMRR) of 88 dB, and power supply rejection ratio (PSRR)
of 100 dB. After the INA bridge amplifier with a gain of 5V/V, the DC component of the
signal is removed using a high-pass filter with a cutoff of 0.33 Hz for further amplification
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and filtering of the BCG. The BCG is then amplified by 47 V/V and low-pass filtered at 16
Hz. The schematic used in the FIT seat is shown in Figure 3.11.
Figure 3.11: The load-cell instrumentation in the FIT seat consists of an instrumentation
amplifier in a half-bridge configuration, followed by a band-pass filter. A potentiometer
is placed between the fixed resistors in order to compensate for the variation between ele-
ments within the load-cell.
The magnitude of the BCG is typically between 3-5 N, which corresponds to approximately
1/1000th of a subject’s total weight. Since the BCG sensors must be sensitive enough to
measure this small signal, any motion including respiration, hand movement, and changing
posture are sources of noise that are often one or more orders of magnitude greater than the
BCG signal, causing the instrumentation to saturate.
3.4 Weight and BCG Mechanical Systems
The toilet seat rests on four standoffs and a floating hinge. A single BCG and a single
weight sensor are integrated into each standoff. This allows the BCG and weight to be
measured independently for each standoff, resulting in more robust post-processing of the
signals. This post processing is needed since the user’s posture will not be consistent
between measurements or even between moment to moment. The BCG and weight sensor
configuration used for each prototype are discussed in more detail in the Section 3.6.
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In order to ensure that no load is being carried by the hinge, a floating hinge design is
utilized. If part of the load was being carried by the hinge, the exact percentage of the total
load on the hinge would be unknown, reducing the accuracy of the body weight estimates
and accuracy of the BCG amplitude. Furthermore, the BCG force is propagated downward
through the torso, so the rear two standoffs on the seat will contain the largest BCG signal.
If the hinge was bearing part of the load, this would significantly reduce the BCG signal on
the rear two standoffs.
Figure 3.12: The floating hinge has an elongated slot that allows the entire seat to move
vertically, but not horizontally. Courtesy of Think Design.
An exploded view of the floating hinge design is showed in Figure 3.12. The floating hinge
is designed so that the seat can move up and down vertically, but has no movement in the
horizontal direction. This is so that the subject does not feel any movement in the seat
when sitting down. Any unusual movement in the seat could reduce patient compliance
and acceptance of the FIT seat. This ensures that no load will be present on the hinges
when the subject sits on the seat.
Another important part of the seat mechanics is the standoff design. The standoffs must
be designed so that all of the load it is bearing is translated to the sensor fixture. Due to
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the application, the standoffs must allow translation of the force to the sensors while being
completely sealed and cleanable. The seat needs to be both waterproof and resistant to
cleaning chemicals. The initial design for the standoffs when a FlexiForce sensor is used
for both the weight and BCG, is shown in Figure 3.13.
Figure 3.13: The first standoff was designed for use with the FlexiForce sensor. This is a
simple mechanical design that transfers all of the force onto the sensor. Courtesy of Think
Design
Piezoresistive sensors are built into each standoff for measuring both the BCG and es-
timated body weight. In order to test and compare the piezoelectric sensors to the Flexi-
Force sensors, the peizoelectric sensors were added to the normative toilet. They are placed
between the standoff and toilet, and are being utilized in compression mode in a custom
housing. This results in a total of eight BCG channels that are being captured for each
subject.
In the integrated system, rather than using a single piezoresistive sensor to measure the
weight and BCG signal, a piezoelectric sensor is used in combination with a load-cell.
This requires specialized mechanical coupling that allows the entire force present on the
standoff to be translated to both sensors. The internal system that allows this is shown in
Figure 3.14, where an insert is used to both support the load-cell and translate the force
onto two piezoelectric sensors. Both sensors are connected in parallel and amplified using
the same circuitry used with a single sensor (Figure 3.10). This is shown in more detail in
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Figure 3.15, which is a rendering illustrating how the force is applied from the standoff,
through the load-cell, onto the piezoelectric sensors.
Figure 3.14: The metal load-cell makes direct contact with the standoff. The insert which
supports the load-cell then translates the downward force onto the piezoelectric sensors.
This image was taken from a bottom view.
Additionally, the standoffs have been redesigned in high-density polyethylene (HDPE) us-
ing a press fit design that does not require caulking or adhesive to ensure a water tight seal.
The system is also very flexible and consists of a single part, compared the the norma-
tive system assembly that contained many different pieces. An exploded view of the new
standoff system is shown in Figure 3.16. This advancement is key to improving the signal
quality of the BCG, as more of the force is transferred directly to the sensor.
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Figure 3.15: A side cutout rendering, illustrating how force is transformed from the stand-
off through the load-cell to each piezoelectric sensor (one shown as the other has been cut
away for rendering). The plastic insert insures that the force is only applied to the sensor,
rather than through the internal structure of the seat. Image courtesy of Think Design.
Figure 3.16: The updated standoff design for the in-hospital version of the FIT seat utilizes
a single flexible piece that is press fit into place. The seat is water tight and does not dampen
the BCG signal, as was the case with the normative standoff system. Courtesy of Think
Design.
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3.5 Hardware and Sensor Validation
3.5.1 Blood Oxygenation Testing
The reference SpO2 is plotted against the FIT seat R-value for two subjects with different
body types in Figure 3.17. The slope of each R-curve varies by approximately 10% between
subjects. The slope is also in agreement with one found in literature with a slope of -33.3
using similar wavelengths [92]. While the variation in slopes is relatively small, the R-
value intercept that corresponds to 100% SpO2 had a large variation, requiring that a single
point calibration per subject be made.
Using a single point calibration, the worst case error for subject 2 (using an averaged R-
curve slope) is 1% for every 10% deviation from the calibration point. As an example,
a value of 91% could be reported for a true value of 90%, and 82% for a true value of
80% if the calibration point was taken at 100% SpO2. If the single point calibration is
not performed and instead the average R-value curve between both subjects is used, then
subject 2 would report 94% for a true value of 90%, and 86% for a true value of 80%. This
error is too high for practical use, leading to the conclusion that a single point calibration
per subject is necessary.
Commercial pulse oximeters do not require a calibration per subject, but also have the ad-
vantage of measuring on the finger or ear where there is less tissue variability between
subjects. There are two possible explanations for FIT seat variation between subjects: the
FIT seat’s PPG design or the choice of measurement location. To determine the under-
lying cause of this variation, FIT seat R-values from the finger and buttock are captured
from three subjects. The R-values obtained from the seated thigh test had large variability
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Figure 3.17: The R-curves for two subjects on the FIT seat is shown. Both slopes are
in close agreement with literature, however the offset is different enough to require a per-
subject single point calibration.
between subjects as expected, but the finger test results fell within a very narrow range
of values for all subjects. These results are shown in Table 3.1. This indicates that the
need for a per-subject calibration is due to measurement location and not the FIT seat pulse
oximeter design. It may be possible to derive this calibration from the subject’s body mass
or weight, which will be investigated in future work.
Subject 1 Subject 2 Subject 3
Buttock 0.58 0.73 0.86
Finger 0.90 0.92 0.93
Table 3.1: Finger R-values compared to the buttock R-values between three healthy sub-
jects, all at an SpO2 of 99%, showing very a small variation in finger R-values relative to
buttock R-values between subjects.
Due to the need for a single point calibration per subject, SpO2 cannot be verified using the
data gathered from normative testing. Additionally, all normative subjects were healthy and
as such, have very stable SpO2 percentages across the entire duration of the normative test.
This results in a single SpO2 point per subject, making it only useful for calibration, not
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verification. No additional SpO2 results will be presented. Despite this, the presented re-
sults indicate that the FIT seat is capable of measuring a subject’s SpO2 using a reflectance
mode pulse oximeter, positioned to make contact with the upper thigh.
3.5.2 Weight and BCG Amplitude Calibration
Methods
In the normative FIT seat, four piezoresistive sensors are used to measure both the BCG
and static weight. FlexiForce sensors, which are a film based force sensor, were chosen
due to mechanical simplicity. A custom test fixture was created to perform accurate static
and dynamic force calibration of the FlexiForce sensors. The test fixture used is shown
in Figure 3.18 and Figure 3.19, where a static load can be applied simultaneously with a
small AC force using standard weights (static) and a custom built solenoid (dynamic). The
entire test fixture was placed inside of an electrical and mechanical isolation table for the
entire calibration process. The current to force relationship for the custom solenoid was
determined using a high-precision force sensor from Futek (LRF400).
The dynamic weight sensitivity at different static loads was determined by performing 4
trials, where each trial consisted of a test at each of 4 static weights: 3.5 lb, 14 lb, 26.5 lb,
and 39 lb. The sensitivity in mV/N was recorded for each test and 5 tests were performed
at each static weight, alternating 3.5 lb, 26.5 lb, and 51.5 lb tests, for a total of 15 tests.
The dynamic sensitivity of each test is then plotted in a scatter plot to determine linearity
and conversion factor for weight. Similarly, the FlexiForce sensors were excited with small
amplitude AC forces in the frequency range from 1-10 Hz and amplitudes of 0.5-1 N to
approximate the ballistic forces of the heart. The sensors were tested to determine the
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Figure 3.18: Image of test fixture used for calibration, while the solenoid current was
calibrated to force using high-precision Futek LRF400 1lb force sensor.
Figure 3.19: Test fixture for exerting force on the FlexiForce sensor and to keep it at a
consistent location throughout testing.
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dominant sources of error, and to provide a calibration to convert from the sensor voltage
output to units of force.
Results and Discussion
The static weight sensitivity was determined by performing 4 trials, where each trial con-
sisted of a test at each of 4 static weights: 3.5 lb, 14 lb, 26.5 lb, and 39 lb. The average
magnitude of the static weight sensitivity for the FlexiForce sensor is shown in Figure 3.20.
The results indicate that the sensor’s sensitivity to dynamic forces are not dependent on the
static weight.
Figure 3.20: Static weight sensitivity for the FlexiForce sensor across multiple trials
demonstrates that the static weight present on the sensor does not impact the amplitude
of the measured dynamic force.
The transfer function found theoretically from analysis of the FlexiForce sensor circuit
accurately matches that measured by the test setup, as shown in Figure 3.21. The theoretical
transfer function is calculated for each stage: the front end (assuming no capacitance for
the PRT), the high-pass filter, and the amplification stage. Using the maximum gain in the
passband, the output voltage can be converted accurately to newtons by multiplying the
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output by the constant 690 N/V. By converting the BCG to newtons, accurate comparisons
can be made between subjects and between different versions of the FIT seat. Furthermore,
amplitude comparisons between subjects can now be made with confidence.
Figure 3.21: The measured (actual) verses theoretical transfer functions for the Flexiforce
sensor for small dynamic forces are closely aligned, with a small phase error across the
range of tested frequencies.
3.6 FIT Seat Versions
While the final version of the FIT seat is capable of in-home deployment for long periods
of time, earlier version of the seat brought the design from proof-of-concept to the final
in-home version. The first prototype functioned as a proof of concept, verifying that the
ECG, PPG, and BCG can be measured from an individual while seated on a toilet. The first
completed system was the normative system, which was used for normative subject testing.
Both the in-hospital and in-home systems are completely integrated and are self-contained.
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The in-hospital system was used for heart failure testing, while the in-home system is the
final design that could be used for in-home deployment. Table 3.2 details the purpose,
capabilities, and key improvements for each design. Each of these systems are discussed
in detail throughout this chapter.
System Name Description Improvements
Proof of Concept Demonstrate feasibility of measur-
ing signals on the buttocks. Out-
puts analog bECG, bPPG, and BCG
waveforms simultaneously.
N/A
Normative System Used for normative subject testing.
Outputs the bECG, bPPG, and BCG
waveforms in addition to tempera-
ture, and weight. DAQ is performed
using an NI DAQ.
Significant signal quality
improvements as well as
the first system integrated
into a toilet seat.
In-Hospital System Used for in-hospital testing with HF
subjects. Self-contained system for
interfacing directly with a PC via
USB.
Battery powered, with in-
tegrated DAQ capabilities,
and further instrumenta-
tion signal quality im-
provements.
In-Home System Used to acquire daily cardiac mea-
surements in the home for an ex-
tended period of time. Self-
contained system with long battery
life that wirelessly interfaces with
an Android device.
Added BLE, on-board data
storage, automatic record-
ings, battery life improve-
ments, as well as a load-
cell BCG and increased
ECG gain..
Table 3.2: Iteration Overview
3.6.1 Proof of Concept Seat
The first prototype was considered a proof of concept. This version of the seat was used to
demonstrate the feasibility of measuring the ECG and PPG on the buttocks. The prototype
consisted of a machined MDF toilet seat purchased at a local hardware store, as seen in
Figure 3.22. Slots were milled out for active ECG electrodes and a PPG PCB. The hinge
59
of the seat was removed for testing so that it did not bear any load, and the standoffs were
used as is. The force sensors were placed underneath the standoffs on the actual toilet in
order to verify that the BCG can be measured when in a seating position. The ECG, PPG,
and BCG signals were acquired using the Biopac MP150 data acquisition system.
Figure 3.22: The first proof of concept FIT seat was created from a machined MDF seat
that was purchased from a local hardware store. The ECG and PPG were placed on the
surface of the seat for testing.
Multiple slots were milled so that different locations for the PPG and ECG could be tested.
The dry, active ECG electrodes were integrated into the circuit board using the schematic
shown in Figure 3.4. The electrode is an exposed copper pad that makes contact with the
subject. The PPG tested at this stage contained only a single wavelength, which was 940 nm
(IR) and utilizes the schematic shown in Figure 3.5. The FlexiForce sensor instrumentation
(Figure 3.9) was built up on a breadboard that sat inside of the toilet, as shown in Figure
3.22.
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3.6.2 FIT Seat for Normative Study
The second prototype was designed for the normative subject testing that took place at
the Rochester Institute of Technology. Normative subject testing is described in Chapter
5. This version of the seat was machined from a solid piece of high-density polyethylene
(HDPE). The normative seat is battery powered using a rechargeable lithium battery, which
is regulated to a 3.3V output. The ECG electrodes are built into the seat, as is a window
for the PPG sensors and the IR temperature sensor. The floating hinge and standoffs are
both used in this prototype. The signal are all acquired via a National Instruments DAQ,
resulting in a large number of wires between each instrument and the DAQ system. This
system is not suitable for in-home testing. Channels were machined on the bottom of the
seat for the wiring. A rendering of this seat can be seen in Figure 3.23 and pictures of the
actual seat can be seen in Figure 3.24.
The PPG consists of two completely separate channels, red and infrared. In order to remove
the need for an embedded system in this prototype, both the red and IR LEDs were left on
continually and optical filters were used to separate out the two channels. Each wavelength
is then able to be measured using two parallel sets of instrumentation. The circuit board
with four LEDs (two for each wavelength), the photodiode, and associated instrumentation
is shown in Figure 3.25
The buttocks based ECG (bECG) is integrated into an elongated toilet seat with dry elec-
trodes on the surface and electronic instrumentation inside of the seat, as shown in Figure
3.26. Three electrodes, differential pair and right leg reference (grounded), each with a
diameter of 28 mm. Stainless steel electrodes are chosen for their non-corrosive, and non-
irritant properties. The differential electrode pair is placed on the seat such that skin contact
is made in close proximity to the gluteal fold when seated. A grounded right leg electrode
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Figure 3.23: The CAD rendering of the normative FIT seat shows where each sensor is
located on the seat as well as the standoffs and hinges.
is placed approximately 12 cm below the differential pair on the right side of the toilet seat,
as illustrated in Figure 3.26. Each electrode is securely fixed to the toilet seat using epoxy
to ensure repeatability across recordings.
Active front-end instrumentation is integrated inside of the seat and connected to each the
differential stainless steel electrodes with welded wires, resulting in a maximum distance of
10 mm between the electrode and the front-end instrumentation. The active electrodes are
powered by a 3.3V boost converter, which in turn is powered by a 3.7V (nominal voltage)
rechargeable lithium polymer battery. The active electrodes also contain ESD protection
and a high-pass filter with a -3dB cutoff frequency of 0.16 Hz that removes any DC bias
present on the body, ensuring that the signal is within the valid input voltage range. The
output from each active electrode is differentially amplified using the ECG instrumentation
(ECG100C) within a Biopac MP150 system (Biopack Systems, Inc., Goleta, CA), which
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Figure 3.24: Picture of the seat used for normative testing is shown. The top view is on
the left, the bottom view is in the center, and the sealed up bottom is on the right.
Figure 3.25: The circuit board used for the normative PPG contains four LEDs (two for
each wavelength), and two sets of photodiodes with matching instrumentation. The photo-
diode and LEDs for each wavelength is shown in a red and blue box. The analog signal is
then amplified and filtered further on a main PCB (not shown).
is also used to gather a 12-lead gold standard ECG. All signals are then acquired using an
NI CompactRIO Data Acquisition System (DAQ), which is controlled by a laptop. The
toilet seat with integrated electrodes and active ECG front-end instrumentation is secured
to an elongated toilet mounted to the floor. A schematic overview of the system is shown
in Figure 3.26. All devices that are not battery powered are plugged into a medical grade
isolation transformer (ILC-1400MED4) to ensure electrical safety.
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Biopac ECG
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NI DAQ
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Figure 3.26: Stainless steel electrodes are integrated into the seat and are connected
directly to the integrated ECG analog-front-end. The output of each front-end is low
impedance, allowing for a low noise connection to the differential ECG amplifier inside
of the Biopac MP150 system. The resulting full-scale ECG signal is acquired on a NI
DAQ.
3.6.3 In-Hospital Heart Failure FIT Seat
The third prototype was used for the in-hospital testing, and is considered the first integrated
version of the seat. It is be powered by a high density primary lithium battery and performs
all data acquisition on-board. The seat incorporates a synchronization signal output that
will allow the data captured on the seat to be synchronized to the commercial medical
instrumentation. While wireless capabilities were built into the hardware, all in-hospital
heart failure subject data is acquired via a USB connection.
The block diagram for the integrated system is broken into two separate sections, a digital
block that is shown in Figure 3.27 and an analog block that is shown in Figure 3.28. This
organization mirrors the physically assembled seat, which has physical separation between
the digital PCB and the analog PCB in order to facilitate isolation. An image of the in-
hospital seat is shown in Figure 3.29. The final system is completely self contained, and is
easily made waterproof with silicon caulk.
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Figure 3.27: The digital side of the integrated system is shown in this block diagram. This
system consists of the digital control circuitry, wireless BLE module, flash memory, and an
accelerometer.
The analog block consists of the instrumentation and data acquisition circuitry. The ECG
instrumentation utilizes an ECG AFE from Analog Devices, the AD8232. The right leg
electrode is configurable for either a ground electrode or a driven right leg. The PPG
consists of a single photodiode and AFE with configurable LEDs. The current for the red
and IR LEDs will be software configurable, allowing for variable intensities. The BCG
will be measured using a two piezoelectric sensors under each standoff (LDT0-028K from
Measurement Specialties), and the static weight will be measured using a separate load-cell
(similar to what is found in a bathroom scale). The ECG, PPG, and weight from unmarked
load-cells from SparkFun Electronics are acquired using the analog MCU’s built in 12-bit
ADC (MSP430FR5969). The BCG is acquired using a separate 24-bit precision ADS1220
from Texas Instruments. This allows the BCG to have a higher dynamic range, making it
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Figure 3.28: The analog side of the integrated system is shown in this block diagram. This
side of the system consists of the data acquisition circuitry, the PPG instrumentation and
the ECG instrumentation.
more robust to subject induced motion artifacts and ambient motion artifacts.
The major changes in instrumentation in the integrated system compared to the normative
system include the PPG circuitry and the standoffs. The standoff mechanical design has
been discussed previously in this chapter.
The PPG in this seat utilizes a pulsed LED based system with active DC cancellation,
requiring a dedicated embedded control system. An MSP430 MCU is used to control the
LED and sample the output from the AFE circuit. When a sample must be captured, the
MCU first turns on the desired LED (red or IR), waits for the AFE to stabilize (which is
approximately 300 µs based on the instrumentation chosen), then it initiates the ADC for
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Figure 3.29: The in-hospital integrated version of the FIT seat is self-contained with all
electronics and sensors inside of the seat. The seat is cleanable and the surface has no
rough edges or crevices. Images of a completed seat and the 3D CAD renderings are
shown (courtesy of Think Design).
sampling the signal. Once the signal has been sampled, the LED is turned off. The overall
duty cycle of the LED is approximately 5 % when a sample rate of 256 Hz is used. This
significantly reduces the power consumption of the PPG AFE, and thus the entire system.
The PPG window, which consists of four LEDs (two red and two IR) and a photodiode is
shown in Figure 3.30.
Due to the measurement location of the bPPG, the scattered signal has much less intensity
than if the sensor were operating in pure reflectance mode. The reduction in signal intensity
is approximately 100 fold compared to using the same sensor on the finger. A typical ADC
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Figure 3.30: The PPG window allows light to enter the body from two out of the four
LEDs depending on which wavelength is currently active. The window also allows the
reflected/scattered light to be sensed by the photodiode at the center.
is not capable of measuring the DC offset on the output of the transimpedance amplifier, so
the output of the 16-bit DAC used for DC compensation is used as the gold-standard. The
signal is then amplified with a gain of 301 V/V before being digitized in order to maximize
signal to noise ratio (SNR). In order to measure SpO2, both DC and AC amplitude infor-
mation is required. The DC output of the DAC is multiplied by 301 and then added to the
AC signal acquired from the ADC in order to create an accurate measure of intensity.
3.6.4 FIT Seat for In-Home
The fourth and final prototype will be used for future studies, including the 6 month in-
home testing for normative and heart failure subjects. It is very similar to the integrated
system (third prototype), but will contain separate firmware which does not have USB
connectivity and increases the power efficiency of the system. The main functional dif-
ference is that the device is be completely wireless and automatically detect use using an
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accelerometer and load-cells. Once the systems determines that an individual is using the
seat, it automatically starts acquiring the desired signals until the subject stands up and
weight is removed from the seat. All of the data captured is sent to an Android or Rasp-
berry Pi base station via an on-board Bluetooth Low Energy (BLE) radio, which will in
turn, transmit the data to a secure server.
The digital circuitry is in an always on state and handles all communication and data trans-
fer. It contains an on-board flash module for storing recordings and an accelerometer that
allows motion wake-up of the entire system if desired. Additionally, the digital circuitry
sends out a synchronization pulse to the Biopac system every second to allow for both
systems to be synchronized post-acquisition. The data captured on each FIT seat will ulti-
mately be stored on a secure server, regardless of the acquisition method. The secure server
is accessible to a number of devices and software tools, including Python and MATLAB.
A schematic overview of this data flow is shown in Figure 3.31.
FIT Seat
Android App
Lockdown Mode
End-User Mode
Super-User Mode
Secure Server
Database
Algorithms
Web App
FIT Seat Android App
FIT Seat Android App
FIT Seat Android App
Upload Data
Download for 
Visualization
Transmit Data
Research Computer
Research Computer
Research Computer
Research Computer
MATLAB
Python
Java
Complete Access
Figure 3.31: Many devices will have the access to access the FIT data from the secure
server. The FIT seat will transmit this data to the secure server via an Android device.
Based on the most recent integrated system design and firmware, the overall data rate for
the FIT seat is 4614 bytes per second (bps). The channels are shown in Table 3.6.4.
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Channels Sample Rate Bit Resolution Bytes/Second
bECG 1 512 Hz 12-bit 1024 bps
bPPG 2 128 Hz 24-bit 768 bps
PZT BCG 4 128 Hz 24-bit 1536 bps
LC BCG 4 128 Hz 12-bit 1024 bps
Weight 4 32 Hz 12-bit 256 bps
Temperature 3 1 Hz 14-bit 6 bps
Total 18 - - 4614
Table 3.3: The total data generated by the 18 data channels in the FIT seat is 4614 bytes per
second. This does not include any data captured on external commercial medical devices
such as the Biopac system.
Assuming approximately 10 minutes of use a day on the FIT seat, the total data generated
per day per FIT seat is 5.5 MB. Throughout the duration of a six month in-home trial,
subjects will generate approximately 0.5 GB of raw, unprocessed, data. Given an expected
usage of 10 minutes per day, the battery life of the in-home system can be estimated. There
are essentially two different operating states for the FIT seat, sleep mode and recording
mode. The FIT seat will spend most of the time in sleep mode since it is expected that the
seat will be in use for less than 10 minutes a day on average. In this mode, the FIT seat will
need to be able to communicate with the base station as well as automatically recognize
when a user sits down (which will put the seat in recording mode). To achieve the lowest
possible sleep mode power consumption, FRAM based MCUs have been used in addition
to the best in class ultra-low power accelerometer and Bluetooth Low Energy.
The FRAM based MSP430 (MSP430FR5969) from Texas Instruments consumes 0.5 µA in
sleep mode with real-time clock (RTC) [93]. The ADXL362 accelerometer from Analog
Devices consumes 0.27 µA in sleep mode with motion wake-up [94]. The BLE113 mod-
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ule from Bluegiga utilizes Texas Instruments ultra-low power radio CC2541. The power
consumption of this device with advertisement and in sleep mode is approximately 0.9 µA
[95]. This results in a theoretical power consumption limit of approximately 1.7 µA in
shut-down mode. This has been verified with direct measurements, where the entire sys-
tem sleep current is 1.85 µA. To achieve this theoretical limit, the rest of the circuitry in the
device is completely shut down or placed in a low-power deep sleep mode when available.
This is made possible through a modular circuit design with a highly customized embedded
system that can turn on and off different blocks as needed.
The second main contributor to the overall power consumption of the system is the ana-
log electronics and data acquisition circuitry during the recording mode. Using ultra-low
power operational amplifiers (OPA) and instrumentation amplifiers, the expected quiescent
current will be less than 1 mA. This estimate assumes 14 OPA channels that utilize 50 µA
each (OPA2313) and 5 INAs that utilize 40 uA each (INA2321) [96, 97]. Due to the low
quiescent current of the analog circuitry, required to run the PPG LEDs will dominate dur-
ing the recording mode. If the LEDs require a current of 150 mA when on and they are
pulsed at a duty cycle of 5%, the resulting an average power consumption is 7.5 mA per
wavelength.
The overall system power consumption is estimated in Table 3.4. This table takes into ac-
count the sleep current and the recording current for each of the main components. The
efficiency of the voltage regulators are not taken into account in order to simplify the esti-
mate. Assuming that the seat will be in use for 10 minutes a day, the overall daily average
power consumption is 1.55 mW. The integrated seat has been designed to hold a 3000 mAh
primary lithium battery with a nominal voltage of 3 V. Without using compressed sensing
for the PPG, this would result approximately 242 days, or 7.9 months of theoretical battery
life.
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Active Sleep Daily
Power Management %/Day Average Power Average Percent
Power 0.18 mW 2.77% 4.9 µW 0.43 µW 5.35 µW 0.34%
BLE112 10.5 mW 5.55% 0.58 mW 2.55 µW 0.59 mW 37.76%
MSP430FR5969 0.42 mW 1.39% 5.8 µW 0.74 µW 6.57 µW 0.42%
ADXL362 6.3 µW 1.39% 0.087 µW 0.79 µW 0.89 µW 0.06%
AT45DB641E 14.7 mW 0.24% 35.9 µW 0.3 µW 36.2 µW 2.33%
Analog 66.0 mW 1.39% 0.92 mW 0 mW 0.92 mW 59.08%
Table 3.4: Estimated Integrated System Power
A deployed FIT seat has many use-cases, allowing different individuals access to data in
the cloud. In addition to the subject being able to access their data through a custom built
Android app, doctors can theoretically have direct access to the subject’s data either via
a web app or a similar Android app. Furthermore, researchers can access the data using
MATLAB or Python for advanced analytics. This can lead to cloud based analysis where
the subject, their physicians, and their family can be warned of a decline in cardiac health
using only automated algorithms. This will allow for subject intervention, reducing the
likelihood of hospitalization and cardiac events such as sudden cardiac death and heart
attacks despite having a large number of deployed devices. There are many use cases that
become feasible given this design.
3.7 Use-Cases and User Adoption
There are four main use cases for the FIT seat. The first is with managing cardiovascular
disease for individuals that have already been diagnosed (e.g., with heart failure). The seat
can be used to reduce the number of yearly doctor visits while also providing an early
warning system for changes that could be detrimental to ones health. A similar use case is
for those who have a family history of cardiovascular disease. The seat can then be used
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for determining the current risk of cardiovascular disease. It can also be used to prevent
or provide warning of unexpected cardiac events, such as a heart attack or sudden cardiac
death.
The third potential use case for the FIT seat is for the monitoring of the elderly, such as
one’s parents or grandparents. In this case, the measurements from the FIT seat can be used
to determine if medication is being taken, monitor weight gain or loss, and monitor cardiac
function over time. Finally, the last presented use case is for parents interested in moni-
toring their young children or children interested in monitoring their elderly parents. This
unexpected use case was discovered during the ethnographic in-home interviews. Many
parents were interested in automatically monitoring their children’s weight and stress lev-
els (through HRV). A schematic overview of many of these use cases, and the types of
individuals a subject would like to have access to their data is shown in Figure 3.32.
Figure 3.32: The cardiac data captured from the FIT seat can be used by individuals to
self monitor their cardiac health, physicians to monitor patients, and even used by family
members to monitor their loved ones.
This system has the potential to change how a consumer’s cardiac health is monitored.
The use of the BCG provides novel insights into cardiac function that were previously not
available without the use of an ultrasound machine, requiring a visit to the doctors office or
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hospital. In comparison to the new wave of wearable medical devices that only use ECG
or PPG to monitor ones HR and HRV, this system contains a multitude of sensors than can
be used in combination to provide a large breadth of measurements. Additionally, the FIT
seat is used while a subject is sitting down and stationary, compare to a wearable device
that is prone to motion artifacts when worn on the wrist
The major obstacle for realizing the full utility of this device will be user adoption. This
was specifically invested during the early stages of the project through in-home interviews
with 22 individuals. Through the use of a professional ethnographer from Storyline, user
adoption of this technology was gauged. Three key criteria for this study are outlined
below.
There are 16 quotes that highlight the results from this market research:
1. “I think the benefits of it may be bigger than they expect.”
2. “Right now, I don’t need [the FIT], but it’s nice to know that you could go out and
get one if you had to.”
3. “They’re my parents and I don’t want them to die.”
4. “This is definitely a unique concept for remote patient monitoring.”
5. “[It] just seems so radical.”
6. “There’s not one person in the world who doesn’t sit on a toilet.”
7. “I would like to track and make sure I’m still healthy all the time. Make sure I’m
healthy and not dying slowly.”
8. “It should just know when my behind sits on it.”
9. “If the doctors buy in and see value to it, then they’re going to have a lot more
influence.”
10. “Whatever it is, catch it early.”
11. “I might not have to go to the doctor’s every three months.”
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12. “Who cares if someone knows your blood pressure?”
13. “I just don’t want people feeling weird . . . wondering ’what is that?’”
14. “What are these lines? You ain’t clean your toilet seat?”
15. “They need to think outside of what they’re sold on; which is the butt.”
16. “When do they come out? Can I be the first to know?”
These results highlight some of the key challenges, necessary features, and potential pitfalls
of this seat from a user-adoption standpoint. Generally, the device was well accepted by
individuals. Both privacy and how inconspicuous the device is are the most important issues
that must be overcome. Furthermore, user adoption will be much greater if physicians
support the device and can aid in the monitoring of an individuals health.
3.8 Conclusion
The presented fully integrated toilet seat for cardiovascular monitoring is the first self-
contained, deployable device that can measure ECG, BCG, and PPG waveforms from a
subject in his or her home. The final version of the FIT seat is waterproof, cleanable, self-
contained, and easy to install. It requires no subject interaction when taking measurements,
allowing the system to be easily integrated into one’s habits. The FIT seat shows promise
within the health-care industry and within the consumer market.
The FIT seat will be verified using two rounds of human subject testing, with both norma-
tive and heart failure patients. While in-home studies are not presented herein, the FIT seat
will be used for future studies both in the home, in the lab setting, and in the hospital. This
work paves the way for future studies by creating a robust tool for medical data acquisition
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in the home, leading to innovations in biomedical signal processing, medical trend studies,
and personalized, preventative cardiology.
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Chapter 4
Algorithms and Signal processing
4.1 Introduction
Advanced algorithms are integral to the success of the FIT seat due to the non-standard
location on the body and the type of sensors utilized. Many custom algorithms were de-
veloped for use with the FIT seat, focusing on signal quality algorithms and best-in-class
feature delineation algorithms. Additionally, this chapter details the verification of the
present algorithms independent of the FIT seat, in order to ensure that no bias is introduced
when using these algorithms to verify the data captured from the FIT seat. These automated
algorithms are required for the adoption of the FIT seat, since the amount of data acquired
is well beyond what can be manually analyzed by trained experts.
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4.2 Automated Analysis Overview
Parameters are extracted from the FIT seat data in a similar process for all studies. The
extracted parameters are then analyzed as needed for each study. Analysis starts by defining
all of the recordings that need to be processed by specifying restrictions for querying data in
the secure database. Analysis parameters include a list of recordings to analyze and signal
and channel specific parameters, such as which channel will be used as a gold-standard and
which channels should be analyzed. All channels are then scaled as needed to convert the
normalized voltage signals to the correct units, such as newtons (N) for BCG.
The first step in analysis is the most critical: signal quality classification. Since the data
acquired from the FIT seat is not always acquired in a controlled environment, poor quality
sections of the signal need to be rejected. This ensures that noise and other artifacts do not
impact the extraction of important medical parameters, which could have a detrimental ef-
fect on the conclusions drawn from the recordings. Regions within the captured waveforms
that are not of sufficient quality are not analyzed.
The beats within the remaining regions are then delineated using signal specific feature
delineation algorithms. The most prominent feature captured by the FIT seat is the R-peak
in the bECG. The R-peak is subsequently used by many of the other channels as a robust
reference point. Beat-by-beat measurements, such as HR and HRV are calculated from the
beat delineation.
Before ensemble averaging, each beat undergoes a second set of signal quality checks,
where poor quality beats are not included in the ensemble average. After the ensemble
averaged waveform is generated (Section 4.8), intra-beat features are delineated (e.g., T-
wave) and intra-beat timing intervals and amplitude parameters are extracted (e.g., QRS
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Figure 4.1: Analysis of all FIT seat data undergoes a similar process. After specifying
which recordings will be analyzed, signal quality is used to reject sections of poor quality
waveforms. Beats are then delineated, which are used to generate ensemble averaged beats.
duration). After each waveform is analyzed, multi-signal measurements are calculated
(e.g., pulse transit time). An overview of this process is shown in Figure 4.1.
4.3 Signal Quality
4.3.1 ECG
Rejecting regions of poor signal quality is necessary for accurately analyzing the bECG
as it is more prone to noise and motion artifacts than traditional ECG systems. Custom
algorithms were developed to automatically assess signal quality and reject noisy waveform
segments using two signal quality indices (SQIs): one based on the kurtosis and a second
that performs spike detection. The kurtosis is a statistic measure that is commonly used to
determine ECG signal quality [98, 99, 100]. The kurtosis is defined as the fourth moment
79
about the mean (µ4), divided by the standard deviation to the fourth power (σ4), as shown in
(4.1). The kurtosis measures the “tailedness” of a distribution, where a normal distribution
has a kurtosis of three. When the kurtosis is lower than three, the distribution under test
has longer tails than a normal distribution. Typically, the kurtosis is calculated across a
large window of at least 10 seconds and is used to locate large motion artifacts or excessive
baseline wander [98]. A clean, sinus rhythm ECG with no motion artifacts nor baseline
wander has a kurtosis greater than five [101].
Kurt[X ] =
µ4
σ4
=
E[(X−µ)4]
(E[(X−µ)2])2 (4.1)
To identify waveform segments with excessive in-band noise, a small moving window of
2 seconds is used herein to calculate the kurtosis from a bandpass filtered ECG in order to
isolate the QRS complex, with a filter bandwidth of 5-15 Hz. By using a smaller window,
the kurtosis measure is no longer dominated by episodic large motion artifact or baseline
wander. A kurtosis threshold of 3.6 was empirically chosen for this work based on the
normative subject data. A separate, more stringent threshold of 5 was used when gener-
ating ensemble averaged beats (Section 4.8). An example of the resulting kurtosis value
compared to the threshold of 3.6 for a typical waveform is shown in Figure 4.2.
Large amplitude spikes due to motion artifacts are detected using a second stage SQI.
Spikes are identified as an increase in the moving standard deviation, which is calculated
using a 2 second window. A threshold of 1.5 times the standard deviation of the entire
signal was empirically determined to provide robust rejection of noisy spikes. Figure 4.2
shows an example of the resulting SQI and threshold.
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Figure 4.2: Signal quality is calculated using a moving kurtosis and standard deviation.
The first signal quality index rejects regions with in-band noise that have a kurtosis below a
threshold of 3.6 and the second rejects noisy spikes that have a moving standard deviation
greater than 1.25 times the overall standard deviation. R-peak delineations are shown to
indicate where each beat is located within regions that have passed the signal quality test.
4.3.2 BCG and PPG
Unlike the ECG R-wave, the BCG and PPG do not have a feature that is clearly defined
with a distinct shape. The PPG signal and BCG signal morphology is very similar to motion
artifacts, making it challenging to determine signal quality without reference points for
each beat. For the FIT seat, a simultaneous ECG will always be available when capturing
the PPG and BCG, allowing the R-peak to be used as a reference for every single beat.
Both the BCG and PPG use the same algorithm to classify signal quality.
To determine the signal quality of a single BCG or PPG beat, correlation and amplitude
based approaches are used to ensure consistent signal quality between beats. Beats that
are dissimilar to the local neighborhood are considered poor quality and are not included
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in ensemble averaging (Section 4.8). Correlation is used to ensure similar shape, while
amplitude testing ensures that large shaped motion artifacts are rejected.
The Pearson correlation coefficient is calculated between each beat and the neighborhood
ensemble average beat. The neighborhood ensemble average beat is calculated by averag-
ing each of the beats within a 15 seconds (the neighborhood), using the methods described
in Section 4.8. The beat under test is not included when calculating the ensemble average.
If fewer than 2 beats are within the neighborhood, the ensemble average is not calculated
and the beat is rejected. If the beat under test has a Pearson correlation coefficient of less
than 0.8 when compared to the neighborhood ensemble average, it is rejected.
Similarly, the amplitude based approach rejects individual beats that do not have a similar
RMS value or vary greatly in amplitude compared to the ensemble average beat. The
ensemble average is calculated for a neighborhood of 15 seconds. The RMS and the range
of the ensemble average beat is calculated for each beat under test. If the RMS of the beat
under test is less than 1/4 or more than 2 times the ensemble average RMS value, it is
rejected. Additionally, if more than 1/8th of the ensemble averaged beat differs from the
neighborhood ensemble average by more than 1/4 of its range, it is rejected.
After undergoing both signal quality checks, the resulting ensemble averaged beat is much
cleaner and does not incorporate wildly varying sections of the signal. This is illustrated in
Figure 4.3, where large variations in the bPPG impact the mean beat if they are included in
the stack during ensemble averaging.
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Figure 4.3: By rejecting beats with poor signal quality, the resulting ensemble averaged
beat (solid blue line on the bottom) and associated standard deviation (light blue region)
contains less smearing and has a higher amplitude accuracy than if every beat was included.
This is illustrated using the bPPG, where approximately 46% of the total number of beats
are rejected due to poor signal quality. An overlay of all of the beats utilized (top) when
generating the ensemble average (bottom) is also shown.
4.4 Beat Classification
In order to compare and verify different delineation techniques and algorithms, a consistent
method for benchmarking such algorithms must be utilized. A gold-standard waveform and
feature must be used in order to determine the effectiveness of each algorithm as described
herein. A gold-standard can be either a hand-annotated dataset or a dataset annotated au-
tomatically using a proven algorithm. Additionally, surrogate waveforms can be used as
a gold standard when a similar feature is located. As an example, it is possible to use the
ECG R-R interval as a gold standard for locating the PPG foot or peak. This works un-
der the assumption that the heart rate as measured on the ECG should be the same as that
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measured on the PPG.
To benchmark the location of interest it must be compared to the gold standard, resulting
in one of three possibilities: a true positive (TP), a false negative (FN), or a false positive
(FP). Feature locations identified within the acceptance interval of the gold standard are
considered a true positive (TP). Locations that are not within the acceptance interval of
the gold standard are false positives (FP). If a feature is not found within the acceptance
interval of the gold standard, it is considered a missed beat, or a false negative (FN). Using
this classification, the sensitivity and positive predictive value can be calculated.
The sensitivity (Se) is found using both the number of TPs and FNs, as shown in (4.2).
Sensitivity represents the percentage of beats that are correctly identified.
Se =
T P
T P+FN
(4.2)
The positive predictive value (PPV) is shown in (4.3) and represents the percentage of the
beats found that are not false positives. In other words, it is the measure of the percentage
of extra beats out of every beat that was located.
PPV =
T P
T P+FP
(4.3)
The sensitivity shows how likely the algorithm is to miss a beat, while the PPV shows how
likely the algorithm is to find an incorrect beat.
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The acceptance interval used will vary depending on the feature being analyzed, the desired
accuracy, and the signal that is used. The acceptance interval allows for a small (yet ac-
ceptable) variation in the resulting feature location. As an example, an acceptance interval
of 100 ms can be used for the ECG R-peak since the QRS complex may be as large as 200
ms. A smaller acceptance interval of 19 ms can be used for the PPG in order to accept only
the most accurately delineated beats.
For the sensitivity and positive predictive value, a larger acceptance interval produces better
results. On the other hand, when calculating the average temporal accuracy of only true
positive beats, a larger acceptance interval could produce worse results as beats with greater
error are included. The larger the acceptance window (and associated allowable error), the
larger the temporal error will be. Care must be taken when choosing the correct acceptance
interval depending on which feature is being analyzed.
4.5 ECG Delineation
4.5.1 Algorithm
ECG R-peaks are delineated on a beat-by-beat basis using a modified version of the well-
known Pan-Tompkins (PT) algorithm [102]. The raw ECG signal is processed in order to
isolate the QRS complex both in the frequency domain and the temporal domain. A first
order Butterworth bandpass filter with a bandwidth of 5-15 Hz is used on the input ECG
waveform; the same filter that was used in the signal quality algorithm (Section 4.3). A five-
point derivative of the filtered ECG is taken and the resulting waveform is then squared. The
squared signal is low-pass filtered using a third order Butterworth filter with a -3 dB cutoff
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frequency of 8 Hz, such that the resulting waveform will have smooth, individual peaks
for each QRS complex. The cutoff frequency of 8 Hz was chosen to match the duration
of a prolonged QRS complex, which is 120 ms [35, 37]. Two thresholds are calculated
from the resulting signal using a 5 second moving average, where the upper threshold is
1.25 times the moving average and the lower threshold is 0.3 times the moving average.
Example waveforms from various stages of the modified algorithm are shown in Figure
4.4, including both thresholds.
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Figure 4.4: The modified PT algorithm processes the raw ECG signal in order to isolate
QRS complexes for delineation. Dual thresholds are calculated using a moving window
average and are continually updated, rather than just updated when an R-peak is found.
The resultant R-peaks are often not exactly at the peak since the processing introduces
shifts in the R-peak location, necessitating a refinement stage.
Each peak in the processed signal is located from largest to smallest amplitude with a
minimum peak distance of 200 ms between peaks, corresponding to the cardiac refractory
period [102]. Peaks that have an amplitude greater than the larger threshold are determined
to be R-peaks. The median beat interval is calculated using all beats within 20 seconds of
the current interval under test, in order to allow for natural variations in HR over time. If
any of the resulting beat intervals are greater than 1.5 times the median beat interval, the
lower threshold is used to locate any missing peaks.
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This algorithm differs from the original PT algorithm in [102], which was designed for real-
time functionality on an embedded system, by using alternate filtering approaches and by
using a different mechanism for calculating the dual thresholds. A Butterworth filter with a
bandwidth that better isolates the constituent frequencies of the QRS complex is used and
a third order low-pass filter was used in place of moving window integration. The modified
PT thresholds are continuously updated to incorporate magnitude information from the
peak, baseline noise, motion artifacts, and other ECG features in order to dynamically
adjust to extreme changes in signal quality typical of dry electrodes.
While locating the exact peak of the R-wave is not critical when calculating HR and HRV,
exact accuracy is needed when ensemble averaging in order to avoid feature smearing. Both
the PT and the modified PT algorithm do not always locate the exact peak of the R-wave
since the exact location is smoothed out by the processing stages, as shown in Figure 4.4.
The R-peak location is refined by locating the two largest peaks in the squared derivative
of the filtered ECG signal, within 150 ms of the original R-peak location. These two peaks
bound the search window for the R-peak, which is defined as the first zero crossing of the
first derivative of the filtered ECG signal.
Once the ensemble averaged beat is generated (see Section 4.8), the Q-wave onset, S-wave
end, and T-wave end become clearly visible on the bECG, allowing a custom algorithm
to accurately locate each feature. The Q-wave onset is defined as the return to baseline
before the Q-wave peak, if visible. The algorithm locates this feature by finding the closest
maximum or minimum of the second derivative (zero-crossing of the third derivative) to the
left of the Q-wave peak. A high-pass filter with a cutoff frequency of 5 Hz is used before
locating the Q-wave peak, which ensures that a Q-wave-like feature becomes visible even if
one is not present in the raw ECG signal. Similarly, the S-wave end is defined as the return
to baseline after the S-wave peak on the high-pass filtered ECG. The algorithm locates the
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inflection point of the second derivative (zero-crossing of the fourth derivative) after the
S-wave peak, as the T-wave can obscure the local extrema of the second derivative. The
QRS duration is calculated as the time between the Q-wave onset and S-wave end.
For the purposes of this work, the T-wave is located by finding the zero crossing of the
second derivative (first derivative extrema) after the minimum of the second derivative.
This results in the T-wave end being defined as the return to baseline after the maximum
point of the downslope (or upslope, as this method is independent of polarity) of the T-
wave. The corresponding QT interval is defined as the interval between the Q-wave onset
and the T-wave end.
These algorithms have not been designed to robustly extract features for non-standard mor-
phologies, such as those present during disease state. For example, the heart failure popula-
tion has a prolonged QRS duration that changes the frequency content of the QRS complex.
The QRS complex also may not have a well-defined peak or S-wave end, requiring the use
of proprietary software or manual expert annotations. Creating a mean beat delineation that
is robust to different morphologies is out of the scope of this work and may be investigated
in the future.
4.5.2 Validation on Standard Databases
Methods
The modified PT algorithm with signal quality based classification is verified using the an-
notated MIT-BIH Arrhythmia Database (MITDB) and European ST-T Database (EDB) as
a gold-standard [103, 104]. The MITDB contains 48 records that are each 30 minutes in
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duration and the EDB contains 90 records that are each 120 minutes in duration, provided
by PhysioNet [105]. The signals from the MITDB and EDB have not been resampled, as
the modified PT algorithm does not require the ECG to be a specific sample rate. The bxb
function in the WFDB application [105] was used to determine the sensitivity and PPV
of the algorithm compared to the gold-standard annotations using a standard acceptance
window (e.g. match window) of 150 ms. The signal quality algorithm described in Section
4.3 is used to indicate periods of shutdown, where the classification results are tallied sep-
arately. The beats that would be missed during the shutdown period are not included when
calculating the number of false negatives, which are described in Chapter 4.
Results and discussion
The algorithms presented herein have been tested on the MITDB and the EDB to ensure that
there is no bias introduced by the delineation algorithms when comparing the bECG to the
Lead II ECG. Both the MITDB and EDB are standard databases that contain hand annotated
gold-standard references and are commonly used to verify beat delineation algorithms.
The sensitivity, PPV, and accepted signal quality percentages for the MITDB and EDB are
shown in Table 4.1.
Database Total Beats Se PPV SQI Pass
MITDB 107504 99.58% 99.95% 98.07%
EDB 760603 99.87% 99.80% 96.55%
Cumulative 868107 99.83% 99.82% 96.73%
Table 4.1: QRS Classification on Standard Databases
The algorithms presented herein have a cumulative (total) sensitivity of 99.83% and PPV
of 99.82% across both databases, which is comparable to best-in-class algorithms that typ-
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ically have a sensitivity and PPV over 99.5%, with very few over 99.8% [106]. Further
improvements on standard databases may be possible if the algorithms were tuned for
waveforms collected with traditional wet electrodes. Three of the most successful ECG
delineation algorithms utilize the wavelet transform [107, 108, 109]. These algorithms
have achieved an error rate of less than 0.34%. A detailed comparison of state-of-the-art
algorithms is shown in Table 4.2. The success of these algorithms can be attributed to both
the basis function used during pre-processing and adaptive thresholding techniques.
MITDB EDB
Algorithm Sensitivity PPV Sensitivity PPV
Present work 99.57% 99.95% 99.87% 99.80%
Saadi et al. [110] 99.90% 99.87% 99.84% 99.71%
Martinez et al. [111] 99.71% 99.97% 99.73% 99.67%
Martinez et al. [107] 99.80% 99.86% 99.61% 99.48%
Di Marco et al. [112] 99.77% 99.86% 99.81% 99.56%
Li et al. [113] 99.89% 99.94% N/A N/A
Pan et al. [114] 99.75% 99.54% N/A N/A
Bahoura et al. [108] 99.83% 99.88% N/A N/A
Table 4.2: Delineation Algorithm Comparison
The present delineation algorithm parameters have not been tuned for use with these databases
since they were designed for use with the bECG. Performance on these databases is ex-
pected to improve if the algorithms were tuned for wet electrode use. This modified Pan
Tompkins algorithm has best-in-class sensitivity and PPV for the EDB, which has many
more annotations and variety than the MITDB. These results demonstrate the accuracy and
utility of the approaches described herein.
90
4.6 PPG Delineation
4.6.1 Introduction
A novel and easily implemented delineation algorithm is presented, which allows the foot
of the photoplethsymogram to be located with sufficient accuracy for heart rate variability
applications. This algorithm combines classical delineation techniques with the robust-
ness of the wavelet transform. It can be implemented with a set of FIR filters and simple
non-adaptive thresholding, making it suitable for real-time ambulatory applications. Re-
sults show that the accuracy of the algorithm matches that of a standard electrocardiogram
delineation algorithm, the current standard for heart rate variability applications. The algo-
rithm presented herein is also compared against four state-of-the-art delineation algorithms.
Using a database that contains exercise data from thirteen patients across six activity lev-
els and 7012 beats, a temporal accuracy of 3.8±2.6 ms (mean±std) was achieved with a
sensitivity of 99.29% and a positive predictive value of 99.23%.
The wavelet transform (WT) is powerful and simple to implement since it is a cascaded set
of FIR filters [107]. The WT has been used in ECG delineation [107, 109] and to reduce
motion artifacts in both the PPG and ECG [115, 116]. This work extends upon previous
research by using a specific wavelet scale to locate each PPG beat (beat segmentation) be-
fore delineation. The performance of the wavelet transfer derivative delineation (WTDD)
technique is compared with the performance of four state-of-the-art delineation algorithms:
one PPG delineation algorithm [117] and three arterial blood pressure (ABP) delineation
algorithms [118, 119, 120]. Comparing PPG delineation algorithms to ABP based algo-
rithms is appropriate since they both have the same temporal features and very similar beat
morphology [120].
91
In [117], [119], and [120], a manually annotated database was used to verify the delin-
eation algorithm, while in [118], a synchronized ECG was used. To avoid human error and
inconsistent results, the QRS complex in a synchronized ECG was used as a reference for
determining the accuracy of the proposed PPG delineator, rather than a manually annotated
database.
The temporal accuracy, sensitivity, and the positive predictive value (PPV) were used to
quantitatively compare each algorithm’s performance. All of these metrics are influenced
by the acceptance interval, which is used for determining if delineated beats are valid. A
large acceptance interval will result in an improved sensitivity and PPV. The acceptance
interval has the opposite effect on the temporal accuracy. It allows less accurate beats to
be included when calculating the temporal accuracy, thereby degrading this metric. For
this reason, a large acceptance interval of 19 ms is used in this work. To demonstrate the
robustness of the WTDD algorithm, exercise data was used that contains motion artifacts,
baseline wander, and a variety of heart rates across a range of patients.
4.6.2 Algorithm
A single photoplethysmogram (PPG) beat contains three distinct features: the foot, the
peak, and the dicrotic notch as shown in Figure 4.5. The foot was selected for delineation
due to its steep up-slope and high correlation to ECG timing [118].
The wavelet transform derivative delineation (WTDD) algorithm consists of two phases, as
shown in the block diagram in Figure 4.6. The first phase locates the valid range for each
beat, also known as beat segmentation. The valid range for the PPG foot is found using the
wavelet transform in combination with a simple moving average window filter. Once the
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  Foot
Peak
Dicrotic Notch
Figure 4.5: An example PPG beat shows the locations of the foot, the peak, and the dicrotic
notch.
valid range is determined, the wavelet transform (WT) is no longer used. In phase two, the
valid range and a filtered version of the original waveform is used to determine PPG foot
location.
PPG Band Pass FIR
Differentiation
Filter
Differentiation
Filter
Differentiation
Filter
Wavelet
Transform
(5th Scale)
Rectify and 
Square
Window Filter
Valid Range
Threshold
Third Derivative Zero 
Crossing
Second Derivative Third DerivativeFirst Derivative
PPG Foot
Maximum 
Second 
Derivative
 Not Found?
Phase One Phase Two
Figure 4.6: Block diagram of the wavelet based PPG delineation algorithm. The wavelet
transform is used with a simple moving average threshold to locate the valid range in phase
one. The foot location is found using the first three derivatives of the original PPG signal
in phase two.
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Phase One
The wavelet used for beat segmentation is the quadratic spline wavelet, where the prototype
wavelet is the derivative of a smoothing function (Gaussian). Each wavelet scale represents
the derivative of a different range of frequencies contained in the original signal [107]. In
this work, the fifth wavelet scale was chosen since it contains the characteristic frequencies
of the PPG foot.
The wavelet transform (WT) can be implemented using an FIR filter bank; the filters used
herein are those shown in [121]. This filtering is typically done by down-sampling the
signal after each stage. Rather than down-sampling the entire signal, the method utilized
herein up-samples the FIR filter taps [107]. Not only does this reduce the complexity of
implementation, but it allows temporal features to remain synchronized throughout each
wavelet scale.
By rectifying and squaring the fifth wavelet scale (referred to as the processed wavelet),
distinct peaks appear at the start of each beat; this process is shown in Figure 4.7. The
processed wavelet is used to generate the threshold, which determines the valid range for
the PPG foot. This threshold is non-adaptive – it is created by using a moving hamming
window of 5 seconds, which functions as a low-pass FIR filter. The valid range (search
window) for the PPG foot is defined as the range where the processed wavelet signal is
above the threshold.
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Figure 4.7: Each beat is located using a squared and rectified wavelet transform (Processed
Wavelet). The valid range is found by locating the points where the threshold crosses over
the processed wavelet. Foot locations are then identified within the valid range.
Phase Two
The PPG is filtered using a bandpass filter with a bandwidth of 0.5-5 Hz. The first, second,
and third derivatives of the PPG are found using a 51-tap FIR differentiation filter. The
location of the PPG foot is defined as the local maximum of the second derivative within
the valid range, representing the signals maximum upward acceleration. Algorithmically,
this is found by searching for the first zero-crossing of the third derivative within the valid
range such that both the first and second derivative are positive. If such a zero-crossing is
not found within the valid range, the maximum value of the second derivative is used as the
location of the PPG foot.
The physiological data set used to validate this algorithm was obtained under informed
consent in a protocol approved by the Rochester Institute of Technology, Institutional Re-
view Board for Protection of Human Subjects. The Biopac MP36 (Biopack Systems, Inc.,
Goleta, CA) was used to capture synchronized ECG and ear PPG from thirteen test subjects
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at a sample rate of 50 kHz. In order to more closely match the Nyquist sampling rate found
in typical PPG measurement systems, both measurements were decimated to a sample rate
of 160 Hz.
A recumbent bike was used to vary the activity level of the test subject in order to test how
well the WTDD algorithm performs across a range of physiological states. One minute
measurements were captured at six different physiological states for each subject. These
physiological states include the subject at rest while sitting, while standing, and while
supine; in addition to three levels of increasing activity, each with an higher heart rate.
The R-peaks in each QRS complex were found using the method published by Pan and
Tompkins in [114]. The PPG foot and the R-peak are synchronized by shifting the ECG
forward, by the median offset for each beat in the measurement [118]. After synchroniza-
tion, the temporal accuracy is defined as the absolute value of the difference between the
R-peak and the PPG foot, for correctly identified beats.
The foot location was compared to each R-peak, resulting in one of three possibilities: a
true positive (TP), a false negative (FN), and a false positive (FP). When foot locations are
identified within the acceptance interval of the R-peak, it is considered a true positive (TP).
Foot locations that are not within the acceptance interval of a R-peak, are false positives
(FP). If a foot is not found within the acceptance interval of the R-peak it is a missed
beat, or a false negative (FN). The acceptance interval used in this paper is 19 ms, which
corresponds to three sample periods.
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4.6.3 Delineation Verification
The sensitivity, PPV, and temporal accuracy of the algorithms presented in [117, 118, 119,
120] are compared to the WTDD algorithm in Table 4.3. These results show that the
algorithm presented herein has a sensitivity and PPV equivalent to previously published
algorithms, while having significantly better temporal accuracy.
Algorithm Signal Beats Sensitivity PPV Interval Time
WTDD PPG 7012 99.29% 99.23% 19 ms 3.8±2.6 ms
[117] PPG 2900 96.89% 94.55% 12 ms N/A
[118] ABP 39848 99.31% 99.74% 20 ms 5.18±12.81 ms
[119] ABP 42569 99.36% 98.43% 16 ms N/A
[120] ABP 2564 99.96% 98.73% 8 ms 4.87±12.94 ms
Table 4.3: PPG Delineation Results
When compared to [117], this algorithm performs significantly better for both the sensitiv-
ity and the PPV, while the temporal accuracy was not reported. This method uses a similar
pre-processing approach, where it rectifies the average of the PPG derivative. It then uses
adaptive thresholding to recognize each beat. This algorithm, while fairly simple to im-
plement, does not perform as well as the algorithm presented herein. This is most likely
caused by incorrect beat segmentation, which is addressed by the use of the WT herein.
The algorithm proposed in [118], which locates the arterial blood pressure (ABP) wave-
form peak, is often used as the standard to which other delineation algorithms are com-
pared. This algorithm uses a slope sum function, adaptive thresholding, and a local search
strategy for locating each beat. The decision rule for locating each beat is a complex pro-
cess, which results in a stellar sensitivity and PPV. While the temporal accuracy was not
directly presented in [118], an estimate was calculated using a histogram reported in [118]
by calculating the standard deviation by locating the range where 95% of the results were
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included. Despite a large acceptance interval and the use of a localized search strategy for
locating each peak, the temporal accuracy of [118] was inconsistent, resulting in a large
standard deviation which will negatively impact heart rate variability applications.
In [119], the proposed algorithm locates the ABP waveform peak. This algorithm first
estimates the heart rate using a band pass filter; the heart rate is then used to adaptively
calculate the cutoff frequencies for the filtering stage. This algorithm is highly complex
and may cause implementation issues in resource constrained systems, such as those used
in real-time, ambulatory heart rate variability applications. Peak detection is completed
using rank-order (percentile-based), non-linear filters, and a nearest neighbor algorithm.
Rather than using manual annotations to test the validity of their approach, they use QRS
detection – the same approach taken herein. The temporal accuracy was not included in
[119].
The algorithm presented in [120] is a complete ABP waveform delineator. It locates the
foot, the peak, and the dicrotic notch of the ABP waveform. This algorithm uses derivative
calculation, zero-crossing detection, and adaptive thresholding to segment each beat. Two
datasets were presented in this paper. Only one data set was used when calculating the time
error of the foot detection, thus the results for only this dataset are presented in Table 4.3.
The sensitivity of [120] is remarkably high, especially considering a very small acceptance
interval was used. While the sensitivity of the WTDD algorithm is not as high as in [120],
the temporal accuracy of [120] has significant variation, which can negatively impact heart
variability applications. The temporal accuracy is especially poor considering such a small
acceptance interval was used. The spread of the temporal error (the standard deviation) will
result in incorrect HRV metrics, since it is the standard deviation in heart rate that directly
causes heart rate variability. The goal for these algorithms is to minimize the standard
deviation due to algorithmic error so that only physiological variation remains.
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Rather than using an adaptive technique for beat recognition, the algorithm presented herein
utilizes the WT for its simplicity. Using the WT does not sacrifice accuracy; on the contrary,
it provides an incredible resilience to noise. The example shown in Figure 4.8 demonstrates
how the PPG can be accurately delineated, despite significantly different beat to beat mor-
phologies. This includes baseline wander and significant changes in amplitude, which is
most likely caused from motion artifacts.
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Figure 4.8: An example showing the correct delineation of non-ideal PPG signal with
significantly different beat to beat morphology. True positives for the WTDD algorithm are
marked in red.
While the WT allows for highly accurate beat segmentation, using the WT alone would not
result in a high enough temporal accuracy for HRV applications. It is for this reason that a
two phase approach was used for locating each foot. A high level of reliability results from
the use of the WT, while the high level of accuracy is achieved by using the derivatives of
the original signal for foot detection.
This algorithm can be applied to non-contact photoplethysmography methods – enabling
new types of devices and applications. An example of such an application is when the heart
rate is extracted from a video of the face [122, 123] or from a smart phone [124]. By simply
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adding a video camera to everyday devices, this algorithm can allow heart rate variability
to be used for determining stress levels and monitoring the level of focused attention in
situations where the use of a PPG or ECG is inappropriate. Examples include use in an
automobile or when monitoring an infant. The PPG delineation algorithm presented herein
is highly successful for accurately delineating the PPG foot. This approach has wide ap-
plicability, not only for the PPG foot, but other PPG features and waveforms. Future work
should investigate the extension of this algorithm to detection of other PPG features, such
as the dicrotic notch and peak.
The WTDD algorithm can enable the proliferation of the PPG for use in ambulatory heart
rate variability applications. The combination of the wavelet transform and standard deriva-
tive based methods, result in an algorithm that is as sensitive and reliable as the best existing
algorithms, while significantly improving upon the temporal accuracy. Such an algorithm
can be implemented on a standard low-power microcontroller, rather than a more special-
ized device such as a DPS or FPGA. The ease of implementation of this algorithm makes
it well suited for portable, low complexity, cost efficient medical devices.
4.7 BCG Mean Beat Delineation
The BCG is not delineated on a beat-by-beat basis, as motion obscures the signal in almost
all cases. As such, ensemble averaging (see Section 4.8) is required in order to locate
each feature within the BCG. The first step in delineating any signal, is finding the most
prominent feature and using it as a reference for all subsequently located features. For the
ECG, this signal is the R-wave peak and for the PPG, this signal is the foot. While the IJK
complex is typically the most prominent in the BCG, this is not always the case. A BCG
100
beat often contains a notched J-wave or a J-wave with low absolute amplitude. While there
are many different BCG features, the peak of the BCG’s first derivative was empirically
determined to be the most consistent feature.
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Figure 4.9: The ensemble average BCG beat is delineated by first locating the peak of
the derivative and then subsequently locating each of the major BCG waves relative to the
derivative peak. The G, H, I, J, and K-wave delineations are shown relative to the BCG
derivative peak.
This feature is always located within 100 ms to 300 ms of the R-peak for normative sub-
jects. More importantly, it is the only large positive peak within this range. This single
beat BCG delineation algorithm locates this feature by finding the maximum of the filtered
derivative of the BCG (0.5-15 Hz bandwidth) within this range. The resulting point is
always between the I-wave and the J-wave.
The I-wave and J-wave are located by looking for the next zero crossing to the left and right
of the derivative peak, respectively. The unfiltered derivative is used when locating these
zeros in order to maintain the original temporal resolution of the signal. This is shown in
Figure 4.9, where the BCG and the filtered derivative is shown with each delineated feature
marked. The remaining waves (G, H, and K waves) are found by looking for the matching
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zero crossing in the unfiltered BCG derivative.
4.8 Ensemble Averaging
Ensemble averaging is a technique used in cardiovascular signal processing to reduce noise
and improve feature prominence for a single averaged beat. For example, features such as
the T-wave may not be visible on a beat-by-beat basis, however ensemble averaging allows
these features to become clear and easily located. This work uses the standard ensemble
averaging technique, where each beat is stacked relative to a consistent feature, such as the
R-peak, and then averaged sample-by-sample as shown in Figure 4.10. Only sections of
the signal that pass the signal quality index algorithm are included when generating the
ensemble average.
Figure 4.10: Ensemble averaging aligns multiple beats based on a common feature such
as the R-wave peak in order to calculate an average beat. This allows small features to
become prominent, despite not being clearly defined on a beat-to-beat basis. This example
utilizes bECG from a normative subject.
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4.9 Conclusion
The present algorithms enable the data acquired during use of the FIT seat to be accurately
analyzed. The FIT seat measurement modalities create many challenges that have been
overcome using these custom algorithms, such as the increased noise in dry-electrode ECG
systems. While these algorithms were designed specifically for the FIT seat, they can
be utilized on any system that contains noisy waveforms. Specifically, the signal quality
algorithms presented herein provide a unique approach to rejecting data that should not be
analyzed. This is integral to the success of the FIT seat.
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Chapter 5
Human Subject Testing and
Gold-Standards
5.1 Introduction
The human subject studies described herein were performed under informed consent using
a protocol approved by the institute review boards at the Rochester Institute of Technology
and the University of Rochester Medical Center. Human subject testing has been performed
in two phases. The first phase verifies the FIT seat functionality on normative subjects, and
the second phase verifies its ability to accurately acquire signals and extract parameters
from the heart failure population. These studies have been designed specifically to validated
the bECG waveform and to provide additional insights into the mechanisms behind the
BCG waveform.
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5.2 Normative Study – Phase I
In this phase, FIT sensors have been hard-wired to a biomedical data acquisition system
(Biopac and LabView DAQ system) enabling time synchronized collection of FIT data with
clinical measures (12-lead ECG, respiration, SpO2, echocardiogram, aortic pulse wave ve-
locity). Baseline feature extraction algorithms have been developed for the bECG, bPPG,
and bBCG. The goal of Phase I is to determine if the FIT Seat can measure cardiology vari-
ables as accurately as current generation commercial medical equipment. Normal subjects
(healthy college students and faculty) have been tested at rest and after mild exercise. The
goal of post exercise testing is to determine the ability of the FIT seat to measure changes
in the cardiology variables across physiological states.
Differences in individual variables and waveforms have been assessed using correlation,
classification metrics, and the Student’s T-test with paired observations. HR calculated
from the ECG are compared to the same variables measured by FIT Seat bECG, bPPG
and BCG. A difference of p ≤ 0.05 are considered statistically significant when using the
T-test.
Normative testing was performed on 26 healthy subjects with no history of heart disease.
The data used herein was obtained under informed consent in a protocol approved by the
Rochester Institute of Technology Institutional Review Board for Protection of Human Sub-
jects. The laboratory used for subject testing was transformed into a hospital-like setting,
as seen in Figure 5.1. The instrumentation in a Biopac MP150 system was used to amplify
and filter a 12-lead ECG, bECG, two ear PPG, SpO2, respiration strap, and a thigh cuff
(when needed). Custom instrumentation was used for the bPPG, IR temperature sensor,
and four BCG channels. A National Instrumentsc RIO-9075 CompactRIO DAQ system
was used to digitize the signals from both the Biopac instrumentation and the FIT seat.
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Figure 5.1: Two layers of privacy curtains were added to the lab for normative subject
testing. The subject sits behind the second layer of curtain on the toilet seat while the data
is acquired on a laptop and the sonographer takes picture on the echocardiogram.
Before the procedures were started, the subject’s relevant medical history was taken as well
as their height and weight with a Health o meter Professional 500KL Eye Level Digital
Medical Scale. Additional measurements were taken so that the length of their aorta can
be estimated. Finally, an initial echo of the subject was taken to ensure that there were
no cardiac conditions that would prohibit them from performing the tasks defined in the
following procedures. The testing consisted of five protocols:
1. Resting FIT measurements
2. Resting FIT + sitting echo
3. Resting supine echo
4. Post stress supine echo
5. Post stress FIT + sitting echo
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In the first protocol, six 150 second (2.5 minute) long recordings were created with the
subject on the FIT seat. Between each recording, the subject was instructed to stand up.
When they were seated again, they took a BP measurement from a wrist cuff (Omron
BP652N 7 Series), and then the next recording was started.
For recordings 1-4, the subject was instructed to sit up straight and attempt to remain still.
For recordings 5-6, the subject was instructed to lean forward between 45-60 degrees. In
recordings 1-2, they were instructed to hold their breath for 15 seconds, 2 minutes into the
recording. For the last four recordings, the subject was instructed to hold their breath for 15
seconds, 2 minutes into the recording, and to perform a Valsalva maneuver for 5 seconds,
1 minute and 45 seconds into the recording.
The second protocol consisted of the subject sitting on the FIT seat while the sonographer
took simultaneous echo captures. Every time a capture was taken, a 10 second retrospective
clip was generated in the NI DAQ system. There is a total of 23 clips in this phase. For
the first 16 clips, the subject was asked to sit upright. For the remaining 7 clips the subject
was asked to lean forward. Five of the clips consisted of a pulse wave Doppler, where the
subject’s blood pressure was taken with a wrist cuff. Additionally, the thigh cuff waveform
was captured for these clips.
The third and fourth protocol consisted of the subject lying supine on an echo table while
the sonographer took a total of 21 and 16 echo captures respectively, at least two times each.
After the third protocol, the subject was asked to raise their HR to 75% of their maximum
heart rate on a recumbent bicycle. This step was repeated after the fourth protocol was
completed. The last protocol is very similar to the resting FIT + sitting echo (protocol 2).
Rather than taking 23 clips, only 16 clips were taken when the subject was sitting upright.
Four of the clips consisted of a pulse wave Doppler, which included the subject’s blood
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pressure (taken on the wrist) and the thigh cuff waveform.
For all echocardiograph measures, Lead I was connected to the GE Vivid i ultrasound sys-
tem for time synchronization of all measures with the echo images. The protocols involving
combined FIT + echo measures enable synchronization of cardiac event timing relative to
ECG and all FIT seat parameters.
5.3 In-Hospital Study – Phase II
Heart Failure subject testing has been completed 25 subjects in a single-center observa-
tional study of patients admitted for heart failure. Patients were recruited shortly before
discharge to have FIT testing combined with traditional transthoracic echocardiographic
(GE Vivid i) and electrocardiographic measurements of cardiac function. A commercially
available Biopac MP150 instrumentation system was used to amplify and filter a 12-lead
ECG, two ear PPG, SpO2, respiration strap, and a thigh cuff plethysmogram. Custom
instrumentation integrated into the FIT seat was used to capture the bECG, two bPPG
channels, IR temperature, four weight channels and four BCG channels. A National In-
struments cRIO-9075 CompactRIO DAQ system was used to digitize the signals from both
the Biopac instrumentation and a trigger based sync signal generated by the FIT seat, which
allows for time synchronized capture of all waveforms. The ECG was also captured by the
ultrasound system with manual clip capture synchronization enabling alignment of the ul-
trasound measures with the NI DAQ system captures.
Before the procedures were started, the subject’s relevant medical history was taken. The
latest height and weight measurement from the subject’s chart was noted. Physical mea-
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surements of bony landmarks relative to the seat were taken to enable estimation of aorta
length (when combined with ultrasound measures as defined below). The testing consisted
of three protocols: resting FIT measurements, resting FIT + sitting echo, and resting supine
echo. Exercise was not performed due to the physical limitations of heart failure subjects.
Figure 5.2: The aortic length of a subject can be estimated from a combination of super-
ficial measurements and ultrasound based measurements. This method for estimating the
total aortic length incorporates the aortic arch, making it robust and accurate compared to
empircal based estimations that utilize only superficial measurements. Image courtesy of
Karl Q. Schwarz, MD.
The length of the artery from the aortic valve to a selected end point along the artery (AL)
can be determined based on direct subject measurement (external). Measurements are done
on an individual in a seated position. The distance between the sternal notch (SN) and the
sternal angle (SA) is measured, either directly or by reference to the seating platform top
(B). The distance between sternal angle (SA) and aortic valve (AV) is measured, e.g., via
ultrasound imaging. The distance between sternal notch and aortic arch (AA) is measured,
e.g., via ultrasound imaging. The 5 measurements that are made are as follows. These
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measurements are shown in Figure 5.2.
1. Buttocks to Sternal Notch (BSN).
2. Buttocks to Sternal Angle (BSA).
3. Sternal Angle to Aortic Valve (SAAV).
4. Sternal Notch to Aortic Arch (SNAA).
The first three measurements are made with a tape measure while the subject is sitting on
the FIT and the last two are made with 2D ultrasound imaging, either to identify the inter-
costal space with the aortic valve (item 4) or by imaging from the sternal angle towards the
aortic arch (item 5). The sternal angle and notch are bony protuberances that are easily pal-
pated and used by surgeons and other providers to locate anatomical structures. Above the
sternal angle is an ultrasound window to view the aortic arch (and measure distance). The
sternal notch is used to identify the second intercostal space. As noted above, ultrasound is
used to find the intercostal space most aligned with the aortic valve and the space number
is calculated based on the sternal notch.
The pulse wave distances are calculated using the following:
AVButtocks = (BSN−SNAA)+(SAAV +(BSN−BSA)−SNAA) (5.1)
In the first protocol, six 150 second (2.5 minute) long recordings were captured with the
subject on the FIT seat. A single recording session consisted of a traditional cuff-based
blood pressure (GE Carescape v100) measurement for systolic and diastolic pressure, fol-
lowed by FIT measures. Between each recording, the subject was instructed to stand up
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to introduce positioning differences and associated impact on signal quality / characteris-
tics when the subject was able. Directly before the next recording was started, the blood
pressure measure was repeated.
For recordings 1-2 the subject was instructed to sit up straight and attempt to remain still.
The recordings consisted of normal respiration with a 15 sec of breath hold. The start time
of the breath hold was manually captured. For recordings 3-4 the subject was instructed
to sit upright. The recordings consisted of normal respiration with a 15 sec breath hold,
followed by a 5 second Valsalva maneuver. The start times for breath hold and Valsalva
maneuver were manually captured. For recordings 5-6, the subject was instructed to lean
forward between 45-60 degrees and the sequence of measures outlined for recordings 3-4
were repeated (including Valsalva).
The second protocol consisted of the subject sitting on the FIT seat while the sonographer
took simultaneous echo captures. For each capture that was taken, a marker was saved
in the recording noting the time of capture. There are a total of 23 clips in this phase.
For the first 16 clips, the subject was asked to sit upright. For the remaining 7 clips the
subject was asked to lean forward at 45-60 degrees as in Procedure 1. Five of the clips
consisted of a pulse wave Doppler, where the subject’s blood pressure was taken with a
wrist cuff. Additionally, the thigh cuff waveform was captured for these clips to be used
for PWV determination (ultrasound aortic valve opening to thigh cuff pulse wave arrival
used in combination with aorta length).
The third protocol consisted of the subject lying supine on an echo table while the sonogra-
pher took a total of 21 echo captures, at least two times each. This provided comprehensive,
high quality echo measurements including left ventricular volume, systolic volume, cardiac
output and cardiac index. For all echocardiograph measures, Lead II was connected to the
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GE Vivid i ultrasound system for time synchronization of all measures with the echo im-
ages.
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Chapter 6
The Buttocks ECG (bECG)
6.1 Introduction
Tracking changes in the electrocardiogram (ECG) from subjects on a daily basis can be
critical in diagnosing and managing cardiovascular disease such as heart failure and hyper-
tension. A toilet seat is the ideal device for monitoring a subject’s ECG in their home since
it is used consistently and requires no change in habit. This work presented in this chapter
demonstrates the ability to accurately capture clinically relevant ECG metrics across sub-
jects and physiological states using a toilet seat based buttocks ECG (bECG), enabled by
advanced custom algorithms designed for noisy ECG signals. When validated on standard
databases, the custom QRS delineation algorithm presented herein has an overall sensitiv-
ity and positive predictive value (PPV) of over 99.8% on the MITDB and EDB. A study
across 25 subjects at both rest and post-stress shows that 81.3% of the bECG captured from
a toilet seat is of sufficient quality for analysis, with lead II showing the highest morpho-
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logical correlation to the bECG. The bECG has a QRS sensitivity and PPV of over 98.4%
compared to Lead II with a HR accuracy within 0.05±0.87 bpm and a HRV accuracy of
-3.50±8.96 ms. The QRS duration and QTc interval have an accuracy of -0.40±7.43 ms
and -9.36±18.91 ms, respectively.
6.2 Toilet Seat bECG for In-Home Monitoring
By integrating an ECG into a toilet seat, many of the challenges associated with in-home
monitoring are addressed. The resulting cardiovascular monitoring system can be inte-
grated into the natural routine of a subject, enabling measurements to be taken at the same
time of the day before any stimulants (e.g. sugar, caffeine, nicotine, etc.) or food. This
results in a daily stable measurement over time that is critical for accurate trend analysis.
Issues with preparation and subject error are greatly reduced, since skin contact is auto-
matic and has sufficient pressure to create a consistent electrode interface at a consistent
location for each individual.
There are examples in literature demonstrating that it is possible to capture an ECG from
a toilet seat [73, 74, 75, 76, 77, 78]. Only the work presented in [76] has quantitatively
compared the seated ECG on a toilet seat to a gold-standard ECG measure, where both
non-contact and wet electrodes placed on the thigh were compared to a standard limb lead
ECG. Their results showed that manual R-peak delineation resulted in less than a 2 ms error
in location and that the estimated HR was within 0.003 bpm for a single test subject. To
date, there has not been a quantitative comparison between the bECG HRV, QRS duration,
QTc interval, waveform morphology to a clinical 12-lead ECG.
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The work presented herein assesses the bECG’s diagnostic capabilities compared to the
12-lead ECG in a controlled study, by quantitatively comparing the accuracy of extracted
R-peaks, HR, HRV, waveform morphology, QRS duration, and QTc interval. Simultaneous
bECG and ECG recordings are captured from 25 subjects both at rest and post-stress. The
purpose of this study is to demonstrate the feasibility of this system for accurately moni-
toring key parameters in a healthy population, as a precursor to studying the HF population
and long-term trend based studies.
6.3 Choosing a Gold-Standard
6.3.1 Methods
In order to determine the accuracy of the bECG QTc interval and QRS duration, a standard
ECG lead is required as a gold-standard. Each of the 12 standard leads is a projection of
the heart dipole and is unique in shape. The bECG is a non-standard lead, so correlation
analysis was used to determine which of the 12 standard leads most closely matches the
bECG. Correlation analysis was performed on the ensemble averaged beats of each lead
from every recording. In order to minimize errors that are introduce by timing differences
in the R-peak locations, R-peaks from a single channel were used across all 12-leads in
order to ensure a consistent reference point when ensemble averaging. The R-peaks from
chest lead V1 were chosen as a reference for all other leads as it contained the least amount
of motion artifacts.
Pearson’s correlation coefficient, which is a measure of the linear correlation between two
variables, was used to determine how closely related the ensemble averaged beats were to
115
the bECG beat. This measure is calculated by dividing the covariance of the two variables
by the product of their standard deviation. Resulting values are between 1 and -1 (where
both extremes represent perfect correlation) Tukey boxplots were generated across the nor-
mative subject dataset, with whiskers 1.5 times the interquartile range to show the range of
correlations between each lead. A paired Student’s t-test is used to determine if the highest
correlated leads are statistically equivalent, or if there is a statistically significant difference
in the correlation to the bECG.
6.3.2 Results and Discussion
As the heart dipole changes magnitude and orientation during the cardiac cycle, ECG fea-
tures measured on each differential pair have different timing, amplitude, and orientation.
Differences in shape impact the extracted cardiovascular intervals and the clinical interpre-
tation of any given ECG lead, which is easily conceptualized by looking at the differences
between the standard 12-lead ECG. In order to determine the lead that the bECG is most
similar to, correlation was chosen as it is a quantitative measure of linear dependence be-
tween two signals. Correlation results between the bECG and each of the standard 12-leads
are shown in Figure 6.1, where the leads are in order of highest median correlation.
The bECG has the highest correlation to Lead II, -aVR, and aVF, with median correlations
of 0.911, 0.908, and 0.898 respectively. The correlations for aVR, V1, aVL, and V2 have
been inverted to facilitate visual comparison for high negative correlation. Despite having
used R-peaks from V1 as reference points for the ensemble averaging of all 12-leads, there
is no bias towards V1 in the correlation analysis as it has lower than average correlation to
the bECG. Since each of the 12-leads were time synchronized, a paired Student’s t-test was
used to determine statistical significance for differences in calculated lead correlations, as
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Figure 6.1: Box plots across all normative subjects (N=140) show the correlation between
the bECG and the standard ECG leads. Leads aVR, V1, aVL, and V2 have been inverted to
facilitate visual comparison. Leads are organized from right to left by best correlation. The
top three correlated leads were Lead II, aVR, and aVF with median correlations of 0.911,
0.908, and 0.898 respectively. Statistical significance is tested using a paired Students t-test
(*p < 0.05, **p < 0.01, and ***p < 0.001).
shown in Figure 6.1. While there was no statistically significant difference between -aVR
and Lead II (p=0.32), Lead II was chosen as the gold-standard for the bECG since -aVR is
an augmented lead calculated from Lead II.
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6.4 Delineation
6.4.1 Methods
The efficacy of the bECG is evaluated by comparing clinically relevant parameters to those
extracted from the highest correlated limb lead, as determined using the methods presented
in Section 6.3. Beat classification is used to determine how consistently and accurately
beats can be located on the bECG. The bECG signal quality must be sufficient for robust
determination of beats, otherwise it cannot be used for further analysis. Six recordings
from each normative subject are used in these analyses: five at rest, and one post-stress.
The sensitivity and positive predictive value (PPV) (also known as precision) are then cal-
culated for the bECG waveform using the corresponding beat delineations from the gold-
standard ECG channel. Feature locations identified within 100 ms on either side of the gold
standard is considered a true positive (TP), while reported time indices that are not within
this acceptance interval are false positives (FP). If a corresponding feature is not found
within the acceptance interval of the gold standard feature it is considered a missed beat,
or a false negative (FN). The interval used when analyzing standard databases is 150 ms
based the bxb function provided by PhysioNet [105]. A more stringent acceptance interval
of 100 ms was chosen, as it is half the myocardium refractory period of 200 ms [102]. This
ensures that multiple beats will not be present for a single gold standard beat within the
acceptance window.
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Figure 6.2: The signal quality of the bECG can change across subjects and measurements
as it is captured using active, dry electrodes. Three examples of signal quality are shown for
the bECG. The superior example (a) shows the best signal quality achieved from the bECG
study. The average example (b) shows the typical signal quality of the bECG. The poor
example (c) shows a very noisy waveform that was determined to have sufficient quality
for analysis.
119
6.4.2 Normative Results and Discussion
One fundamental difference between the standard clinical ECG and the bECG is the signal
amplitude. Both the electrode location relative to the heart dipole and the type of electrode
can reduce signal amplitude. Example bECG waveforms that have been preprocessed with
a bandpass filter (1-45 Hz) and notch filter (60 Hz) for visualization are shown in Figure
6.2, illustrating superior, average, and poor signal quality compared to a time synchronized
Lead II. Each of these waveforms have passed the SQI test, and were considered to have
sufficient quality for analysis. Utilizing signal quality effectively and having robust algo-
rithms is an absolute requirement in this application, since the bECG is acquired using dry
electrodes and is much more prone to noise and motion artifacts than typical ECG signals.
Despite the challenges with dry electrodes on a toilet seat, the percentage of acceptable
waveforms and corresponding sensitivity and PPV is more than sufficient for accurate esti-
mation of physiologic parameters.
One subject was rejected from inclusion in the present study due to a prolonged QRS
duration and abnormal ECG morphology, as verified by a cardiologist. Of the remaining
25 subjects, there were a total of 13 male and 12 female subjects ranging from 20 to 50
years of age, with a mean age of 26.7 years. Across 25 subjects with a total of 375 minutes
of data, 81.3% of the bECG passed the signal quality algorithm with an overall sensitivity
and PPV of 98.7% and 98.5% respectively, compared to Lead II. Summary statistics and
per-subject statistics are shown in Table 6.1. Motion artifacts result in transient noise in
the bECG waveform as the electrode interface changes whenever the subject moves on the
seat. As such, the bECG motion artifacts are more subject dependent than if wet electrode
were used. The signal quality across subjects were very polarized, with 16 out of the 25
subjects having over 90% of the bECG waveforms pass the signal quality check compared
to subjects 2, 5, and 25 which all had less than 40%. A total of 8 recordings were completely
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Subject Se PPV SQI Pass
1 99.8% 99.7% 94.3%
2 95.0% 91.8% 15.8%
3 99.9% 100.0% 93.9%
4 94.4% 97.4% 66.9%
5 99.6% 98.7% 37.8%
6 96.4% 97.1% 91.6%
7 99.3% 98.8% 96.7%
8 99.9% 99.4% 92.0%
9 97.1% 97.1% 65.0%
10 98.2% 97.5% 84.2%
11 99.7% 98.9% 94.9%
12 99.7% 99.1% 95.4%
13 99.9% 100.0% 98.1%
14 99.9% 99.8% 93.8%
15 100.0% 99.9% 94.3%
16 99.0% 98.6% 91.8%
17 99.5% 99.0% 74.6%
18 99.8% 98.0% 91.0%
19 99.9% 99.4% 95.8%
20 97.6% 98.3% 93.8%
21 100.0% 99.6% 91.7%
22 98.2% 98.8% 83.1%
23 86.9% 85.9% 75.9%
24 96.6% 98.2% 91.2%
25 97.4% 96.4% 29.6%
Total 98.7% 98.5% 81.3%
Table 6.1: Buttocks ECG QRS Classification Results for Normative Subjects
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rejected because 100% of the waveform in those recordings failed the signal quality metric
for QRS delineation.
6.4.3 Heart Failure Results and Discussion
ECG R-peaks were delineated using a custom, automated algorithm following acceptable
region identification with the SQI algorithm. 25 subjects were evaluated, none were ex-
cluded. The SQI algorithm resulted in 64.8% of the bECG having sufficient quality for
analysis. Data rejection was polarized, with 16 subjects having over 60% of bECG seg-
ments accepted, and 6 subjects having less than 25%. Many HF subjects have a patient
monitoring system, an IV, and a swan catheter at all times, which periodically resulted
in poor Lead II signal quality. On average, 92.8% of Lead II data had acceptable signal
quality. Only periods when both the bECG and Lead II had acceptable signal quality were
analyzed. Further investigation is required to explore causative factors impacting robust
bECG capture in the HF subject population.
The sensitivity and positive predictive values were then calculated for the bECG waveform
using the Lead II ECG as the gold standard reference. Results are presented in Table 6.2
for all subjects. A total of 179 recordings were analyzed, of which 158 were of suitable
quality for inclusion in the analysis (i.e. some part of them passed the automated SQI
algorithm for both bECG and Lead II). An overall sensitivity of 79.2% suggests the bECG
provides sufficient waveform quality to enable robust R-wave determination as compared to
the standard Lead II ECG. Similarly, the positive predictive value (PPV) of 83.7% suggests
a reasonably high true positive rate. Both measures used an acceptance interval of ±75 ms.
Given the abnormal QRS morphology in the HF subjects, the normative R-peak delineator
may find a location anywhere within the QRS as an R-peak. A typical QRS duration for
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Subject Se+ PPV SQI Pass
101 95.4% 93.1% 94.9%
102 88.7% 95.3% 57.3%
103 78.2% 90.2% 79.8%
104 6.9% 50.0% 2.5%
105 84.3% 95.4% 59.5%
106 64.6% 65.6% 96.2%
107 92.0% 99.2% 92.7%
108 77.1% 74.8% 63.2%
109 94.0% 94.5% 92.3%
110 82.2% 77.6% 98.8%
111 53.6% 62.0% 42.0%
112 57.9% 64.9% 77.3%
113 53.6% 54.9% 79.4%
114 98.5% 96.7% 21.1%
115 12.6% 12.9% 94.0%
116 3.6% 14.8% 7.8%
117 55.9% 76.9% 79.0%
118 54.1% 57.5% 13.6%
119 90.0% 99.5% 99.0%
120 99.5% 99.9% 96.0%
121 81.0% 92.3% 88.6%
122 37.5% 51.9% 53.2%
123 60.1% 80.7% 24.6%
124 70.3% 75.4% 86.0%
125 34.9% 36.5% 13.4%
Overall 79.2% 83.7% 64.8%
Table 6.2: Sensitivity, positive predictive value, and percentage of waveforms that pass
SQI in the analysis for the HF subjects.
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a HF patient is great than 120 ms, and in extreme circumstances can be over 150 ms. The
same acceptance interval used for the normative analysis (±100 ms) was chosen. After
subject testing was initiated, many of the first patients had ECG amplitudes much lower
than expected. Lower ECG amplitude can be attributed to massive cell death in cases of
extreme heart failure.
6.5 Heart Failure Arrhythmia Analysis
6.5.1 Methods
In order to show that the FIT bECG can be used for arrhythmia analysis, professional grade
Holter analysis software (M12A Holter System software by Global Instrumentation) was
used to detect arrhythmias on both the FIT bECG and Lead II ECG after initial preprocess-
ing and filtering. The following parameters were calculated using this software:
1. Number of beats located
2. Number of ventricular ectopic beats
3. Number of supraventricular ectopic beats
4. Average HR
The total number of beats located and the average HR are compared to those found using the
custom algorithms discussed in Section 6.4. The Holter software does not classify signal
quality, and as such will find a different number of beats for the FIT bECG compared to
the Lead II ECG. Comparing the HR and beats located to custom algorithms provide a
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reference for comparing the number of ectopic beats between the FIT bECG and Lead II
ECG. This also provides a frame of reference for what is expected from a professional grade
ECG delineation and analysis algorithm. Recordings from Protocol 1 are only 2.5 minutes
in length, making them ill-suited for use with the Holter software, which has been designed
for use with longer recordings. One recording (from Heart Failure Protocol 2) was used for
the arrhythmia analysis with the Holter software, as it is typically over 5 minutes in length.
6.5.2 Results and Discussion
Each of the 25 files from the heart failure population were manually converted to a format
the Holter software could analyze. The bECG is a non-standard lead and has a much lower
amplitude than the standard leads. As such, the software was unable to analyze 14 of the
25 recordings. In these cases, the software found fewer than 50% of the FIT bECG beats
compared to the Lead II ECG (rejection criteria). These recordings were excluded from the
arrhythmia analysis. The noise present on the bECG is atypical of a chest worn ECG with
gel electrodes, which will negatively impact the software’s ability to correctly classify and
delineate beats.
As expected, the correlation between the FIT bECG and the Lead II ECG heart rate is
very high for the 9 recordings analyzed, as shown in Figure 6.3-(a). The percent of ven-
tricular and supraventricular ectopic beats are shown in Figure 6.3-(b) and Figure 6.3-(c)
respectively. These values are compared as percentages, since the total number of beats
located are different for the bECG and the Lead II ECG. This is also the default output
for the Holter software, as it is typically used to report on an entire 24 hours (or more).
These percentages correlate very well for the relatively small number of beats present in
the recordings. This highlights the power of the bECG in capturing important arrhythmia
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(c)
Figure 6.3: The average heart rate for the bECG very closely matches the heart rate from
the Lead II ECG (a), the percentage of heart beats in the bECG that are classified as a
ventricular ectopic beat closely match the Lead II ECG (b), and the percentage of heart
beats in the bECG that are classified as a supraventricular ectopic beat closely match the
Lead II ECG (c) as determined by the commercial Holter analysis software for the HF
population.
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information from shorter uses of the FIT seat.
6.6 Cardiac Intervals
6.6.1 Methods
For each recording the HR, HRV, QRS duration, and QTc interval measured from the bECG
are compared to the gold standard limb lead with the highest correlation to the bECG. The
HR for a specific recording is calculated by taking the median RR interval after rejecting
RR intervals that were more than 60% out of tolerance to the initial median RR interval.
Multiple methods can be used to calculate HRV, however in this work the standard deviation
of the RR intervals (SDNN) is used.
QTc and QRS intervals are extracted from the delineated feature timing on the ensem-
ble averaged waveform for both the bECG and Lead II ECG. Results are compared using
Bland-Altman plots. Correcting the QT interval for different heart rates is necessary when
looking for trends or comparison across recordings. The corrected QT interval (QTc) is
calculated using the Bazett formula [40].
6.6.2 Normative Results and Discussion
Heart rate and heart rate variability are calculated per recording for the bECG and Lead
II ECG waveforms for all subjects at rest and post-stress. A total of 142 recordings were
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analyzed with matched pairs shown as a Bland-Altman plot in Figure 6.4. The automated
delineation algorithms resulted in an excellent agreement between the bECG and the gold-
standard HR, with all data points having less than 2 bpm error and virtual no bias. The
SDDN heart rate variability is clustered very close to the zero error line, but with positive
bias induced by a small number of significant outliers. While the results are excellent for a
dry electrode system and no skin preparation, further enhancements to the automated SQI
algorithm may offer opportunities to further improve results.
The more stringent requirements on signal quality when creating the ensemble averaged
beats result in the rejection of additional segments compared to the statistics described in
Table 6.1; on average 85.9% of the delineated R-waves in Table 6.1 were used to generate
ensemble averaged beats. Results are presented as Bland-Altman plots for the bECG QRS
duration and QTc interval in Figure 6.5 (a) and (b).
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Figure 6.4: Heart rate (a) and heart rate variability (b) extracted from the bECG signal for
both rest (red x) and post-stress (blue o) are closely aligned with those extracted from the
gold standard Lead II ECG. The dashed line shows the mean error, while the dotted lines
show 1.96 times the SD corresponding to a 95% limits of agreement.
The bECG QRS durations are generally within 10 ms compared to those extracted from the
Lead II ECG. The Bland-Altman plot show near zero bias in the measures and a 1.96 times
standard deviation of 14.56 ms. The visible 1 ms quantization in Figure 6.5 (a) is caused by
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Figure 6.5: The error in the bECG QRS duration compared to Lead II (a) shows a very low
error of less than 15 ms (for within 95% limits of agreement), corresponding to 15 samples.
The QTc interval (b) shows excellent agreement between the bECG and Lead II extractions
compared to what can be achieved though manual determination with a caliper (between
20-40 ms) [125]. Data points for both rest (red x) and post-stress (blue o) are shown.
the 1000 Hz sampling rate. The bECG based QTc interval extractions are generally within
25 ms of those extracted from the Lead II ECG, with an overall negative bias. The Bland
Altman plot shows a -9.36 ms bias in the QTc interval with an error of 37.06 ms (1.96
times the SD). Manual determination of QT interval with a caliper has an error between
20-40 ms [125], and for four different automated approaches the standard deviation in QT
differences to a gold-standard is over 20 ms for each [126].
This indicates that the bECG QTc interval compared to the gold-standard, which has a stan-
dard deviation of 18.91 ms, is more than sufficient for diagnostic purposes. A small number
of significant outliers greatly impact the error calculated from the standard deviation. Since
the Q, S and T wave feature locations are more sensitive to noise than the R-wave delin-
eation, improved signal quality classification algorithms have the potential to improve QRS
duration and QTc interval estimation more so than the other results presented herein.
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6.6.3 HF Results and Discussion
The bECG was captured on HF subjects using fully integrated instrumentation in the FIT
seat and compared to the traditional Lead II ECG. While the Lead II ECG is captured
with traditional adhesive gel electrodes on the chest, the bECG relies on dry skin contact
with the buttocks and is more sensitive to motion artifacts. These motion artifacts result in
transient noise in the bECG waveform. The automated SQI algorithm rejects these regions
of poor signal quality. The accepted segments can then be used for feature delineation and
waveform averaging. Examples from two subjects of Lead II and bECG ensemble averaged
waveforms are shown in Figure 6.6. While these waveforms present new challenges for
feature delineation algorithms due to their non-standard shape, the bECG reliably captures
waveform morphology as compared to the Lead II ECG.
Heart rate was calculated per recording for the bECG and Lead II ECG waveforms for 25
heart failure subjects at rest. A total of 158 recordings were analyzed with matched pairs
plotted in Figure 6.7. The automated algorithms for R-wave determination resulted in an
excellent agreement between the two lead vectors, with nearly all data aligned along the
perfect correlation line, and all but three values well within the ±10% error bounds.
The algorithms for estimating HRV, QRS, and QTc interval failed to produce acceptable re-
sults on the HF population. They were developed for the normative subject population with
classic ECG morphology. However, this HF population has non-standard waveforms; some
with additional waves within the QRS complex resulting in delineation errors. Additional
work is required to refine the algorithms for robust and consistent time accuracy on the
identified features. The current algorithms fail on both the bECG and Lead II ECG wave-
forms, suggesting a fundamental algorithm issue rather than challenges with the bECG
specifically.
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(a) (b)
Figure 6.6: Example ensemble averaged waveforms from two heart failure (HF) subjects
(a) and (b) with Lead II (top) and bECG (bottom). The bECG reliably captures waveform
characteristics in this diseased population, but the non-standard waveform shape creates
challenges for feature delineation.
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Figure 6.7: Heart rate extracted from the bECG signal are closely aligned with those ex-
tracted from the gold standard Lead II ECG. The dashed line represents perfect correlation,
while the dotted lines represent ±10% error. Data from 25 heart failure subjects.
6.7 Conclusion
The work presented herein demonstrates that a toilet seat based dry electrode buttocks
ECG (bECG) provides robust determination of HR, HRV, QRS duration, and QTc interval
as compared to a standard Lead II ECG captured using traditional gel electrodes. Advanced
ECG signal processing algorithms custom designed for noisy, dry electrode ECG signals
have been presented for use with the bECG. A key component of these algorithms is the
classification of ECG signal quality, which allows automatic rejection of noisy segments
before feature delineation and interval extractions. The bECG was most closely corre-
lated to standard Lead II with an average HR and HRV accuracy of 0.02±0.5 bpm, and
-3.33±12.27 ms respectively. Similarly, the estimated QRS duration has an accuracy of
-0.38±6.6 ms and the QTc interval has an accuracy of -9.8±22.6 ms. By further improving
the signal quality classification algorithm, it is expected that the accuracy of all the bECG
measures compared to a gold-standard Lead II will be greatly improved.
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These results lay the foundation for future studies by demonstrating the accurate extraction
of key cardiac intervals from the bECG as compared to a clinical gold-standard on a nor-
mative population. Future studies will investigate the clinical utility of the bECG for heart
failure subjects and the ability of a deployed, self-contained, toilet seat based system to
monitor long-term trends in the home. Such a device has the potential to capture long-term
trend data that has been previously unattainable, as it facilitates daily measurements taken
at rest prior to food and stimulants (e.g. caffeine, nicotine, etc.) at consistent times each
day, with no required change in habit. This, in combination with intra-day circadian trends
will enable new approaches and capabilities in the diagnosis and treatment of cardiovascu-
lar disease for those with heart failure, hypertension, and those undergoing chemotherapy
treatments.
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Chapter 7
BCG, PPG, and Blood Pressure
7.1 Introduction
Robust non-invasive absolute blood pressure estimation using pulse wave velocity (PWV)
has not been demonstrated in literature. Many devices exist that require a patient based
calibration that is only valid for the current physiologic state [51, 127, 128, 129]. The
ability of these systems to produce accurate blood pressure measurements break down over
time and require constant recalibration.
This chapter discusses the steps needed to robustly estimate blood pressure from the FIT
seat using PWV. A per-subject calibration is used, which will not break down over time.
This calibration leverages a first principle, physics based hemodynamic model of the aorta
to generate a per-subject calibration that is ultimately used to estimate diastolic blood pres-
sure [130, 131, 132, 133]. The BCG is used for proximal timing of the pulse transit time
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and the bPPG is used for distal timing. Advanced signal processing techniques allow for
the robust extraction of timing features from the BCG and bPPG. Extreme accuracy is crit-
ical when calculating the pulse wave velocity, as small timing differences result in large
blood pressure variation.
7.2 PPG Delineation
The PPG plays an integral roll in the estimation of blood pressure, since accurate periph-
eral pulse wave timing is critical to the extraction of the pulse transit time. This sections
demonstrates that the bPPG on the FIT seat contains robust foot timing that can be used for
blood pressure estimation.
7.2.1 Thigh Cuff as Failed Gold-Standard
It was initially believed that a thigh cuff based plethysmogram could be used as a gold
standard for FIT bPPG timing. As the pressure necessary to acquire a pulse varies based on
a subject’s blood pressure the effects of pressure on feature timing was also investigated.
The timing consistency of the thigh cuff foot was tested on three subjects, for pressures
between their systolic and diastolic BP.
A single recording for each subject was captured, where the thigh cuff pressure was slowly
decreased from 10 mmHg above the subject’s systolic BP to 10 mmHg below their diastolic.
The delay between the R-peak and the foot of the thigh cuff plethysmogram was used to
determine the time shift of the foot relative to pressure. A plot is generated showing the
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R-peak to thigh cuff foot timing on a beat-to-beat basis for the entire recording.
In order for the thigh cuff to be used as an acceptable gold standard, the foot locations must
be consistent across a range of cuff pressures. As demonstrated in Figure 7.1, the location
of the thigh cuff foot varies drastically as the thigh cuff pressure is changed. These figures
show how the foot location changes as the thigh cuff is deflated from 10 mmHg above a
subject’s systolic BP to 10 mmHg below a subject’s systolic BP. This process was repeated
twice, as indicated in the figure.
(a) (b)
Figure 7.1: Change in thigh cuff foot timing for Subject 1 (a) and Subject 2 (b) relative to
R-peaks from a Lead II ECG as the thigh cuff pressure varies across time.
Both subjects show a change of over 30 ms between systolic and diastolic pressures. These
results are valid under the assumption that the pulse arrival time is not drastically changing
throughout the course of the recording (2 minutes). This indicates that the thigh cuff based
foot locations cannot be used as an accurate temporal gold standard for the bPPG.
Given that the thigh cuff is only present during a small percentage of a subject’s overall
data and that there is a variable time shift between features, better options exist for deter-
mining bPPG foot classifications. The ECG R-peaks from Lead II are better suited for this
purpose, given that it is a very clean and reliable signal present continuously throughout all
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recordings. Assuming that the pulse arrival time does not change drastically within a single
recording, the difference between the ECG R-peaks and bPPG feet can be considered a
per-recording constant and removed before classification.
7.2.2 Buttocks PPG (bPPG) Delineation Results
Methods
The FIT bPPG is used to estimate both pulse transit time and blood oxygenation (SpO2).
The efficacy of the FIT bPPG was determined by comparing waveform delineations to those
found in a gold-standard Lead II ECG waveform. Custom algorithms were developed to
automatically assess signal quality and reject noisy waveform segments as described in
Chapter 4. The bPPG foot locations are found in order to preliminarily locate each beat.
These locations are found using a derivative based method with a narrow bandpass filter.
For this study, the bPPG foot is defined as the maximum point in the second derivative
(point of maximum upward acceleration).
Once the foot locations are found, a neighborhood is defined for each beat and the beat
under test is compared to the beats within the neighborhood using correlation. If the cor-
relation is below a pre-determined threshold, the beat is considered to be of poor quality.
This correlation based SQI is generated on a beat-by-beat basis, with accepted and rejected
regions determined using a simple threshold in combination with segment length criteria.
The percent of data rejected is captured in the delineation statistics. Final foot locations
were then recalculated taking into account signal quality classifications. This ensures that
noisy parts of the signal do not cause incorrectly delineated beats.
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The sensitivity and PPV of the bPPG feet are found using the Lead II R-peaks as a gold-
standard. An acceptance interval of ±75 ms was chosen over a small interval, since it
will better indicate how many beats were correctly located rather than how accurate the
delineations are in time. This is especially important since the delay between ECG R-
peaks and bPPG feet is not constant on a beat-by-beat basis. The time shift between these
two features is called the pulse arrival time, and it needs to be removed before classifying
each beat. The average delay between the R-peak and bPPG foot is found using cross
correlation. To visualize ability of the bPPG to accurately estimate the heart rate (HR), the
bPPG based HR is plotted versus the corresponding Lead II extractions.
Normative Results and Discussion
The sensitivity and positive predictive values were then calculated for the bPPG feet using
the Lead II ECG R-peak as the gold standard reference. Results are presented in Table
7.1 for all subjects across rest and post-stress protocols. A total of 150 recordings were
analyzed. Approximately 45% of all bPPG data was of suitable quality for inclusion in the
analysis (i.e. they pass the automated SQI algorithm). While this number is much lower
than the bECG, it still results in sufficiently long regions of acceptable bPPG that can be
used to estimate HR, pulse transit time, and SpO2.
The bPPG within in the FIT seat that was used for normative testing was a very early pro-
totype. Due to DAQ restrictions (all data was continuously acquired on a single DAQ), the
two wavelength bPPG could not be pulsed as is typically done. As such, the bPPG consisted
of two photodetectors each outfitted with optical filters to separate out each wavelength.
These filters result in attenuation of the bPPG. Furthermore, the added distance between
the photodetector and the body resulted in additional attenuation of an already small sig-
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Subject Sensitivity PPV Pass SQI
3 86.6% 96.7% 44.2%
4 64.0% 89.3% 43.2%
5 82.1% 92.3% 40.7%
6 95.8% 98.9% 84.5%
7 76.5% 91.3% 16.7%
8 88.4% 95.3% 41.4%
9 73.8% 90.9% 12.8%
14 73.3% 89.4% 26.2%
15 77.8% 94.8% 26.6%
21 91.0% 97.4% 72.6%
24 85.3% 92.8% 30.6%
26 74.2% 86.8% 39.7%
27 96.0% 99.1% 87.5%
31 88.7% 93.7% 61.6%
32 86.2% 92.3% 9.3%
33 97.2% 99.6% 90.8%
35 70.9% 82.0% 6.2%
36 85.3% 95.2% 57.6%
38 70.4% 87.1% 13.8%
41 96.3% 99.3% 82.4%
44 88.2% 96.1% 64.1%
63 89.0% 95.7% 56.9%
84 80.3% 88.4% 22.7%
85 93.5% 99.1% 74.9%
88 64.9% 73.0% 10.2%
Overall 89.8% 96.5% 45.2%
Table 7.1: Sensitivity, positive predictive value, and percentage of waveforms that pass
SQI in the bPPG analysis for the normative subjects at rest and post-stress.
nal. Supply noise was also problematic since this prototype used for normative testing was
more prone to mains noise than future the current version of the seats. These issues have
all been addressed in the next current version of the seat, which uses a custom integrated
PPG AFE that pulses each LED (removing the need for optical filters) and optimizes signal
to noise ratio on a per-sample basis.
Despite lower than desired signal quality, the overall sensitivity of the bPPG was still
89.8%. The much higher positive predictive value (PPV) of 96.5% suggests a very high
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true positive rate compared to the sensitivity. This is a desirable algorithm behavior, since
it is better for the algorithm to miss beats than to incorrectly identify beats where none
exist.
Figure 7.2: Heart rate as extracted from the bPPG signal is closely aligned with that ex-
tracted from the gold standard Lead II ECG. The dashed line represents perfect correlation,
while the dotted lines represent ±10% error. At rest (red) and post-stress (blue) extractions
are shown.
Heart rate is calculated per recording for the bPPG and Lead II ECG waveforms for 25
normative subjects at rest and post-stress. A total of 108 recordings were analyzed with
matched pairs plotted in Figure 7.2. The automated algorithms for PPG foot detection
resulted in an excellent agreement between the two lead vectors, with nearly all data well
within the ±10% error bounds. The errors in HR are likely due to noise in the bPPG
waveform impacting delineation accuracy. While the results are excellent for the system
as described, further enhancements to the bPPG instrumentation and optics are expected to
significantly improve results.
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Heart Failure Results and Discussion
The sensitivity and positive predictive values were then calculated for the bPPG feet using
the Lead II ECG R-peak as the gold standard reference. Results are presented in Table
7.2 for all subjects across protocols 1 and 2 (Chapter 5). A total of 179 recordings were
analyzed. Approximately 51% of all bPPG data was of suitable quality for inclusion in the
analysis (i.e. they pass the automated SQI algorithm). While this number is much lower
than the bECG, it still results in sufficiently long regions of acceptable bPPG that can be
used to estimate HR, pulse transit time, and SpO2.
The overall sensitivity of the bPPG was still 88.4%. The much higher positive predictive
value (PPV) of 93.1% suggests a very high true positive rate compared to the sensitivity.
This is a desirable algorithm behavior, since it is better for the algorithm to miss beats than
to incorrectly identify beats where none exist. These results show an overall improvement
in signal quality by approximately 6% compared to normative subject testing despite the
reduction in signal quality with the HF population. This is attributed to enhancements made
with the integrated electronics.
Heart rate is calculated per recording for the bPPG and Lead II ECG waveforms for 25
heart failure subjects at rest. A total of 179 recordings were analyzed with matched pairs
plotted in Figure 7.3. The automated algorithms for PPG foot detection resulted in an
excellent agreement between the two lead vectors, with nearly all data well within the ±10%
error bounds. The errors in HR are likely due to motion artifacts in the bPPG waveform
impacting delineation accuracy.
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Subject Sensitivity PPV Pass SQI
101 40.7% 93.8% 5.3%
102 97.4% 98.8% 77.8%
103 76.1% 90.5% 36.7%
104 41.6% 99.2% 23.1%
105 96.6% 98.6% 76.8%
106 84.6% 90.3% 55.6%
107 84.3% 96.0% 70.0%
108 79.9% 85.2% 61.6%
109 74.8% 92.6% 13.2%
110 33.3% 62.5% 1.0%
111 68.5% 68.8% 85.1%
112 96.5% 94.4% 65.4%
113 79.3% 85.7% 43.7%
114 81.9% 80.4% 49.5%
115 98.9% 100.0% 96.1%
116 94.3% 98.5% 77.2%
117 94.7% 96.1% 74.7%
118 89.0% 83.5% 40.3%
119 94.4% 99.2% 81.4%
120 77.4% 97.9% 18.8%
121 80.0% 94.0% 40.3%
122 85.0% 82.5% 59.1%
123 95.8% 98.5% 81.9%
124 96.7% 96.9% 97.4%
125 93.4% 96.5% 89.1%
Overall 88.4% 93.1% 51.4%
Table 7.2: Sensitivity, positive predictive value, and percentage of waveforms that pass
SQI in the bPPG analysis for the normative subjects at rest and post-stress.
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Figure 7.3: Heart rate as extracted from the bPPG signal is closely aligned with that
extracted from the gold standard Lead II ECG for the HF population. The dashed line
represents perfect correlation, while the dotted lines represent ±10% error.
7.3 Blood Pressure and BCG Timing
7.3.1 Methods and Calibration
Arterial radii and wall thickness in the aorta are measured using an ultrasound machine
at systolic by a cardiologist (Karl Q. Schwarz, MD), diastolic and mean arterial blood
pressures [130]. An example capture from the ultrasound machine is shown in Figure 7.4,
where three measurements are taken for each blood pressure.
By capturing these features at multiple pressures, a physics based model can be used to
create a subject specific PWVp (pressure dependent pulse wave velocity) to blood pressure
curve (Figure 7.5). This is used to estimate diastolic BP. From this curve, a 6 ms time shift
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Figure 7.4: Example calibration measurements from a test subject, captured from a GE
Vivid i echocardiogram. The aortic wall thickness is measured at three distinct arterial
pressures. These values are used to create a PWV to BP curve from a physics based model.
in the pulse transit time (for a subject with an aortic length of 0.63 m) corresponds to a
10 mmHg shift for diastolic blood pressure. This highlights the need for the algorithms
developed throughout this work, which focuses on a high temporal accuracy for delineated
features.
Figure 7.5: From the ultrasound based calibration, the pulse wave velocity to blood pres-
sure curve is created using the first principle physics based hemodynamic model of the
aorta. Three curves are shown, based on errors in the aortic measurements.
The measured PWV from the FIT seat (PWVm) consists of both the pressure dependent
PWV (PWVp) and a flow velocity (Vf), as shown in (7.1) [131, 132]. The flow velocity
is the bulk flow of blood due to ventricular ejection, while the pressure dependent PWV
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is created during ejection. The pressure dependent PWV, which is used to estimate blood
pressure using the subject calibration curve, cannot be measured directly, except when the
flow velocity is zero.
PWVp+Vf = PWVm (7.1)
In diastole, the flow velocity is zero, making the measured PWV equal to the pressure
dependent PWV. For systolic blood pressure, the flow velocity is non-zero. In order to
estimate systolic blood pressure using the physics based model, the flow velocity first needs
to be estimated and subsequently subtracted from the measured PWV. The pulse wave
velocity can be calculated from the pulse transit time and the aortic length (measured as
described in Chapter 5).
7.3.2 In-Home Data
A single subject underwent the calibration procedure described Section 7.3.1, the result of
which is an individualized PWVp to BP curve. The resulting aortic dimensions are shown
in Table 7.3. The same subject used a FIT seat in their home for the duration of this test.
The subject was instructed to measure their blood pressure three times before sitting on the
FIT seat. Multiple blood pressure recordings were required due to the high variability of
in-home automated blood pressure cuffs. The three blood pressure readings (taken using an
Omron 10 Series BP786N Upper Arm cuff) are used to calculate an average gold-standard
blood pressure for each FIT recording, creating a single time point for this test. The subject
was also instructed not to perform a bowel movement (BM) during this event, as blood
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Ao Diameter Diastole (cm) 2.9390
Ao Diameter Mid Systole (cm) 3.0473
Ao Diameter End Systole (cm) 3.0753
Ao Wall Diastole (cm) 0.1663
Ao Wall Mid Systole (cm) 0.1117
Ao Wall End Systole (cm) 0.1157
Table 7.3: Aortic Dimensions for BP Calibration
pressure is expected to change during a BM.
A total of 38 blood pressure events were captured by the subject throughout the course of 11
weeks. 36.8% of the events were rejected due to poor signal quality in the FIT recordings.
This is expected, as the FIT seat was not in a controlled hospital or laboratory environment.
The resulting 24 events were then used to estimate the subject’s blood pressure over time.
7.3.3 BCG Interval Timing
A FIT seat based pulse transit time (PTT) can be calculated by using the bBCG for proximal
timing and the bPPG for distal timing. The PWVm is calculated from the measured PTT
and an aortic length, where the aortic length is estimated from a combination of superficial
and ultrasound based measurements. For the diastolic pulse transit time, the starting point
(proximal) is the moment of ventricular ejection and the end point (distal) is the onset of
the peripheral pulse. For systolic pulse transit time, the starting point is the moment of peak
flow velocity, which approximates peak ejection pressure, and the end point is the moment
of peak pressure at the peripheral pulse.
The timing of each BCG feature is compared to the ultrasound based valve opening time,
shown in Figure 7.6. These results were generating using manual annotations of the BCG,
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not automated algorithms. Figure 7.6-(a) shows the offset and standard deviation of each
BCG feature compared to aortic valve opening, while Figure 7.6-(b) compares the same
feature to the moment of peak velocity. The gold standard timing values for valve opening
and peak ejection were measured from a simultaneous ultrasound captured on each nor-
mative subject. The start of diastolic pulse transit time (valve opening) is not well defined
on the BCG, as the closest feature (G-wave) has a large standard deviation. The I-wave,
despite being offset in time, has a much lower standard deviation when compared to valve
opening than any other feature.
This indicates that the G-wave is not the best feature to use for accurately locating valve
opening. As an example, the moment of valve opening can be estimated by adding a
negative offset to the I-wave, or any feature associated with the I-wave or its integrals.
This offset could be expressed as a fixed time interval, as a percentage of the heart rate
period, or as a combination of both. When using the I-wave location, the combined total
of this negative offset should be between 73 ms and 129 ms on a per subject basis (taking
into account two standard deviations), based on the mean and standard deviation of the
difference between the I-wave and valve opening.
The foot location on the bPPG was chosen to be the diastolic pulse transit time end point
because it is the most prominent and well defined feature of the PPG. The true endpoint of
the diastolic PTT is the PPG minimum, which is much less prominent and less consistent
than the PPG foot. The average time difference between the bPPG foot and minimum is
35 ms. The diastolic pulse transit time is calculated from the moment of valve opening to
the bPPG foot as shown in Figure 7.7. The aortic valve opening time is calculated from the
BCG I-wave using a temporal offset.
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(a)
(b)
Figure 7.6: The timing difference from aortic valve opening (AVo) to each BCG wave
indicates that the G-wave is the closest approximation, although the I-wave with a fixed
temporal offset may yield a more consistent determination due to the smaller standard
deviation of measure (a). The timing difference between the moment of peak ejection to
each BCG wave indicates that the I-wave location is the closest in proximity to the moment
of peak ejection velocity, with an offset of 17 ms (b).
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Figure 7.7: The start of the systolic and diastolic pulse transit times can be estimated by
time shifting the I-wave appropriately. There is variability across patients when shifting
from the I-wave. This variability can be reduced by integrating a time shift that is propor-
tional to the HR period, or by choosing more prominent features.
7.3.4 BCG Features for Diastolic BP Estimate
An optimization based approach was used to explore BCG feature correlation with the
moment of ventricular ejection as there is no definitive, temporally aligned feature for ac-
curately estimating when this event occurs. The BCG measured by the FIT seat is propor-
tional to acceleration, due to the sensor and measurement modality chosen. By taking the
integral(s) of the BCG, other non-standard features relating to ejection velocity or displace-
ment become apparent. The optimization algorithm determines the feature and associated
time shift that best correlates with ventricular ejection.
Equation (7.2) is used to model diastolic PWVp from two distinct features measured with
the FIT seat. Flow velocity is zero for diastole, so it is not included in this equation,
making PWVm equivalent to PWVp. The end point for the diastolic PTTtd,end is the bPPG
foot location, which is well defined and does not require a time shift. As of the potential
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starting features for PTTtd,start require a time shift, two constants (c0 and c1) have been
included to account for this time shift. Constant c0 incorporates a percentage of the HR
interval (Thr) and c1 incorporates a fixed time delay. It is important to have both a constant
time shift (c1) and one that is dependent on HR (c0), since it is not clear how BCG feature
locations change relative to HR variability.
xa
td,end−AVo = PWVm,diastolic = PWVp,diastolicAVo = td,start + c0 ∗Thr + c1 (7.2)
Potential starting features (Td,start) include the I-wave of the BCG, the trough of the first
integral (velocity), the peak of the second integral (displacement), and the following zero
crossing of the second integral (displacement). These features are shown in Figure 7.8,
where a typical BCG waveform has been integrated to clearly show the potential PTT start
location. For each end feature, the associated time shift is found using the optimization
process, allowing the PTT to be calculated using the bPPG foot (td,end). The resultant PTT
is converted to a PWV using the aortic length (xa).
Optimization is performed in order to minimize the error of the estimation compared to the
range of the three daily gold-standard measurements (BP). The optimization structure is
shown in (7.3). The constants c0 and c1 are used to estimate valve opening (AVo), which
in turn is used to estimate the diastolic pulse transit time and pulse wave velocity using the
subject’s aortic length. The resulting pulse wave velocity is used to calculate the estimated
blood pressure (BˆP) using the subject specific curve. Optimization is performed on each of
the aforementioned features (tstart), resulting in constants for each, where constant c0 is a
percentage of the heart rate period (TRR) and c1 is a fixed offset.
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Figure 7.8: Eight different features are potential candidates for the starting point of the
PTT. All of the potential features are related to the IJ complex and are on the BCG, the first
integral of the BCG, or the second integral of the BCG. The feature that results in the best
diastolic BP estimation is the first zero of the BCGs second integral (“
∫∫
zero 1”).
argmin
c∈R2
E[ fe(BˆP,BP)] where
BP ∈ R3
fe(BˆP,BP) =

|BˆP−max(BP)| if BˆP > max(BP)
|BˆP−min(BP)| if BˆP < min(BP)
0 otherwise
PWVm =
xa
tend−AVO
AVO = tstart + c0 ∗THR+ c1
(7.3)
The results from this optimization process indicate that the zero crossing of the second
integral (“
∫∫
zero 1”) is the feature which most consistently represents the moment of ven-
tricular ejection. The matching constants, c0 and c1 are 5.1% of the HR period and 75 ms
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respectively. The average time shift can then be calculated by multiplying the average HR
across all recordings by c0 and adding the fixed offset from c1. The resulting AVo timing as
estimated by the optimization process can compared to the normative data valve opening
AVo location, by taking into account the appropriate mean time shift for the normative data
and the optimization based time shift. For each recording analyzed, 101 ms was subtracted
from the I-wave location and used as the “normative mean AVo location”. The AVo location
as estimated from the zero crossing of the second integral is calculated using optimization
based on the time shift of c0 and c1 and the average time shift between the bPPG minimum
and foot. The difference between the “normative mean AVo location” and the optimization
based location is then compared to the normative results in Figure 7.6. A mean difference
of 3.8 ms was found between the normative data and the optimization based approach.
This is demonstrated in Figure 7.9, where the expected time shift range is shown in blue
and the per-recording time shift range is shown in red. Additionally, this time shift is in line
with what was extracted from the test subject’s individualized calibration data (as compared
to a synchronized echocardiogram), which showed a time shift of 103 ms, which is 2 ms
different from the normative mean AVo timing. These points are shown as a green “x” in
Figure 7.9. This partially validates the optimization based approach, where a custom time
shift from a different feature results in a much more consistent estimate of aortic valve
opening.
It was initially expected that the time shift associated with the chosen feature is not sub-
ject dependent, but would be fixed across a population. This has been tested across the
normative data set, by utilizing the previously found constants. If this results in a low stan-
dard deviation error compared to the ultrasound based gold-standard, the constants can be
considered globally valid on the normative population.
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Figure 7.9: The estimate of aortic valve opening from the in-home study significantly im-
proves upon the timing estimate for aortic valve opening across the normative population.
This indicates that the resulting constants from the optimization based approach have a
physical basis.
The results from these tests are shown in Table 7.4, where the resulting c0 and c1 from
the 11-week optimization are utilized to estimate valve opening timing. The individual
subject’s timing captured during calibration using the ultrasound shows an error of 2 ms.
The standard deviation for the entire normative population is 22 ms, while the standard
deviation using a fixed offset from the I-wave is 14 ms. This indicates that the constants
found for the previous subject are not valid across the normative population.
Time Shift AVo Error
11-Week BP Study Optimized 10 ms (1-SD)
Echo Calibration Optimized 2 ms (N=1)
Normative Optimized 22 ms (1-SD)
Normative I-wave Constant 14 ms (1-SD)
Table 7.4: Timing results across the normative population using the individualized con-
stants from the 11-week trial, compared to the unoptimized I-wave timing.
Despite there being inherent measurement error in the AVo gold-standard, these results
indicate that a per-subject time shift may be required to accurately estimate AVo. An alter-
native approach could utilize other timing intervals to calculate the time shift between each
feature and AVo, resulting in a different model equation from that in (7.3).
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7.3.5 Diastolic BP Estimate
Using the best feature (“
∫∫
zero 1”) and associated constants, the resultant BP estimate
shows excellent agreement with the cuff-based gold standard. The resultant BP estimates
are compared to the gold-standard measurements in Figure 7.10. The darkest error bars
represent the measured range (maximum and minimum) of the three BP cuff gold-standard
values, without any error measurement error taken into account. On average, the diastolic
BP estimate falls outside of the measured range by only 2.72 mmHg, which are well within
the limits required by the AAMI standards organization [134].
Figure 7.10: The diastolic BP estimate from the FIT seat accurately tracks trends in BP
over the course of 6 weeks. The resulting accuracy is compared to the range of the gold
standard measured using a commercial BP cuff. The errors in estimation are in line with
what one would expect when accounting for the accuracy of the commercial BP cuff.
Blood pressure cuffs are notoriously inaccurate. The manufacturer quoted error for the BP
cuff utilized was 2% or 3 mmHg, whichever is greater. A study where commercial BP
cuff accuracy was compared to a hospital grade system was conducted at Ottawa Hospital
in 2011 [135]. Across 210 clinical patients, blood pressure cuffs are off by more than 5
mmHg for 30% of the clinical patients [135]. This corresponds to a standard deviation
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of 4.8 mmHg. The mid-range error bars in Figure 7.10 incorporate the error quoted by
the manufacturer of the BP cuff used by the subject. This is calculated by adding this
error to the range of BP measurements. The lightest error bars are the measured values
incorporating the error presented in the Ottowa Hospital study. This provides a reference
for the type of accuracy that can be expected from devices currently used for in-home
monitoring of BP.
7.3.6 Proposed Signal Processing Improvements
While signal processing algorithms can be continually improved, there are specific areas
where improvement will directly improve the accuracy of BP estimation. This section
outlines recommended area to focus on in future work, specifically ensemble averaging and
signal quality algorithm improvements, with the goal of improving the temporal accuracy
of features in the BCG and PPG.
Beat to beat variability between features introduces smearing in ensemble averaging. As
an example, even though we know the bPPG foot can be used as the most robust end point
for diastolic PTT, beat averaging still introduces smearing, which may introduce error in
the timing extraction. This is illustrated in Figure 7.11, where the variability in the foot
location is as high as 100 ms. The physiologic parameter or cause that can be attributed to
these shifts is not known, unlike the shifts within the ECG. This variability may average out
for a single recording, but the specific method of ensemble averaging impacts the location
of each feature.
As such, ensemble averaging has a significant impact on estimating BP. Future work should
investigate the best way to ensemble average both the bPPG and BCG, where the goal is
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Figure 7.11: There is a large amount of beat-to-beat variability when ensemble averaging
the bPPG relative to the R-wave peak. The PPG minimum and foot location can vary as
much as 100 ms within a one minute recording. This introduces smearing in the ensemble
averaged beat, potentially reducing the temporal accuracy of the feature.
to minimize feature smearing. Different types of beat resampling should be investigated,
such as normalization to the RR-interval. Improved signal quality metrics for beat rejection
will also have the potential to reduce feature smearing when ensemble averaging. This may
include rejection criteria based on amplitude variations, and beat timing from preceding or
subsequent beats.
With improved ensemble averaging techniques, the location and prominence of specific
features may change. The surrogate features currently used when estimating BP may be
replaced with features that are directly related to key physiologic events. As an example,
the features (G-wave) closest in proximity to valve opening is currently non-distinct. With
improved signal processing methods, the direct use of the G-wave or other more robust
features may be possible.
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7.4 BCG Amplitude and Cardiac Function
7.4.1 Methods
There are many ways to assess ventricular systolic contraction and cardiac function (e.g.
LV stroke volume, stroke rate, strain, strain rate, among others). The rate of ventricular
systolic ejection can be measured by using the product of the velocity of blood flow in
left ventricular outflow tract (LVOT) and its area. The LVOT velocity is measured with
pulsed wave Doppler ultrasound (Figure 7.12-(a)) and the LVOT area is estimated using the
formula for a circle and the measured diameter (Figure 7.12-(b)). In the example shown,
the LVOT diameter is 1.1 cm and the LVOT peak velocity is 100 cm/s, which yields a peak
stroke rate of 346 cc/s.
(a) (b)
Figure 7.12: An example Doppler ultrasound capture used to measure the LVOT velocity
(a). This measure, combined with the LVOT diameter (b) can be used to calculate stroke
rate. Courtesy of Karl Q. Schwarz, MD.
As the BCG is a measure of the mechanical activity of the heart, it is believed that the IJ am-
plitude has a correlation to stroke rate. This hypothesis will be validated by determining the
IJ amplitude using the delineation algorithms described in Chapter 4 across all normative
subjects. The ultrasound measure with the highest linear correlation will be presented.
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7.4.2 Results and Discussion
The correlation between IJ amplitude and cardiac function is highlighted in Figure 7.13,
where the rest and post-stress ensemble averaged BCG waveform is shown for a single
subject.
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Figure 7.13: For a single subject, the BCG morphology remains consistent at both rest and
post-stress. At post-stress, the IJK complex has been shifted towards the R-wave and the
IJK amplitude has been significantly increase when compared to the rest ensemble average.
The time axis (in seconds) is the same for both rest and stress. Courtesy of Karl Q. Schwarz,
MD.
The correlation between ventricular systolic contraction is compared to the BCG using
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Figure 7.14: The correlation of BCG amplitude measures to stroke rate is shown for both
rest and post stress. This measure has a very high linear correlation to the echocardiogram
gold standard. The stroke rate has an R-value of 0.77 compared to the magnitude of the
IJ-wave in the FIT BCG.
the rate of ventricular systolic ejection (stroke rate), shown in Figure 7.14-(a). There is
a clear and distinct correlation between the magnitude of the BCG’s first integral and the
stroke rate. The stress data points are clustered at the higher range of both measures,
indicating that the FIT seat is capable of discerning between physiologic states using the
BCG. Heart failure echocardiogram analysis must be completed manually by a cardiologist
due to abnormal BCG morphologies present in the heart failure population. However, it is
expected that the HF results will be clustered closer to the origin due to the lower cardiac
output and poor cardiac function of these subjects.
By looking at the IJ amplitude for three distinct groups of cardiac function, low (HF),
normal (normative at rest), high (normative post-stress), a clear and statistically significant
distinction can be made between each. This is shown in Figure 7.15. This highlights the
ability of the BCG to differentiate between levels of cardiac function.
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Figure 7.15: The IJ amplitude of the low (HF), normal (normative at rest), high (norma-
tive post-stress) groups of cardiac function have statistically significant differences. This
demonstrates the ability of the FIT seat to differentiate between these groups.
7.5 Conclusion
The FIT seat can accurately measure diastolic blood pressure trends across time for a cali-
brated subject. An optimization based approach was utilized to find the optimal features for
estimating pulse transit time. The estimated pulse transit time is converted to a pulse wave
velocity using the aortic length, allowing direct BP estimation through a physics based
model and a single ultrasound based calibration. Using FIT only measurements for six
weeks, the estimated diastolic BP has an error of 2.72 mmHg on average when compared
to an off the shelf BP cuff. The approach described herein did not successfully estimate
systolic BP, however, it is believed that the BCG may be capable of estimating flow veloc-
ity, enabling accurate systolic BP estimation. This should be investigated through future
human subject testing, designed specifically for the validation of blood pressure based ap-
proaches.
The bPPG delineation algorithm, which was validated in Chapter 4, demonstrates robust
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foot extractions from the normative and HF population. Additionally, the variability of
different BCG features relative to key cardiac timing intervals has been demonstrated across
normative subjects. These results enable the accurate extraction of diastolic blood pressure
across subjects using a per-subject physics based calibration using the FIT seat. As such,
the FIT seat is the first device to demonstrate blood pressure estimation across long periods
of time without needing continual recalibration.
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Chapter 8
Sub-Nyquist Compressed Sensing
8.1 Introduction
The work presented in this chapter demonstrates sub-Nyquist sampling of the photoplethys-
mogram (PPG) on custom hardware. The purpose of this work is to significantly reduce
the power consumption of the PPG, which is the device that is responsible for the largest
percent of power consumption compared to other medical instrumentation in the FIT seat.
Existing sub-Nyquist techniques based on compressed sensing to reduce power consump-
tion are not ideal for signals such as the photoplethysmogram, which require an energy
source to generate the signal. By directly generating the compressed sensing measurement
vector, the sampling and measurement stages can be combined, which allows the signal
to be truly under-sampled. A novel system for the direct generation of the measurement
vector ia proposed.
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A custom photoplethysmogram analog-front-end is used to quantitatively demonstrate a
significant reduction in power consumption using the methods presented herein. Further-
more, physiological signals often contain a characteristic spectrum, allowing the use of
additional a priori information to create a weighting vector that can be used during re-
construction. This allows for a reduction in the number of measurements needed to accu-
rately reconstruct the signal, which further reducing power consumption. These methods
are tested across a range of subjects and physiological states to demonstrate robustness.
An error rate of less than 3% for the normalized root mean square deviation, root mean
square error, and temporal accuracy was achieved with an average sample rate one-tenth
the Nyquist rate. Results show an overall decrease in power consumption by 83.5% for
a custom photoplethysmogram analog-front-end, when sampling at one-tenth the Nyquist
rate.
8.2 Background
Compressed sensing is the process of reconstructing a sparse signal from a small number
of measurements[136, 137, 138, 139, 140]. It has been used in the past to reduce the
power consumption of wireless transmission in medical devices [141, 142], but it has not
been effective in reducing the power consumption that is associated with the analog-front-
end during data collection. Classically, compressed sensing does not reduce the number of
samples required, but rather reduces the number of measurements needed to reconstruct the
original signal [143]. These measurements are generated from the Nyquist sample vector
using a random sensing matrix. In essence, this is real-time block compression.
If the number of samples needed can be reduced, the PPG can see a significant improve-
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ment in power consumption. This can be done by using an identity based sensing matrix
to combine the sampling and measurement stages. The identity based sensing matrix is
structured so that matrix multiplication is not required when generating the measurement
vector. By generating the measurement vector directly, rather than from a Nyquist based
sample vector, a signal can be sampled at a rate less than Nyquist.
There have been many recent key advances in analog compressed sensing, but reducing the
power consumption of the PPG requires a different approach. The digital to information
converters presented in [144, 145, 146, 147] require the analog signal to be continuously
present, so that it can be modulated at, or above, the Nyquist rate. The goal when using
compressed sensing of the PPG is to reduce the on-time of the LED light source, which is
not possible if the PPG signal needs to be modulated at or above the Nyquist rate.
The aforementioned digital to information converters and the analog compressed sensing
method presented in [148] are very complex. For every compressed sensing measurement
taken, separate analog modulation circuitry is required. This must be duplicated for every
channel being measured, since the analog signal cannot be multiplexed. This makes scaling
up to a large number of channels impractical.
It has been shown that compressed sensing can be used on a variety of physiological signals,
including the ECG [149, 150, 151, 152, 153], the EMG [142], the EEG [154, 155], and
the PPG [156, 157]. These physiological signals tend to have a characteristic frequency
spectrum, which allow a weighting vector to be created from the use of additional a priori
information.
The work presented in [156] and [157] originally proposed the use of weighted reconstruc-
tion and an identity based sensing matrix for sub-Nyquist sampling of the PPG. In this
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work we demonstrate this in a hardware platform and quantify the performance at different
sub-Nyquist sampling rates across subject populations and physiological states. This effec-
tively combines the sampling and measurement stages of compressed sensing in a custom
PPG analog-front-end.
The identity based sensing matrix can be used on any signal that can be compressively
sensed and that is sparse in the frequency domain, and weighted reconstruction can be used
on any signal that contains a characteristic spectrum. In this work, the PPG signal was used
to quantitatively evaluate both methods. Since PPG power is dominated by the illumination
source [158, 159], this also served as a platform to evaluate potential power consumption
reduction using these techniques.
Both a commercial PPG and a custom PPG analog-front-end (AFE) are used for testing the
methods presented herein. The accuracy of these methods are tested across multiple sub-
jects and physiological states using the commercial PPG. True sub-Nyquist sampling and
the associated power savings is demonstrated with the custom hardware implementation.
8.3 Compressed Sensing Theory
8.3.1 Generating the Measurement Vector
The Nyquist-Shannon sampling theorem states that a signal must be sampled at a rate twice
the maximum frequency of the signal being sampled for it to be perfectly reproduced [160].
However, sampling at the Nyquist rate is inefficient for signals that contain a relatively
small amount of information with respect to their bandwidth.
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The result from uniformly sampling a signal at the Nyquist rate is an N dimensional sam-
ple vector, ~x ∈ RN . In classic compressed sensing, the measurement vector ~y ∈ RM is
determined by multiplying the Nyquist sample vector with a sensing matrix (A ∈ RM×N)
[137, 138], as shown in (8.1).
A~x =~y (8.1)
In compressed sensing, the number of measurements is much less than the number of
Nyquist samples in the sample vector (M  N). This creates an under-determined lin-
ear system, which is then used as a constraint during reconstruction. The method originally
proposed by Candes and Donoho uses `1 minimization (convex optimization) to reconstruct
the original signal, xˆ [137, 138], as shown in 8.2.
min
xˆ∈RN
‖Ψxˆ‖1 subject to~y = Axˆ, (8.2)
Successful compressed sensing, where xˆ approximates ~x, requires the original signal to
be sparse in at least one domain, where sparsity is defined as the percentage of non-zero
coefficients in~s of the sparse domain. This definition is relaxed when dealing with signals
that contain noise; sparsity is then defined as the percentage of non-negligible coefficients
[143]. The sparse domain coefficients~s ∈ RN are found by multiplying~x with the matrix
transform Ψ ∈ RN×N . An example of a sparse signal is shown in Figure 8.1, where the
PPG is shown to be sparse in the discrete Fourier domain.
If the sparsity level is known, one can estimate the minimum number of measurements
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Figure 8.1: A short PPG clip (a) and its discrete Fourier transform (b) are shown.
M needed to accurately reproduce~x from the number of samples (N) and number of non-
negligible coefficients (K) [143]. The lower bound for the number of measurements needed
to represent the signal is shown in (8.3).
M ≥ O
(
Klog(
N
K
)
)
(8.3)
The size of the sensing matrix (M×N) is based on the number of measurements needed.
This matrix must be incoherent to the domain in which the signal is sparse [143, 137].
Coherence is defined as the maximum correlation between elements in two matrices; in
this case, A and Ψ. In other words, each row in A must be spread out in the sparse domain,
allowing the maximum information to be captured from~x. It has been shown that by using
normal, uniform, or symmetric Bernoulli distributions to populate A, it will be incoherent
to Ψ with an overwhelming probability [143, 161].
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When A is populated with a random distribution, all of the samples in~x are used to deter-
mine~y. Such a sensing matrix would require all the digital values to have been previously
sampled at the Nyquist rate. This can result in power savings for a system that simply
needs to compress data before storage or transmission, but in applications where the act of
capturing data requires a large amount of energy or resources, a different approach must be
taken.
Given that only M measurements are required to represent ~x, only M samples should be
needed for accurate reconstruction. By creating the measurement vector directly from the
analog signal, only M samples are used, making Nyquist sampling unnecessary. This is
illustrated in Figure 8.2 where the analog signal is randomly sampled, directly populating
the measurement vector. This is compared to classic compressed sensing, which requires a
sensing matrix to generate the measurement vector.
Sample Vector
Sensing Matrix
Measurement Vector Measurement Vector
Samples
Classic Compressed Sensing Direct Generation of the Measurement Vector
Figure 8.2: Classic compressed sensing creates the measurement vector from the Nyquist
based sample vector and a sensing matrix. The sensing matrix is often random, requiring
every Nyquist sample to be used and resulting in large matrix multiplication on the sensor
node. By directly generating the measurement vector, the sensing matrix is removed from
the compressed sensing paradigm. Not only does this simplify the sensor node, but it also
allows for true sub-Nyquist sampling.
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When generating the measurement vector directly, the notation shown in (8.4) can be used
to reconstruct the desired signal. This results in the removal of the sensing matrix from the
compressed sensing paradigm. In Figure 8.2 and (8.4), the vector aˆ ∈ RM contain random
indices, so that each i-th value of xˆ is equal to the ai-th value of~y.
min
xˆ∈RN
‖Ψxˆ‖1 subject to~yi = xˆai (8.4)
Given that a sensing matrix is still required for many forms of reconstruction, it is desirable
to construct a sensing matrix that exactly represents the process of directly generating the
measurement vector. Such a sensing matrix is created from an identity matrix, which is
an orthogonal set of impulse functions. The process used for this is shown in (8.5), where
(N−M) random rows are removed from an identity matrix of size N to create A.
A =

1 0 0 0 0 0
0 1 0 0 0 0
0 0 1 0 0 0
0 0 0 1 0 0
0 0 0 0 1 0
0 0 0 0 0 1

=

1 0 0 0 0 0
0 0 0 1 0 0
0 0 0 0 0 1
 (8.5)
Previous research has shown that limited quantization and the use of structured matrices
do not negatively impact reconstruction accuracy [150, 161, 142]. An identity based sens-
ing matrix allows only one sample to be captured for each measurement needed, taking
quantization and matrix structuring to their extremes.
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Candes alludes to this method during a very important example when discussing incoher-
ence [143], and Baheti proposes the use of impulse basis functions when constructing the
sensing matrix [156, 157]. Their work shows that impulse functions are maximal incoher-
ence to sinusoidal basis functions, such as those used in the Fourier domain. The methods
presented herein improve upon this notion of using impulse basis functions by combining
the sampling and measurement stages, as shown in Figure 8.2, and by demonstrating that
the PPG can successfully be sampled at a rate less than Nyquist in custom hardware.
8.3.2 Weighted Reconstruction Using a Characteristic Spectrum
Compressed sensing theory states that the sparsity of the signal directly impacts the ac-
curacy of reconstruction [138, 137]. Signal reconstruction is the process of finding the
sparsest signal which adheres to the constraints imposed during measurement. The con-
straints typically used are from the under-determined linear system formed by the sample
vector, measurement vector, and sensing matrix. Reconstruction is typically done by min-
imizing the `1 norm of the coefficients for the domain in which the signal is sparse. This
type of convex optimization is shown in (8.2).
Other variations of this approach assume that a small measurement error is present, al-
lowing for more robust reconstruction when the measurement vector’s sparsity is affected
by noise [162, 163]. Given that there exists many ways to solve this minimization prob-
lem, Dixon has completed a comparison of multiple techniques, including different types
of convex optimization and greedy algorithms such as matching pursuit [162]. Their work
has shown that although convex optimization is not the fastest method for reconstruction,
it reliably provides accurate results.
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Weighted reconstruction changes classic reconstruction by allowing a less sparse, but a
more accurate signal to be chosen. The weighting vector is calculated in (8.6) using the
characteristic spectrum s¯ of the signal, and the constant σ , which restricts the maximum
possible value of the weighting vector. When a coefficient in the characteristic spectrum
is zero, the maximum weighting becomes 1/σ . For the work presented herein, σ = 16 is
used.
[w]i =
1
[s¯]i+σ
i = 0,1, · · · ,N−1 (8.6)
The coefficients of the reconstructed signal’s sparse domain are scaled by the weighting
vector during the optimization process in (8.7), placing a higher priority on the coefficients
that are known to characterize the given physiological signal. This is done by minimizing
the pointwise product of the weighting vector and the sparse coefficients.
min
xˆ∈RN
‖〈~w,(Ψxˆ)〉‖1 subject to~y = Axˆ, (8.7)
The weighting vector effectively decreases the sparsity of non-characteristic signals by
significantly increasing the coefficients which are not characteristic. This allows a recon-
structed waveform to be chosen that will more accurately represent a given signal, despite
the fact that it may be less sparse than other solutions. Many types of compressed sensing
reconstruction (e.g. greedy algorithms) search for the sparest solution. For this reason,
the weighting vector can be easily integrated into most compressed sensing reconstruction
methods by modifying the sparse vector.
171
8.4 Methods
The identity based sensing matrix and weighted reconstruction are both tested in two sep-
arate phases. The first phase uses a commercial system to test robustness across subjects
and varying physiological states, while the second phase uses a custom hardware imple-
mentation to measure the achievable power savings when compared to standard Nyquist
based sampling. Each phase utilizes the same error metrics to benchmark the reconstruc-
tion accuracy. For all the tests presented herein, the Fourier domain was used as the sparse
domain for the PPG.
8.4.1 Testing Across Subjects and Physiological States
The physiological data sets used were obtained under informed consent in a protocol ap-
proved by the Rochester Institute of Technology Institutional Review Board for Protection
of Human Subjects. The Biopac MP36 (Biopack Systems, Inc., Goleta, CA) was used
to capture synchronized ECG and ear PPG from six test subjects at a sample rate of 50
kHz [164, 165]. One minute measurements were captured at six different physiological
states for each subject. These physiological states include the subject at rest while sitting,
standing, and supine in addition to three activity levels that were varied using a recumbent
bike.
To ascertain the reliability of these approaches across subjects and physiological states,
each metric’s average and standard deviation is calculated across six physiological states
for each subject. The weighted reconstruction is compared to classic non-weighted re-
construction and the identity based sensing matrix is compared to the standard random
172
Gaussian sensing matrix. The comparisons are made using the error metrics discussed in
Section 8.4.3.
In order to match the Nyquist sampling rate used in the custom hardware compressed sens-
ing implementation, each one minute recording is decimated to a sample rate of 170 Hz.
Each recording is tested at an undersampling ratio (USR) of 5, 10, 15, and, 20 with a vector
size N = 2040, corresponding to a window size of 12 seconds. A single identity based
sensing matrix and a single Gaussian based sensing matrix were used across all subjects
and physiological states.
8.4.2 Direct Generation of the Measurement Vector in Hardware
In order to have complete control of the signal acquisition process, a custom PPG analog
front end (AFE) was built. The physical implementation uses off-the-shelf components
and consists of the AFE, a TI MSP430 microcontroller, power management, and a wireless
module. The schematic used for the custom AFE is the same as shown in Figure 3.7.
The AFE consists of a photodiode, a transimpedance amplifier, and an amplification stage.
The differential amplifier uses a DC reference to actively remove the DC offset from the
output of the transimpedance amplifier. The DC reference is generated using the MSP430
by averaging samples measured from the output of the transimpedance amplifier. This DC
value is only measured when the PPG is sampled, so that additional samples are not needed
when directly generating the measurement vector.
The light source for the PPG consists of a red LED that is pulsed when a sample is ac-
quired. The Nyquist sampling rate used herein is 170 Hz. The LED on-time is 0.99 ms
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for each sample, which corresponds to a duty cycle of 16.9%. Modern ultra-low power
devices such as the integrated Analog Front-End from Texas Instruments (AFE4490) has a
programmable duty cycle from 1-25%, with a typical duty cycle of 5% [166].
When the measurement vector is generated directly, there is no Nyquist sample vector for
which to compare the reconstruction. In order to benchmark the sub-Nyquist sampled
signals, 5 parallel ADC channels are used, one for the Nyquist rate and one for each USR
being tested.
A total of 12 files, consisting of 18 minutes of PPG data were captured from a single subject
at a sample rate of 170 Hz for verifying the custom AFE. The USRs and identity matrix
used for reconstruction was the same as when testing across subjects and physiological
states.
When measuring the AFE’s power consumption and generating the measurement vector
directly, separate vectors need to be captured for each USR. At a USR of 5, 10, 15, and 20,
three measurement samples containing a total of four minutes of PPG data were captured
from a single subject at rest within one hour. The AFE and LED currents were measured
during each of these captures and then averaged to determine the corresponding power
consumption for each USR.
8.4.3 Error Metrics
The overall signal quality is tested by using the NRMSD, shown in (8.8). This essentially
measures the normalized RMS of the error signal between the reconstructed PPG and the
original PPG.
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NRMSD =
√
E[(~x− xˆ)2]
(~xmax−~xmin) (8.8)
The percent change in a signals RMS is used to determine how reconstruction errors affect
the estimated SpO2 levels. The percent difference between the RMS of the reconstructed
vector and the original sample vector is calculated using (8.9). This is a normalized metric
for showing how the RMS of the entire signal has changed.
RMSdi f f =
|RMS(~x)−RMS(xˆ)|
RMS(~x)
(8.9)
The PPG foot represents the start of a single heartbeat [167]. The error in foot location
is defined as the temporal difference between the reconstructed foot location and Nyquist
foot location, shown in (8.10).
∆ f oot = |t f oot~x− t f ootxˆ| (8.10)
The wavelet transform derivative delineation (WTDD) algorithm presented in [165], was
used to locate the foot in each PPG beat. The WTDD algorithm consists of two phases.
The first phase locates the valid range for each beat, also known as beat segmentation. The
valid range for the PPG foot is found using the wavelet transform (WT) in combination
with a simple moving average window filter. The WT is implemented as a cascaded set
of FIR filters. The second phase uses the valid range and the first three derivatives of the
PPG signal to determine the foot location. The derivatives are calculated using FIR filters.
This algorithm has been shown to be reliable and robust across subjects and physiological
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states.
8.5 Results and Discussion
8.5.1 Robust Reconstruction
The results shown in Figure 8.3 (left) compares weighted reconstruction to classic `1 re-
construction across subjects and physiological states. These results show that weighted re-
construction performs significantly better than non-weighted reconstruction, reducing both
the overall error rate and the variation of the error for each error metric. This demonstrates
that higher USRs can be used with weighted reconstruction while maintaining a given tar-
get accuracy, further increasing the usefulness of compressed sensing.
Weighted reconstruction does not add any complexity to the reconstruction system, there-
fore, it is very easy to implement. Only one additional vector multiplication is needed each
time the `1 norm of the sparse domain is calculated. Existing systems do not need to be
physically modified to utilize weighted reconstruction as it requires no changes be made to
the sensor node, since the weighting vector is only used during reconstruction.
Furthermore, these results show that a single weighting vector can be used across a range
of subjects and physiological states to increase the accuracy of the PPG. The characteristic
spectrum never needs to be reprogrammed or updated since it is not something that is
subject specific, it is specific to the physiological signal being measured.
Given that the identity based sensing matrix allows for fewer samples to be used when gen-
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Figure 8.3: Classic exact reconstruction is compared to weighted reconstruction (left)
across a wide range of USRs, subjects, and physiological states. Similarly, the identity
based sensing matrix is compared to the random Gaussian sensing matrix (center). Fi-
nally, both weighted reconstruction and the identity based sensing matrix are compared to
classic compressed sensing (right) using exact `1 reconstruction and a Guassian matrix.
These results show that the identity based sensing matrix does not have any negative im-
pact on reconstruction accuracy when compared to a Gaussian based sensing matrix and
that weighted reconstruction significantly improves upon classic `1 exact reconstruction.
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erating the measurement vector, it must be shown not to reduce accuracy when compared
to the standard Gaussian based identity matrix. This is demonstrated by the comparison be-
tween the identity based and a Gaussian based sensing matrix in Figure 8.3 (center). These
results show that there is no discernible difference between the accuracy of the Gaussian
matrix and the identity based sensing matrix for the NRMSD, the RMS error, and the foot
error.
The magnitude of the variance for each metric has also not increased, showing that robust-
ness has not been reduced when using an identity based sensing matrix. This demonstrates
that this sensing matrix can be used without any negative impact on reconstruction accu-
racy. Therefore, the measurement vector can be directly generated.
The results when using both weighted reconstruction and the identity based sensing matrix
are compared to standard compressed sensing in Figure 8.3 (right). The overall error rate is
reduced and the variance of the error is reduced when using both the identity based sensing
matrix and weighted reconstruction. Compared to classic compressed sensing utilizing a
Gaussian sensing matrix and `1 reconstruction, each metric shows a significant decrease in
error.
These results have quantitatively demonstrated the validity of both the identity based sens-
ing matrix and weighted reconstruction within the existing compressed sensing framework
across subjects and physiological state.
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8.5.2 Hardware Validation Using the Identity Based Sensing Matrix
A comparison of truly sub-Nyquist sampled PPG waveforms captured at different average
sample rates, is shown in Figure 8.4. As the USR increases, additional extrema appear
within the frequency range of interest and slope deformations start to become apparent. At
an average sample rate of 8.5 Hz (USR = 20), the waveform extrema are both exaggerated
and attenuated. This results in an overall decrease in signal accuracy.
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Figure 8.4: As the USR increases, the reconstructed signal becomes deformed. This de-
formation results in non-smooth slopes and elongated extrema.
The results when using both the identity based sensing matrix and weighted reconstruction
on the custom hardware are shown in Table 1. These results are generated by comparing
each simultaneously sub-sampled PPG signal to the Nyquist sampled PPG signal, as de-
scribed in 8.4.2. This is done so that the weighted reconstruction and sub-sampling can be
benchmarked using the error metrics shown in Section 8.4.3.
These results show similar error rates to the commercial hardware used in Section 8.5.1.
This verifies that the hardware works as expected so that it can be used to demonstrate the
possible power savings when directly generating the measurement vector.
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USR NRMSD RMSdiff foot
5 2.18% 1.20% 2.79 ms
10 4.09% 3.79% 3.49 ms
15 6.05% 7.89% 4.07 ms
20 8.20% 13.14% 4.25 ms
Table 8.1: Reconstruction Results with Custom Hardware
8.5.3 Significant Power Reduction with Sub-Nyquist Sampling
When sub-Nyquist sampling a single PPG channel, there is a drastic reduction in power
consumption. This is shown in Figure 8.5. These results show a continued decrease in
power consumption as the average sample rate decreases. At an average sample rate of
11 Hz, the power consumption is reduced by 86.7%, which closely matches the theoreti-
cal power reduction of 87.7%. This corresponds to a very significant 7.5-fold increase in
battery life.
The theoretical power consumption is calculated using the analog front end’s quiescent
power, which was measured to be 1.5 mW. The difference between the current consumption
at Nyquist and the quiescent power will be scaled by the USR. The reduction in power
consumption asymptotically approaches the circuit’s quiescent power, as can be seen by
the results shown in Figure 8.5, where the theoretical reduction in power is compared to
the actual observed power consumption.
Devices with a lower quiescent power will see a more effective reduction in power con-
sumption for lower average sample rates. Using advanced PPG designs or commercial
devices such as those in [159, 166, 168], will show similar reductions in power based on
the Nyquist and quiescent power consumption when generating the measurement vector
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directly.
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Figure 8.5: As the USR increases, the power consumption will approach the device’s
quiescent power. The actual measured power closely approximates the estimated power
reduction based on the quiescent power and power consumption while Nyquist sampling.
In addition to consuming less power, systems which generate the measurement vector di-
rectly are less complex and easier to implement when compared to the existing compressed
sensing framework. In this case, a sensing matrix is not used, reducing the memory re-
quirements of the sensor node and removing the need for matrix multiplication. No pre-
processing is needed. One can simply ”sub-sample, then send”.
Not only can this technique be used on signals which consume a large amount of power
when generating the signal, it can be used when the ADC or the act of sampling consumes
a large percentage of the device’s power. Examples include high sample rate ECGs, or
systems with many channels, such as an EEG or an implantable neural sensor array [169,
170]. While the exact amount of power savings will depend on the system and signal
sparsity, the reduction in data rate is directly proportional to the USR.
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8.6 Conclusion
This work has demonstrated for the first time in custom hardware, that compressed sens-
ing can be used to sub-Nyquist sample the PPG. Compressed sensing can now reduce the
power consumption of PPG analog-front-end circuitry without adding any complexity to
the system, in addition to reducing the amount of data needed to represent the signal.
An overall power savings of 86.7% was achieved when sampling the PPG at a rate one fif-
teenth the Nyquist rate. This resulted in a NRMSD error of 4.26% an RMS error of 6.60%,
and a foot error of 3.98 ms. By generating the measurement vector directly, the complexity
of the sensor node is significantly reduced when compared to classic compressed sensing
without sacrificing reconstruction accuracy.
Furthermore, weighted reconstruction increases the effectiveness of this compression by
reducing the number of measurements needed for accurate reconstruction across subject
populations and physiological states. This will be extended in future research by investi-
gating custom physiological models to further increase the sparsity, and thus accuracy, of
signal reconstruction.
The simple “sub-sample then send” paradigm has the possibility to effectively reduce the
complexity of devices with a multitude of channels and minimize the power consumption
when sampling a sparse signal. Future research will investigate the implementation of these
methods on a large scale using devices with a large number of channels. The direct gener-
ation of the measurement vector and weighted reconstruction can be used in parallel with
existing low-power technologies to create devices that achieve remarkably lower power
consumption than is currently possible.
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This has the potential to significantly improve the battery life of the FIT seat. The PPG
alone results in over 75% of the device’s overall power consumption. If the number of PPG
samples can be reduced ten-fold, the battery life of the FIT seat can be improved from 8
months, to almost 2 years. This is a remarkable improvement that will help drive consumer
adoption and patient compliance.
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Chapter 9
Future Work and Final Remarks
9.1 Introduction
The present work details the design and verification of a revolutionary cardiovascular mon-
itoring system incorporating commonly used medical instrumentation. The FIT seat has
proven to be a robust cardiovascular monitoring device that can function unattended for
months at a time. As this work lays the foundation for many future studies that can build
upon the success of the present work. This chapter provides concluding remarks and details
future studies and analyses, where the FIT seat can be used as a tool for automatic cardio-
vascular data acquisition. Additionally, the data captured herein as well as data captured
throughout the course of future studies, can be used in the development and verification of
algorithms utilizing machine learning.
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9.2 Future Studies
9.2.1 In-Home Studies
Future in-home studies utilizing the FIT seat should be structured to investigate the systems
ability to pick up trends, for both the normative and the heart failure populations. Normative
and heart failure in-home studies can be run in parallel, where both subject groups should
have the seat deployed in-home for a minimum of 90 days. This is recommended because
it is the duration of the bundled payment provided to hospitals by the Centers for Medicare
and Medicaid Service. Furthermore, over 40% of readmissions happen within the first 90
days after discharge.
This study should incorporate weekly visits for the in-lab testing of normative subjects,
since they are expected to be mobile and do not have the physical limitations present in the
heart-failure population. Gold standard measures captured during these visits will be used
to verify the in-home trend results. Heart failure subject will not be able to participate in
weekly visits, however their gold-standard measures can be updated during any hospital
readmissions.
The normative population will demonstrate robust extraction of physiologic parameters,
with the goal of tracking one’s health. The heart failure population will demonstrate the
ability of the FIT seat to predict outcome variables such as hospital readmissions, the need
for a ventricular assist device, or death. The focus of this study should be to predict hospital
readmissions, since the reduction of long-duration hospital readmissions have the greatest
potential to positively impact the healthcare industry.
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9.2.2 Posture Testing
One of the key challenges that will be faced with in-home deployment is automatic subject
identification. Multiple individuals often use the same toilet in a household, and it is critical
to only include data from a single individual when analyzing any FIT seat data, especially
trend data over long periods of time. One of the most likely differentiating factors between
subjects is body weight, which will require accurate weight estimation from the FIT seat
measurements. This is a challenging problem because both posture and body type greatly
impact the absolute weight present on the seat. Furthermore, slight differences in seating
position for a subject can result in significantly different weight estimations from the FIT
seat.
Machine learning techniques hold promise for robust weight and posture estimation using
data from the four standoffs within the FIT seat. A posture based study will be required in
order to gather training data for any machine learning based approach. The study should in-
clude a large number of subjects with different weights, heights, and body types. The more
diverse the study population, the more accurate and robust the resultant weight estimation
algorithm will be.
The posture based study will require each subject to partake in a single session, where
multiple FIT seat recordings are taken at different pre-determined postures. Gold standard
weight measurements can be used in combination with the pre-determined postures, to
provide a training and verification set for machine learning based approaches. The result of
this study will be an algorithm that accurately estimates weight, regardless of posture and
body type, when deployed in the home or in the hospital.
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9.2.3 Trend Studies
In order to further investigate the ability of the FIT seat to accurately extract blood pressure
and weight, a study structured to verify trend data is required. A trend study is proposed,
where gold-standard and FIT seat measurements are captured on a large number of subjects
in a lab environment. There should be five measurements per subject each week, for a total
of eight consecutive weeks.
Each subject will have a baseline measurement in the morning before consuming any stim-
ulants, such as caffeine or nicotine. A maximum of two measurements should be taken each
day, with at least four hours separation between measurements. The subject’s blood pres-
sure, heart rate, weight, and SpO2 will be captured multiple times during a single session
using hospital grade equipment. This data will allow the accuracy of the trends captured
from the FIT seat to be quantitatively assessed across the normative population.
9.3 Future Analysis and Data Science
The data captured from the normative and heart-failure studies discussed in Chapter 5 can
be hand annotated by trained experts. The resulting datasets, where each ECG and BCG
feature is hand annotated, will facilitate the development and verification of advanced al-
gorithms for use with the heart failure population and those with cardiovascular disease.
Machine learning and other classification techniques can be used to identify features on
ensemble averaged beats with unusual morphologies. This will also facilitate the auto-
matic detection of arrhythmias, which is a critical feature of any cardiovascular monitoring
system
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The present and proposed studies have will result in a large amount of data and analyses.
With accurate daily monitoring, the potential for diagnosis and prevention through predic-
tion using advanced data science techniques is unmatched. Big data techniques utilizing in-
home data can be used to predict outcome events and to provide automated diagnosis. This
allows the long-term goal of the FIT seat to be realized, where the device can be deployed
to one’s home for unattended use. The system will continue to function independently,
providing insight to the users about their health by recommending areas of improvement,
providing early warning for potentially devastating events, and by automatically diagnosing
subjects prior to any hospital visit or doctor checkup.
9.4 Conclusion
A fully integrated toilet seat for inconspicuous daily medical analysis has been presented.
Novel algorithms have also been presented that fill in gaps within the current body of
knowledge with state-of-the-art signal quality classification and delineation algorithms.
The FIT seat hardware and algorithms have been verified using normative and heart fail-
ure human subject testing. Such a device has the potential to capture long-term trend data
that has been previously unattainable, because it facilitates daily measurements taken at
rest prior to the intake of food and stimulants at consistent times each day, with no required
change in habit. This will enable new approaches and capabilities in the diagnosis and treat-
ment of cardiovascular disease for those with heart failure and hypertension, as well as for
those who are at risk of cardiotoxicity while undergoing chemotherapy treatments. There
are no existing devices that has the capability to automatically and simultaneously acquire
such an extensive and diverse set of measurements from a subject. The present algorithms
enabling robust parameter extraction from the FIT seat, which would not be possible with
188
the existing state-of-the-art. This device truly has the potential to revolutionize in-home
cardiovascular health-care.
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